

# MC-Rx/Jai Medical Systems Managed Care Organization 2024 Therapeutic Formulary

This formulary describes the circumstances under which pharmacies participating in a particular medical benefit program will be reimbursed for medications dispensed to patients covered by the program. This formulary does not:

- a) Require or prohibit the prescribing or dispensing of any medication.
- b) Substitute for the independent professional judgment of the physician or pharmacist.
- c) Relieve the physician or pharmacist of any obligation to the patient or others.

## **I. Non-Prescription Medication Policy**

The only over-the-counter (OTC) medications that are covered by Jai Medical Systems are listed within the program formulary. All OTC medications, with the exception of OTC emergency contraception, can be reimbursed only if it is written on a valid prescription form by a licensed prescriber. OTC emergency contraception may be obtained without a written prescription; see page 6 of the formulary for limitations.

## **II. Unapproved Use of Formulary Medication**

Medication coverage under this program is limited to non-experimental indications as approved by the FDA. Other indications, which are accepted as safe and effective by the balance of current medical opinion and available scientific evidence, may also be covered. The Pharmacy Benefits Manager (PBM), MC-Rx, utilizing the procedures outlined in Section IV, will make decisions about reimbursement for these other indications. Experimental, investigational drugs and drugs used for cosmetic purposes are not eligible for coverage.

## **III. Prior Authorization Procedure**

To promote the most appropriate utilization of selected high risk and/or high-cost medication, a prior authorization procedure has been created. The criteria for this system have been established by the MC-Rx/Jai Medical Systems Managed Care Organization program, with input from pharmacists and physician practitioners and in consideration of the available medical literature. The Pharmacy and Therapeutics Committee will have final approval responsibility for this list. In order for a dispensed prior authorization medication to be reimbursed to the pharmacy, the patient's prescribing physician must apply for pre-authorization for a specific patient and drug. The physician may phone or fax the PBM to initiate a request for prior authorization:

**MC-Rx**  
**Prior Authorization Desk**  
**1267 Professional Parkway**  
**Gainesville, Georgia 30507**  
**(800) 555-8513**  
**(800) 583-6010 (fax)**  
**(866) 999-7736 (alternate fax)**

**Please have patient information, including member ID number, complete diagnosis, medication history, and current medications readily available. Special request forms are required for Hepatitis C treatments and for opioids. All forms can be found online at [www.jaimedicalsystems.com/providers/pharmacy/](http://www.jaimedicalsystems.com/providers/pharmacy/).**

A completed, signed prior authorization form is needed in order for a request to be reviewed, but providers may call the MC-Rx Prior Authorization department to request forms and for help with the prior authorization request process. These phone lines are dedicated to physicians making requests for medications that require prior authorization and non-formulary items. Members cannot be assisted if they call the prior authorization toll-free number, but they may call the MC-Rx Customer Service Department at 800-213-5640 for help getting a prior authorization form faxed to their provider. For all requests for drugs requiring prior authorization, a decision will be provided within 24 hours of receiving the completed request. That decision will be to either approve, deny, or request more information. The requesting provider will receive a telecommunication response informing them of this decision. If the requested information is not received, this process could take up to 14 calendar days. If the request is approved, information in the online pharmacy claims processing system will be changed to allow the specific patient to receive the requested drug. A prior authorization number will be issued to the prescribing physician and may be clearly written on the top of the prescription to inform the dispensing pharmacist of the approval. This number is for identification purposes only and does not need to be submitted for adjudication to occur. If the request is denied, information about the denial will be provided to the prescribing physician along with the patient and the patient's PCP, when appropriate.

Additionally, most injectables (except Depo-Provera, enoxaparin sodium, insulin, Glucagon Kit, and formulary epinephrine products) require prior approval. Questions about injectable drugs administered by home health or healthcare providers should be directed to MC-Rx at 800-555-8513. If the medication will be billed on a medical claim rather than through the pharmacy, the provider may contact the Provider Relations or Utilization Management Departments at 888-524-1999 with any questions.

Our prior authorization criteria can be found on our website, [www.jaimedicalsystems.com](http://www.jaimedicalsystems.com), as well as in this formulary. Any updates made to our criteria will be posted on the website above within 30 days.

#### **IV. Unique Patient Needs Non-Formulary Medication**

This formulary attempts to provide appropriate and cost effective drug therapy to all enrollees of the Jai Medical Systems Managed Care Organization program. If a patient requires medication that is not covered by the formulary, a request can be made for payment of the non-covered item. It is anticipated that such exceptions will be rare, and that formulary medications will be appropriate to treat the vast majority of medical conditions. Requests for non-formulary medications should be made in writing (on the prior authorization form) and mailed or faxed to:

**MC-Rx  
Prior Authorization Desk  
1267 Professional Parkway  
Gainesville, Georgia 30507  
(800) 555-8513  
(800) 583-6010 (fax)  
(866) 999-7736 (alternate fax)**

Appropriate documentation must be provided to support the request. For all requests for drugs requiring prior authorization, a decision will be provided within 24 hours of receiving the request. That decision will be either to approve, deny, or request more information. The requesting provider will receive a telecommunication response informing them of this decision. If the requested information is not received, this process could take up to 14 calendar days. Approval of non-formulary items will be considered based upon Maryland Medicaid HealthChoice Benefit Coverage, availability and appropriateness of alternative medications on the formulary, and any applicable criteria sourced or developed by the Pharmacy and Therapeutics Committee of Jai Medical Systems Managed Care Organization, Inc. and the PBM, including the FDA-approved prescribing information for the medication and other information sources, such as UpToDate.

Physicians are expected to comply with this formulary when prescribing medication for those patients covered by Jai Medical Systems Managed Care Organization, Inc. If a pharmacist receives a prescription for a non-formulary medication, the pharmacist should attempt to contact the prescribing physician to request a change to a product included in this formulary guide.

The pharmacy will not be reimbursed for non-formulary medications unless they received prior approval from Jai Medical Systems Managed Care Organization, Inc.

**In an emergency situation outside of the PBM's regular business hours where the physician cannot be contacted, the pharmacist is authorized to dispense a 72-hour emergency supply of a medication, unless the medication is classified as a DESI, LTE, or specifically excluded drug category (see Section VI) product or is one of the treatments for Hepatitis C, which should not be dispensed until the member has prior authorization to begin treatment.**

**The pharmacist should contact the PBM's Help Desk at (800) 213-5640 to arrange for reimbursement for the emergency supply.**

## **V. Newly Marketed Products**

Standard medications will be reviewed for coverage decisions within 180 calendar days of FDA approval. Priority medications will be reviewed for coverage decisions within 90 calendar days of FDA approval. Newly marketed drug products will not normally be placed on the formulary during their first year on the market. Exceptions to this rule will be made on a case-by-case basis using the medical necessity procedure.

## **VI. Specific Exclusions**

The following drug categories are not part of the Jai Medical Systems Managed Care Organization formulary and are not covered by the 72-hour emergency supply reimbursement policy:

- Antiobesity products
- Blood and blood plasma
- Cosmetic drugs
- Cough and cold products (except those listed in the formulary)
- DESI drugs
- Diagnostic products (except those listed in the formulary)
- Erectile/sexual dysfunction agents

- Medical supplies and durable medical equipment (except certain diabetic supplies and specific Optichamber spacers)
- Most vitamins (except those listed in the formulary)
- Nutritional and dietary supplements
- Research drugs
- Most non-prescription medications, including topical minoxidil (except non-prescription medications listed in the formulary)
- Fertility treatment medications, such as ovulation stimulants (except when covered as part of a pre-approved fertility preservation service for members at risk of iatrogenic infertility due to upcoming cancer treatment or gender affirming care)

#### **VII. Fee-for-Service Carve-outs**

In addition to the above exclusions, the following are also excluded from the formulary and are covered by the Maryland Department of Health:

- Mental health drugs (refer to Section VIII). A list of Mental Health medications can be found online at: <https://health.maryland.gov/mmcp/pap/pages/paphome.aspx> under the Mental Health Formulary link
- Substance use disorder medications, including, but not limited to, buprenorphine, buprenorphine/naloxone, Campral®, Chantix®, Revia®, naloxone, Nicotrol®, nicotine patches, gum, and lozenges. (Refer to Section VIII). A list of substance use disorder medications is available online at: <https://health.maryland.gov/mmcp/pap/pages/paphome.aspx> under the Substance Use Disorder Medication Clinical Criteria Final link

#### **VIII. Behavioral Health Medication Policy**

Please refer to the Maryland Department of Health’s Mental Health Formulary for a complete listing of behavioral health medications. Any behavioral health medications that are covered by Jai Medical Systems Managed Care Organization are listed in the prescription formulary.

- Kapvay – For recipients 6 -17 years old, extended-release clonidine (Kapvay) is part of the mental health formulary and billed fee-for-service. For individuals not in this age range, extended-release clonidine continues to be a part of the MCO pharmacy benefit and would require prior authorization as a non-formulary medication.
- Intuniv – For recipients 6 -17 years old, extended-release guanfacine (Intuniv) is part of the mental health formulary and billed fee-for-service. For individuals not in this age range, extended-release guanfacine continues to be a part of the MCO pharmacy benefit and would require prior authorization as a non-formulary medication.

#### **IX. Mandatory Generic Substitution & Therapeutic Interchange**

Generic substitution is mandatory when a generic equivalent is available, unless the brand is specified as the preferred medication on the formulary. All branded products that have 3 or more generic equivalents available will be reimbursed at the maximum allowable cost. No other therapeutic interchange is permitted.

## **X. Gender Affirming Care**

Certain medications, including medications on the drug list with prior authorization requirements, such as Testosterone, Nafarelin, and Leuprolide and medications that are usually excluded like Clomiphene, may be covered for gender affirming care, in accordance with the Gender-Affirming Treatment Services Under the Maryland Medicaid Program document, available on our website at <https://www.jaimedicalsystems.com/providers/pharmacy/> under Gender Affirming Care. Please ensure that all necessary documentation required under the criteria is included to show consent for treatment and medical necessity (documentation requirements may vary depending on patient age, type of treatment requested, and specialty of requesting provider).

## **XI. Specialty Medications**

Specialty medications will be covered under the pharmacy benefit for Jai Medical Systems. All requests will undergo prior authorization review when available drug-specific prior authorization criteria will apply. When prior authorization criteria do not exist, the request will be reviewed for FDA approved indications according to Jai Medical Systems Managed Care Organization, Inc.'s approved medical necessity review process. All specialty drug requests should contain the following:

- Drug name, strength, dose, and quantity requested
- Diagnosis for use
- Any previous drug therapies tried and failed, or why medications on the drug list are not appropriate
- Any additional clinical information pertinent to the drug review

## **XII. High Cost, Low Utilization Medications**

In accordance with the Maryland Department of Health's High Cost, Low Volume Drug Risk Mitigation Policy and the Social Security Act 1927 (d)(5), Jai Medical Systems **will not pay** for any of the aforementioned high-cost drugs that are not appropriately pre-authorized by Jai Medical Systems. The current list of NDCs and J-Codes Covered by High Cost Low Volume Risk Mitigation Policy can be found on our website at <https://www.jaimedicalsystems.com/providers/pharmacy/> under the High Cost Low Volume Drugs heading and will be updated as Maryland Medicaid updates the list.

Our health plan will not conduct any retrospective review for these drugs; they must be pre-authorized and approved by our plan beforehand. **THERE WILL BE NO EXCEPTIONS TO THE REQUIREMENT FOR PRE-AUTHORIZATION.** Please be advised that this policy includes both Physician Administered Drugs and retail pharmacy drugs.

Please be advised that this list is subject to change. If you are unsure of whether or not a medication requires prior authorization and/or pre-certification, please contact our Utilization Management Department at 1-888-JAI-1999.

## **XIII. General Parameters**

- Members must be enrolled in Jai Medical Systems Managed Care Organization, Inc. at the time the medication is dispensed.
- Valid DEA and NPI numbers are required.
- Prescribers must be appropriately registered and active with Maryland Medicaid's ePREP system. Jai Medical Systems reserves the right to review the current ePREP status of a prescriber, in accordance with Section 6401 of the Affordable Care Act and Code of Federal Regulations section 42 CFR §

455.410(b). Jai Medical Systems may deny a prior authorization request if the prescriber is not registered and in an active status with Maryland Medicaid's ePREP system.

- Refill too soon - 75% of the days supplied must elapse before the prescription can be refilled. For opioid medications, 85% of the days supplied must have elapsed before the prescription can be refilled.
- The standard maximum allowable quantity is a 30-day supply. The allowed quantity limit for formulary asthma controller medications and certain statins on the drug list (which cost less than \$100 for a 90-day supply and when the member has already received a 30-day supply first) is a 90-day supply. The quantity limit on most medications is a 400-unit maximum limit per month. Most narcotics have individualized quantity and dosage form limitations, which are listed on page 14 of the formulary. If necessary, a healthcare provider may request a quantity override by contacting MC-Rx's Prior Authorization Department. Even with an override, the quantity may not exceed a 100-day supply, except for contraceptives as described below. Opioid prescriptions have separate days' supply limits as described below.
- If a member is new to opioid treatment (no pharmacy claims history of any opioid medication in the previous 90 days), their first fill is limited to no more than a 7-day supply. Effective November 1, 2021, after the initial fill, members are limited to 14-day supplies for their opioid medications unless their provider requests prior authorization, or unless they were already receiving greater than 14-day supplies when the change was implemented. If a member stops filling opioid medication for 90 days, they will be considered new to treatment and will lose their approval for greater than 14-day supplies and will need to follow the rules about initial fill limits. Opioid prescriptions cannot exceed a 30-day supply.
- Oral contraceptives will be available in up to 12-month supplies when ordered by a qualified practitioner.
- All generic oral contraceptives (including emergency contraceptives) and brand oral contraceptives that do not have a generic version available are formulary. Examples are listed on pages 6 and 7.
- Contraceptive implants and IUDs are covered under the medical benefit and should be billed for on a medical claim.
- Jai Medical Systems covers most common vaccines through the medical benefit and pharmacy benefit, including all COVID-19 vaccines, most flu vaccines, and most other standard age-appropriate vaccines (as determined by Maryland Medicaid.)
- A current listing of HIV medications covered by Jai Medical Systems are listed on page 3.
- Requests for some medications require special forms. All pharmacy prior authorization request forms can be found online at:  
<http://www.jaimedicalsystems.com/providers/pharmacy/>.
- Prior authorization is required for all extended-release opioid products as well as methadone prescribed for pain and any other opioids prescribed for quantities greater than 90 MMEs per day. A specialized form is required for these requests and can be found online at <http://www.jaimedicalsystems.com/providers/pharmacy/>.
- Prior authorization requests for medications for the treatment of Hepatitis C require a special prior authorization request form. While prior authorization is still required, Jai Medical Systems prefers Mavyret, generic Epclusa, generic Harvoni, and Zepatier, unless they are not medically appropriate. These forms and prior authorization criteria can be found at <http://www.jaimedicalsystems.com/providers/pharmacy/>.

- Vacation fill overrides may be requested by contacting Jai Medical Systems at 1-800-524-1999. Information from the prescribing doctor or primary care provider may be required before the request can be approved. Requests for vacation overrides for opioids are not generally available.
- Overrides for lost or stolen prescriptions may be requested by contacting Jai Medical Systems at 1-800-524-1999. Information from the prescribing doctor or primary care provider may be required before the request can be approved. Requests for override for lost or stolen opioids are not generally available.

### **XIII. Where to Call?**

#### **PHYSICIANS**

Formulary Questions: MC-Rx (800) 555-8513

Medical Necessity: MC-Rx (800) 555-8513

Prior Authorization: MC-Rx (800) 555-8513

Provider Relations: Jai Medical Systems  
Managed Care Organization, Inc. (888) JAI-1999

#### **PHARMACISTS**

Provider Network Questions: MC-Rx (800) 213-5640

Provider Relations: MC-Rx (800) 213-5640

### **XIV. Abbreviations**

Providers are encouraged to prescribe generically available drugs whenever possible and to prescribe first-line lower cost options when appropriate. Drugs are ranked by cost with the following abbreviations:

*	=	This product has a MAC price attached to some or all
\$	=	Cost per Rx is <\$20
\$\$	=	Cost per Rx is <\$40
\$\$\$	=	Cost per Rx is \$40 - \$80
\$\$\$\$	=	Cost per Rx is \$80 - \$160
\$\$\$\$\$	=	Cost per Rx is >\$160

### **XV. Reference**

The formulary is available online at Formulary Navigator. This is updated monthly and will have the most up-to-date information. Formulary access is free and available at:

<https://client.formularynavigator.com/Search.aspx?siteCode=9386334079>

Links to all Maryland Medicaid Managed Care Organization Formulary Navigator pages can be found on the website listed below:

<https://health.maryland.gov/mmcp/pap/pages/Weblinks-for-Providers.aspx>

A link to a pdf copy of the Jai Medical Systems formulary and copies of our recent formulary change notices is also available in the Providers section of our homepage:

<http://www.jaimedicalsystems.com/providers/pharmacy/>

## **XVI. Copays**

Beginning on May 1, 2024, HealthChoice MCOs are required to charge the following pharmacy copays:

<b>Copayment Charge</b>	<b>New and Refill Drug Type</b>
\$3.00	Non-preferred and non-formulary brand name drugs
\$1.00	All generic drugs (preferred and non-preferred)
\$1.00	Preferred brand name drugs
\$1.00	HIV/AIDS drugs

Individuals under the age of 21, pregnant individuals, individuals in long-term care facilities, and Native Americans are not required to pay copayments for prescription drugs in HealthChoice because of other federal and state statutory requirements. Copayments also do not apply to family planning drugs and adult vaccines and their administration, provided that the vaccine is approved by the FDA for use by adults and is administered in accordance with recommendations of the Advisory Committee on Immunization Practices (ACIP). COVID-19 prescription drugs and vaccinations temporarily have copayments waived until further federal guidance is issued. Additionally, in alignment with Medicaid fee-for-service regulations, pharmacy providers are not permitted to deny prescriptions to any Medicaid participant who is unable to pay the copayments.

## **XVII. Prior Authorization Auto-Renewal**

Jai Medical Systems offers automatic prior authorization renewals for Advair, Symbicort, Wixela, and their generic equivalents. For members with a current approved prior authorization, claims will continue to process as long as the member has filled for that medication within the last 4 months. No yearly renewal will be needed for compliant members. Prior authorization will be required for members new to the plan, new to therapy, or with no claim history of that medication within the last 4 months.

## **XVIII. Notice of Non-Discrimination**

Jai Medical Systems Managed Care Organization, Inc. complies with applicable Federal civil rights laws and does not discriminate on the basis of language, age, race, color, sex, sexual orientation, national origin, disability, medical condition, or religion against members, contracted providers, staff, and/or non-affiliated individuals. This includes women, individuals of minority and non-minority groups, individuals of the LGBT community, individuals with disabilities, and/or members with limited English proficiency. Jai Medical Systems Managed Care Organization, Inc. does not exclude people or treat them differently because of language, age, race, color, sex or sexual orientation, national origin, disability, medical condition, or religion.

To ensure effective communication for individuals with disabilities, Jai Medical Systems Managed Care Organization, Inc. shall:

- Provide equal access to auxiliary aids and services as necessary for individuals with disabilities, in accordance with applicable law.
- Include taglines for language accessibility in top 15 languages on the website, and in larger significant publications and significant communications.
- Include taglines for language accessibility in two popular languages in significant publications including Member Handbook, and significant communications.
- Provide free language assistance and interpretation services for members with limited English proficiency to communicate effectively.
- Provide free sign language interpretation for members with hearing disabilities.

- Provide free oral language assistance and written translation through Jai Medical Systems Managed Care Organization, Inc.'s multilingual staff, oral interpreters, and translators.

If you need these services, contact our Non-Discrimination Compliance Coordinator at <customerservice@jaimedical.com>. Additionally, information is made available in languages other than English upon request.

### **XIX. Equal Employment Opportunity Statement**

Jai Medical Systems Managed Care Organization, Inc. provides equal employment opportunity for everyone regardless of language, age, sex, color, creed, national origin, pregnancy, ancestry, marital status, political belief, genetic information, and physical or mental disability that does not prohibit performance of essential job functions. In addition, Jai Medical Systems Managed Care Organization, Inc. complies with Section 1557 of the Affordable Care Act, all applicable federal, state, and local anti-discrimination laws. This policy is reflected in all of Jai Medical Systems Managed Care Organization, Inc.'s practices and policies regarding hiring, training, promotions, transfers, rates of pay, layoffs, and other forms of compensation. All matters relating to employment are based upon ability to perform the job, as well as dependability and reliability once hired.

If you believe that Jai Medical Systems Managed Care Organization, Inc. has failed to provide these services or discriminated on the basis of language, age, race, color, sex or sexual orientation, national origin, disability, medical condition, or religion, you can file a grievance with:

Non-Discrimination Compliance Coordinator Jai Medical  
Systems Managed Care Organization, Inc.  
301 International Circle, Hunt Valley, MD 21030  
Phone: 410-433-2200 | Fax: 410-433-4615 |  
Email: <customerservice@jaimedical.com>

You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, our Non-Discrimination Compliance Coordinator is available to help you. Grievances must be submitted to the Coordinator within sixty days of the date you become aware of the alleged discrimination.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, and by mail or phone at:

U.S. Department of Health and Human Services,  
200 Independence Avenue, SW Room 509F, HHH Building  
Washington, D.C. 20201  
Phone: 1-800-368-1019, 800-537-7697 (TDD)

Complaint forms are available at: <http://www.hhs.gov/ocr/office/file/index.html>

## XX. Language Accessibility Statement

### Interpreter Services are Available for Free

*Help is available in your language:*

**1-888-524-1999 (TTY: 1-800-735-2258).**

*These services are available for free.*

#### **Español/Spanish**

Hay ayuda disponible en su idioma: 1-888-524-1999 (TTY: 1-800-735-2258). Estos servicios están disponibles gratis.

#### **አማርኛ/Amharic**

አገዛ በ ቋንቋዎ ማግኘት ይቻላል:-: 1-888-524-1999 (TTY:

1-800-735-2258): እነዚህ አገልግሎቶች ያለክፍያ የሚገኙ ነጻናቸው

#### **العربى/Arabic**

1-888-524-1999 (المعالمين سمعياً) 1-800-735-2258

المساعدة متوفرة في لغتك. اتصل على الرقم 1-888-524-1999 أو 1-800-735-2258. هذه خدمة متوفرة للمعالمين سمعياً.

#### **Français/French**

Vous pouvez disposer d'une assistance dans votre langue : 1-888-524-1999 (TTY: 1-800-735-2258). Ces services sont disponibles pour gratuitement.

#### **ગુજરાતી/Gujarati**

તમારી ભાષામાં મદદ ઉપલબ્ધ છે: 1-888-524-1999 (ટીટીવાય: 1-800-735-2258). સેવાઓ મફત ઉપલબ્ધ છે

#### **kreyòl ayisyen/Haitian Creole**

Gen èd ki disponib nan lang ou: 1-888-524-1999 (TTY: 1-800-735-2258). Sèvis sa yo disponib gratis.

#### **Igbo**

Enyemaka di na asusu gi: 1-888-524-1999 (TTY: 1-800-735-2258). Oru ndi a di na enweghi ugwo i ga akwu maka ya.

#### **한국어/Korean**

사용하시는 언어로 지원해드립니다: 1-888-524-1999 (TTY: 1-800-735-2258). 무료로 제공 됩니다

#### **Português/Portuguese**

A ajuda está disponível em seu idioma: 1-888-524-1999 (TTY: 1-800-735-2258). Estes serviços são oferecidos de graça.

#### **Русский/Russian**

Помощь доступна на вашем языке: 1-888-524-1999 (TTY: 1-800-735-2258). Эти услуги предоставляются бесплатно.

**中文/Chinese**

用您的语言为您提供帮助：1-888-524-1999 (TTY: 1-800-735-2258)  
的这些服务都是免费的

**فارسی/Farsi**

ماسٲ خط) 1-800-735-2258 ڊی کن یم تبصح ماش که ی باز هب مک ن تلف خط  
1-888-524-1999 (ناشنوا افراد

رسم س ڊر ن گه یرا فر ص ه ب ف خ ن یا

ن م س

**Tagalog**

Makakakuha kayo ng tulong sa iyong wika: 1-888-524-1999 (TTY: 1-800-735-2258). Ang mga serbisyong ito ay libre.

**اردو/Urdu**

آپ کی زبان میں منڊ دستياب ہے: 1-888-524- (ٹی ٹی والی): 1-800-735-2258  
1999  
یڊ بایٲ سڊ ڊلے کتفم تامنڊ

**Tiếng Việt/Vietnamese**

Hỗ trợ là có sẵn trong ngôn ngữ của quý vị 1-888-524-1999 (TTY: 1-800-735-2258). Những dịch vụ này có sẵn miễn phí.

**Yorùbá/Yoruba**

Iranlo wo wa ni arọ wọ tọ ni èdè rẹ: 1-888-524-1999 (TTY: 1-800-735-2258). Awon ise yi wa fun o free.

**MC-Rx/Jai Medical Systems Therapeutic Formulary**

<u>Generic Name</u>	<u>Brand Name</u>	<u>Annotation</u>
<b>I. ANTI-INFECTIVE AGENTS</b>		
<b><u>PENICILLINS</u></b>		
\$ Amoxicillin*	AMOXIL	<i>no chewables</i>
\$ Ampicillin*	AMPICILLIN	
\$ Penicillin G Benzathine	BICILLIN	
\$ Penicillin V Potassium*	PENICILLIN V POTASSIUM	
<i>Penicillinase-resistant</i>		
\$ Dicloxacillin Sodium*	DICLOXACILLIN SODIUM	
\$ Oxacillin*	OXACILLIN	
<i>Penicillin Combinations</i>		
\$\$\$ Amox & K Clavulanate*	AUGMENTIN	<i>no chewables</i>
<b><u>CEPHALOSPORINS</u></b>		
<i>Cephalosporins - 1st Generation</i>		
\$\$ Cephalexin*	KEFLEX	<i>no tablets</i>
\$\$ Cephradine*	CEPHRADINE	
<i>Cephalosporins - 2nd Generation</i>		
\$\$ Cefaclor*	CEFACTOR	
\$\$\$ Cefprozil*	CEFPROZIL	
\$\$\$ Cefuroxime*	CEFTIN	<i>Oral tablets only</i>
\$\$\$ Loracarbef	LORABID SUSPENSION	<i>AL under 12 yrs</i>
<i>Cephalosporins - 3rd Generation</i>		
\$ Cefixime	SUPRAX	<i>QL = 1 tab</i>
\$\$\$ Ceftriaxone*	ROCEPHIN	
\$\$\$ Cefdinir*	CEFDINIR	
<b><u>MACROLIDE ANTIBIOTICS</u></b>		
<i>Erythromycins</i>		
\$ Erythromycin Base*	ERY-TAB	
\$ Erythromycin Estolate*	ERYTHROMYCIN ESTOLATE	
\$ Erythromycin Ethylsuccinate*	E.E.S.	
\$ Erythromycin Stearate*	ERYTHROCIN	
<i>Lincomycins</i>		
\$\$ Clindamycin*	CLEOCIN	
<i>Misc. Macrolide Antibiotics</i>		
\$\$ Azithromycin*	ZITHROMAX	
\$\$\$ Azithromycin suspension*	ZITHROMAX	<i>QL = 1 single dose packet</i>
\$\$\$ Clarithromycin*	BIAXIN	
<b><u>Misc. Antibiotics</u></b>		
\$\$\$ Rifaximin	XIFAXAN	<i>550mg only</i>
<b>Prior Authorization Required</b>		
<b><u>TETRACYCLINES</u></b>		
\$\$\$ Doxycycline*	VIBRAMYCIN	
\$ Tetracycline*	SUMYCIN	<i>no tablets</i>
<b><u>FLUOROQUINOLONES</u></b>		
\$\$\$ Ciprofloxacin*	CIPRO	
\$\$\$\$ Levofloxacin*	LEVAQUIN	
\$\$\$\$ Moxifloxacin*	AVELOX	<i>QL 14 per 30 days</i>
<b>Prior Authorization Required</b>		
<b><u>ANTIMALARIAL</u></b>		
\$ Chloroquine*	ARALEN	<i>no 500mg tabs</i>
\$ Hydroxychloroquine*	PLAQUENIL	
\$\$\$\$ Pyrimethamine	DARAPRIM	

**MC-Rx/Jai Medical Systems Therapeutic Formulary**

<u>Generic Name</u>	<u>Brand Name</u>	<u>Annotation</u>
<b><u>ANTHELMINTIC</u></b>		
\$\$ Albendazole	ALBENZA	
\$\$ Ivermectin*	STROMECTOL	tablets only
\$\$ Pyrantel Pamoate*	PIN - X	OTC product
<b><u>AMINOGLYCOSIDES</u></b>		
\$ Gentamicin Sulfate*	GARAMYCIN	
\$ Neomycin Sulfate*	NEOMYCIN	tablets only
<b><u>SULFONAMIDES</u></b>		
\$ Erythromycin/Sulfisoxazole*	ERYTHROMYCIN/SULFISOXAZOLE	
\$ Sulfadiazine*	SULFADIAZINE	
\$ Sulfasalazine*	AZULFIDINE	no EN tabs
\$ Sulfisoxazole*	SULFISOXAZOLE	
\$ Trimethoprim/Sulfamethoxazole*	BACTRIM / DS	
<b><u>ANTIMYCOBACTERIAL AGENTS</u></b>		
\$\$\$\$ Cycloserine	SEROMYCIN	
\$\$\$ Ethambutol*	MYAMBUTOL	
\$\$\$ Ethionamide	TRECTOR	
\$ Isoniazid*	ISONIAZID	
\$\$\$ Pyrazinamide*	PYRAZINAMIDE	
\$\$\$\$ Rifabutin*	MYCOBUTIN	
\$\$\$\$ Rifampin*	RIFADIN	
<b><u>MISC. ANTIINFECTIVES</u></b>		
\$ Metronidazole*	FLAGYL	
\$ Trimethoprim*	TRIMETHOPRIM	
\$\$ Chlorhexidine*	PERIOGARD	0.12% oral rinse
<i>Leprostatics</i>		
\$ Dapsone*	DAPSONE	
<b><u>ANTIFUNGALS</u></b>		
\$ Griseofulvin Microsize*	GRIFULVIN V	
\$ Griseofulvin Ultramicrosize*	GRIS-PEG	
\$ Nystatin*	NYSTATIN TAB	
<i>Imidazole-Related Antifungals</i>		
\$ Ketoconazole*	NIZORAL	
\$ Miconazole*	MONISTAT	OTC product
\$\$ Terbinafine*	LAMISIL	
\$\$ Itraconazole*	SPORANOX	
<b>Prior Authorization Required</b>		
<i>Triazoles</i>		
\$ Fluconazole*	DIFLUCAN	150mg x2 tablets/month is formulary. Authorization required for higher quantity or other strengths
<b>Prior Authorization Required</b>		
<b><u>ANTIVIRAL</u></b>		
<i>Neuraminidase Inhibitors</i>		
\$\$ Oseltamivir Phosphate	TAMIFLU	QL=1 course of treatment per calendar year
\$\$ Zanamivir	RELENZA	QL=1 course of treatment per calendar year
<i>CMV Agents</i>		
\$\$\$\$ Ganciclovir*	CYTOVENE	

**MC-Rx/Jai Medical Systems Therapeutic Formulary**

<u>Generic Name</u>	<u>Brand Name</u>	<u>Annotation</u>
<i>Hepatic Agents</i>		
\$\$\$\$ Lamivudine HBV	EPIVIR	
\$\$\$\$ Tenofovir Disoproxil Fumarate	VIREAD	QL = 30 tabs / month
\$\$\$\$ ENTECAVIR	BARACLUDE	QL = 30 tabs / month
\$\$\$\$ Elbasvir-Grazoprevir	ZEPATIER	Preferred for types 1,4
\$\$\$\$ Glecaprevir-Pibrentasvir	MAVYRET	Preferred all types
\$\$\$\$ Sofosbuvir-Velpatasvir*	GENERIC EPLUSA	Preferred all types
\$\$\$\$ Sofosbuvir-Velpatasvir-Voxilaprevir	VOSEVI	Retreatment only
\$\$\$\$ Peginterferon	PEG-INTRON, PEGASYS	
\$\$\$\$ Ribavirin*	REBETOL	
\$\$\$\$ Ledipasvir-Sofosbuvir*	GENERIC HARVONI	Preferred for 1,4,5,6
<b>**Special PA forms required. Please see <a href="http://www.jaimedicalsystems.com/providers/pharmacy">www.jaimedicalsystems.com/providers/pharmacy</a> for forms and full Maryland Medicaid prior authorization criteria.**</b>		

<i>Herpes Agents</i>		
\$\$ Amantadine*	AMANTADINE	
\$\$\$ Acyclovir*	ZOVIRAX	PA for ointment & susp.

<i>HIV Agents</i>		
\$\$\$\$ Abacavir	ZIAGEN	QL = 60 tabs / month
\$\$\$\$ Abacavir-Lamivudine	EPZICOM	QL = 30 tabs / month
\$\$\$\$ Abacavir-Lamivudine-Zidovudine	TRIZIVIR	QL = 60 tabs / month
\$\$\$\$ Atazanavir Sulfate	REYATAZ	QL = 30 tabs / month
\$\$\$\$ Efavirenz / Emtricitabine / TDF	ATRIPLA GENERIC	QL = 30 tabs / month
\$\$\$\$ Bictegravir / Emtricitabine / TAF	BIKTARVY	QL = 30 tabs / month
\$\$\$\$ Emtricitabine / Rilpivirine / TDF	COMPLERA	QL = 30 tabs / month
\$\$\$\$ Efavirenz	SUSTIVA	QL = 60 tabs / month
\$\$\$\$ Atazanavir and Cobicistat	EVOTAZ	QL = 30 tabs / month
\$\$\$\$ Elvitegravir / Cobicistat / FTC / TAF	GENVOYA	QL = 30 tabs / month
\$\$\$\$ Etravirine	INTELENCE	QL = 60 tabs / month
\$\$\$\$ Raltegravir	ISENTRESS	QL = 60 tabs / month
\$\$\$\$ Dolutegravir / Rilpivirine	JULUCA	QL = 30 tabs / month
\$\$\$\$ Lopinavir / Ritonavir	KALETRA	QL = 120 tabs / month
\$\$\$\$ Lamivudine	EPIVIR	QL = 30 tabs / month
\$\$\$\$ Lamivudine-Zidovudine	COMBIVIR	QL = 60 tabs / month
\$\$\$\$ Emtricitabine / Rilpivirine / TAF	ODEFSEY	QL = 30 tabs / month
\$\$\$\$ Darunavir and Cobicistat	PREZCOBIX	QL = 30 tabs / month
\$\$\$\$ Darunavir Ethanolate	PREZISTA	QL = 60 tabs / month
\$\$\$\$ Elvitegravir / Cobicistat / FTC / TDF	STRIBILD	QL = 30 tabs / month
\$\$\$\$ Darunavir / Cobicistat / FTC / TAF	SYMTUZA	QL = 30 tabs / month
\$\$\$\$ Emtricitabine / Tenofovir DF	TRUVADA GENERIC	QL = 30 tabs / month
\$\$\$\$ Emtricitabine / Tenofovir Alafenamide	DESCOVY	QL = 30 tabs / month
\$\$\$\$ Tenofovir Disoproxil Fumarate	VIREAD	QL = 30 tabs / month
\$\$\$\$ Dolutegravir	TIVICAY	QL = 30 tabs / month
\$\$\$\$ Dolutegravir / Abacavir / Lamivudine	TRIUMEQ	QL = 30 tabs / month
\$\$\$\$ Zidovudine	RETROVIR	QL = 60 tabs / month
\$\$\$\$ Fosamprenavir	LEXIVA	QL = 60 tabs / month
\$\$\$\$ Ritonavir	NORVIR	QL = 30 tabs / month
\$\$\$\$ Nevirapine	VIRAMUNE	QL = 60 tabs / month
\$\$\$\$ Stavudine	ZERIT	QL = 60 tabs / month
\$\$\$\$ Dolutegravir/Lamivudine	DOVATO	QL = 30 tabs / month

**II. ANTINEOPLASTICS**

**ANTINEOPLASTICS**

<i>Alkylating Agents</i>	
\$\$\$\$ Busulfan	MYLERAN

<i>Nitrogen Mustards</i>	
\$\$\$\$ Chlorambucil	LEUKERAN
\$\$\$\$ Cyclophosphamide*	CYTOXAN
\$\$\$\$ Melphalan	ALKERAN

**MC-Rx/Jai Medical Systems Therapeutic Formulary**

<u>Generic Name</u>	<u>Brand Name</u>	<u>Annotation</u>
<i>Nitrosoureas</i>		
\$\$\$\$ Lomustine	LOMUSTINE	
<i>Antimetabolites</i>		
\$\$\$\$ Capecitabine*	XELODA	
\$\$\$ Fluorouracil*	EFUDEX	2% and 5% cream only
\$\$\$\$ Mercaptopurine*	PURINETHOL	
\$\$\$ Methotrexate*	RHEUMATREX	
\$\$\$\$ Thioguanine	TABLOID	
<i>Progestins-Antineoplastic</i>		
\$\$\$ Megestrol*	MEGACE	Tabs & Oral Susp
<i>Antiandrogens</i>		
\$\$\$\$ Flutamide*	FLUTAMIDE	
<i>Aromatase Inhibitors</i>		
\$\$\$\$ Letrozole*	FEMARA	
\$\$\$\$ Anastrozole*	ARIMIDEX	
\$\$\$ Exemestane*	AROMASIN	
<i>Antineoplastic Hormones Misc.</i>		
\$\$\$\$ Bicalutamide*	CASODEX	
\$\$\$ Tamoxifen*	TAMOXIFEN	
\$\$\$\$ Leuprolide	LUPRON	
<b>Prior Authorization Required</b>		
<i>Mitotic Inhibitors</i>		
\$\$\$ Etoposide*	ETOPOSIDE	
<i>Antineoplastics Misc.</i>		
\$\$\$\$ Afatinib Dimaleate	GILTRIF	
\$\$\$\$ Erlotinib	TARCEVA	
\$\$\$ Hydroxyurea*	HYDREA	
\$\$\$\$ Mitotane	LYSODREN	
\$\$\$\$ Procarbazine	MATULANE	
\$\$\$\$ Sorafenib	NEXAVAR	
\$\$\$\$ Interferon Alfa-2A	ROFERON-A	
\$\$\$\$ Interferon Alfa-2B	INTRON-A	
\$\$\$\$ Interferon Alfa-n3	ALFERON N	
<b>Prior Authorization Required</b>		
<i>Systemic Enzyme Inhibitor</i>		
\$\$\$\$ Imatinib Mesylate	GLEEVEC	QL = 90 tabs / 30 days

**III. ENDOCRINE & METABOLIC DRUGS**

**CORTICOSTEROIDS**

*Glucocorticosteroids*

\$ Cortisone*	CORTISONE	
\$ Dexamethasone*	DEXAMETHASONE	no dose paks
\$ Hydrocortisone*	CORTEF	
\$ Methylprednisolone*	MEDROL	tabs & dose packs
\$ Prednisone*	PREDNISONE	
\$ Prednisolone*	PRELONE	
\$\$ Prednisolone Na Phosphate*	PEDIAPRED	
\$\$ Prednisolone Na Phosphate*	ORAPRED	
\$ Prednisolone Acetate	FLO-PRED	

*Mineralocorticoids*

\$ Fludrocortisone*	FLUDROCORTISONE	
---------------------	-----------------	--

**ANDROGEN-ANABOLIC**

*Androgens*

\$\$\$ Methyltestosterone	ANDROID	
\$\$\$ Danazol*	DANAZOL	
\$\$\$ Testosterone Gel, Injection	ANDROGEL, TESTIM	

**Prior Authorization Required**

**MC-Rx/Jai Medical Systems Therapeutic Formulary**

<u>Generic Name</u>	<u>Brand Name</u>	<u>Annotation</u>
<b><u>ESTROGENS</u></b>		
\$ Estradiol*	ESTRACE	
\$\$ Esterified Estrogens	MENEST	
\$\$ Estrogens, Conjugated	PREMARIN	
\$\$\$ Estradiol TD Patch*	CLIMARA	
<i>Estrogen Combinations</i>		
\$\$ Conjugated Estrogens & Medroxyprogesterone	PREMPRO	
<b><u>CONTRACEPTIVES</u></b>		
<b>***All generic oral contraceptives are formulary***</b>		
<i>Progestin</i>		
\$\$\$ Norethindrone*	NOR-QD, ORTHO MICRON	<i>Females only</i>
\$\$ Norethindrone*	LYLEQ	<i>Females only</i>
<i>Combinations</i>		
\$\$ Desogestrel & Ethinyl Estradiol*	DESOGEN, ORTHO-CEPT	<i>Females only</i>
\$\$ Drospirenone-Ethinyl Estradiol*	YASMIN, YAZ	<i>Females only</i>
\$\$ Drospirenone-Eth Estrad Levomefolate	SAFYRAL, BEYAZ	<i>Females only</i>
\$\$ Ethynodiol Diacet-Eth Estrad*	ZOVIA	<i>Females only</i>
\$\$\$ Etonogestrel-Ethinyl Estradiol	NUVARING, ELURYNG	<i>QL= 1 ring / month, Females only</i>
\$\$ Levonorgestrel & Ethinyl Estradiol*	NORDETTE, AVIANE, ICLEVIA, DOLISHALE	<i>Females only</i>
\$\$ Norethindrone-Ethinyl Estradiol*	MODICON, BREVICON	<i>Females only</i>
\$\$ Norethindrone Ace-Ethinyl Estrad*	LOESTRIN	<i>Females only</i>
\$\$ Norgestrel-Ethinyl Estradiol*	CRYSSELLE, OGESTREL	<i>Females only</i>
\$\$ Norgestimate-Ethinyl Estradiol*	ORTHO-CYCLEN	<i>Females only</i>
\$\$ Norethindrone & Ethinyl Estrad FE*	FEMCON FE	<i>Females only</i>
\$\$ Norethindrone Ace-Ethinyl Estrad FE*	LOESTRIN FE	<i>Females only</i>
\$\$\$ Norelgestromin-Ethinyl Estradiol*	XULANE, ZAFEMY	<i>Females only</i>
<i>Biphasic</i>		
\$\$ Desogest-Eth Estrad & Eth Estrad	MIRCETTE	<i>Females only</i>
\$\$ Norethindrone-Mestranol	NORINYL, NECON	<i>Females only</i>
\$\$ Norethindrone-Ethinyl Estradiol FE	LO LOESTRIN FE	<i>Females only</i>
<i>Triphasic</i>		
\$\$ Desogest-Ethin Est*	CYCLESSA	<i>Females only</i>
\$\$ Levonorgestrel-Eth Estradiol*	TRIVORA	<i>Females only</i>
\$\$ Norethindrone-Ethinyl Estradiol*	ORTHO NOVUM 7/7/7	<i>Females only</i>
\$\$ Norgestimate-Ethinyl Estradiol*	ORTHO TRI-CYCLEN / LO	<i>Females only</i>
\$\$\$ Norethindrone Ac-Ethinyl Estrad FE*	ESTROSTEP FE	<i>Females only</i>
\$ Norethindrone-Ethinyl Estradiol*	NYLIA 7/7/7	<i>Females only</i>
\$\$ Norethindrone-Ethinyl Estradiol*	TRI-NYMYO	<i>Females only</i>
<i>Four Phase</i>		
\$\$ Estradiol Valerate-Dienogest	NATAZIA	<i>Females only</i>
<i>Extended</i>		
\$\$ Levonorgestrel-Ethinyl Estradiol*	SEASONIQUE, QUARTETTE, LOSEASONIQUE	<i>Females only</i>
<i>Continuous</i>		
\$\$ Levonorgestrel-Ethinyl Estradiol	AMETHYST	<i>Females only</i>
<b><u>PROGESTINS</u></b>		
\$ Medroxyprogesterone*	PROVERA	<i>Tabs only / females only</i>
\$\$\$ Medroxyprogesterone Acetate	DEPO-PROVERA, DEPO-SQ PROVERA 104	<i>Females only</i>
\$ Norethindrone Acetate*	AYGESTIN	<i>Females only</i>
<b><u>EMERGENCY CONTRACEPTIVE</u></b>		
\$\$ Levonorgestrel*	PLAN B ONE STEP PLAN B	<i>1 kit / month; 3 kits / yr Females only No prescription required for OTC formulation</i>

**MC-Rx/Jai Medical Systems Therapeutic Formulary**

<u>Generic Name</u>	<u>Brand Name</u>	<u>Annotation</u>
<b>ANTIDIABETIC</b>		
<i>Thiazolidinediones/Combination</i>		
\$\$\$\$ Pioglitazone*	ACTOS	QL = 30 tabs / month
\$\$\$\$ Pioglitazone-Glimepiride*	DUETACT	QL = 30 tabs / month
\$\$\$ Pioglitazone-Metformin*	ACTOPLUS MET	QL = 30 tabs / month
\$\$\$\$ Pioglitazone-Metformin SR	ACTOPLUS MET XR	QL = 30 tabs / month
<i>Human Insulin</i>		
\$ Insulin Aspart	NOVOLOG, FIASP, NOVOLOG 50-50	
\$ Insulin Isophane	HUMULIN N, NOVOLIN N	
\$ Insulin Reg & Isophane	HUMULIN 50/50	
\$ Insulin Reg & NPH	HUMULIN 70/30, NOVOLIN 70/30	
\$ Insulin Regular	HUMULIN R, NOVOLIN R	
\$ Insulin Lispro	HUMALOG, ADMELOG	
\$ Insulin Glargine	TOUJEO, BASAGLAR	
\$\$ Insulin Glargine-aglr	REZVOGLAR	
\$\$\$ Insulin Glargine-yfgn	INSULIN GLARGINE-YFGN	
<i>Sulfonylureas</i>		
\$\$ Glimepiride	AMARYL	
\$\$ Glipizide	GLUCOTROL/XL	
\$\$ Glyburide	DIABETA, GLYNASE	
<i>Alpha-Glucosidase Inhibitors</i>		
\$\$\$\$ Acarbose*	PRECOSE	QL = 90 tabs / month
<b>Prior Authorization Required</b>		
<i>Dipeptidyl Peptidase-4 inhibitors</i>		
\$\$\$\$ Sitagliptin Phosphate	JANUVIA	Step Therapy
\$\$\$\$ Alogliptin	NESINA	Step Therapy
<i>Incretin Mimetic</i>		
\$\$\$\$ Exenatide	BYDUREON	
\$\$\$\$ Liraglutide	VICTOZA	
\$\$\$\$ Dulaglutide	TRULICITY	Brand Only
<b>Prior Authorization Required</b>		
<i>Sodium-Glucose Cotransporter 2 Inhibitors</i>		
\$\$\$\$ Dapagliflozin	FARXIGA	
\$\$\$\$ Empagliflozin	JARDIANCE	
<b>Prior Authorization Required</b>		
<i>Meglitinides</i>		
\$\$\$\$ Repaglinide	PRANDIN	
<b>Prior Authorization Required</b>		
<i>Diabetic Other</i>		
\$ Metformin*	GLUCOPHAGE	
\$ Metformin Extended Release	GLUCOPHAGE XR	
\$\$\$\$ Glucagon	GLUCAGON EMERGENCY KIT	
\$\$\$\$ Empagliflozin/linagliptin	GLYXAMBI	
<b>Prior Authorization Required</b>		
<b>THYROID</b>		
<i>Thyroid Hormones</i>		
\$ Levothyroxine*	LEVOXYL, SYNTHROID, THYQUIDITY	
\$ Liothyronine*	CYTOMEL	
\$ Thyroid*	THYROID	
<i>Antithyroid Agents</i>		
\$ Methimazole*	TAPAZOLE	
\$ Propylthiouracil*	PROPYLTHIOURACIL	
<b>OXYTOCICS</b>		
\$ Methylergonovine*	METHERGINE	
<b>MISC. ENDOCRINE</b>		
<i>Calcium Regulators</i>		
\$\$\$ Calcitonin (Salmon)	MIACALCIN INJ	
\$\$\$ Calcitonin (Salmon)*	MIACALCIN NASAL	
<b>Prior Authorization Required</b>		

**MC-Rx/Jai Medical Systems Therapeutic Formulary**

<u>Generic Name</u>	<u>Brand Name</u>	<u>Annotation</u>
<i>Hormone Receptor Modulators</i>		
\$\$\$\$ Raloxifene*	EVISTA	
<b>Prior Authorization Required</b>		
<i>Gonadotropin Releasing Hormones</i>		
\$\$\$\$ Nafarelin	SYNAREL	
<b>Prior Authorization Required</b>		
<i>Growth Hormone</i>		
\$\$\$\$ Somatropin	HUMATROPE ONLY	
<b>Prior Authorization Required</b>		
<i>Posterior Pituitary</i>		
\$\$\$ Alendronate*	FOSAMAX	
\$\$\$ Alendronate + Cholecalciferol	FOSAMAX PLUS D	
\$\$\$ Ibandronate*	BONIVA	
\$\$\$ Risedronate	ACTONEL	
\$\$\$\$ Desmopressin*	DDAVP	(all dosage forms)
<b>Prior Authorization Required</b>		
<i>Parathyroid Hormone</i>		
\$\$\$\$ Teriparatide	FORTEO	

**IV. CARDIOVASCULAR AGENTS**

**CARDIOTONICS**

<i>Digitalis</i>		
\$ Digoxin*	LANOXIN	no caps
<i>PED Inhibitors</i>		
\$\$\$\$ Sildenafil Citrate	REVATIO	20mg tablets and 10mg/mL liquid
<b>Prior Authorization Required</b>		

**ANTIANGINAL AGENTS**

<i>Nitrates</i>		
\$ Isosorbide Dinitrate*	ISORDIL, ISORDIL TEMBIDS	5mg, 10mg, 20mg, 30mg
\$ Nitroglycerin (oral)*	NITROSTAT	
\$\$\$ Nitroglycerin (topical)*	NITRODUR, NITROBID	
\$\$ Isosorbide Mononitrate*	IMDUR	
<i>Antianginals-Other</i>		
\$ Dipyridamole*	PERSANTINE	

**BETA BLOCKERS**

<i>Beta Blockers Non-Selective</i>		
\$ Propranolol*	INDERAL/LA	
\$ Timolol*	TIMOLOL	
\$ Betaxolol	BETAXOLOL	
\$\$\$ Sotalol*	BETAPACE	
\$\$\$ Carvedilol*	COREG	
<i>Beta Blockers Cardio-Selective</i>		
\$ Atenolol*	TENORMIN	
\$ Metoprolol Tartrate*	LOPRESSOR	
\$\$\$ Metoprolol Succinate*	TOPROL XL	
<i>Alpha-Beta Blockers</i>		
\$\$\$ Labetalol*	TRANDATE	

**CALCIUM BLOCKERS**

\$\$\$ Amlodipine*	NORVASC	
\$\$\$ Amlodipine & Benazepril*	LOTREL	
\$\$\$ Diltiazem*	CARDIZEM/CD, DILACOR/XR	
\$\$ Felodipine*	FELODIPINE	
\$\$\$ Nifedipine*	ADALAT CC, PROCARDIA XL	
\$\$ Verapamil*	CALAN, SR	

**MC-Rx/Jai Medical Systems Therapeutic Formulary**

<u>Generic Name</u>	<u>Brand Name</u>	<u>Annotation</u>
<b>ANTIARRHYTHMIC</b>		
\$\$\$ Amiodarone*	CORDARONE	
\$ Disopyramide*	NORPACE, CR	
\$\$\$ Flecainide*	TAMBOCOR	
\$ Procainamide*	PROCAINAMIDE	
\$ Quinidine Sulfate*	QUINIDINE SULFATE	
\$\$\$\$ Mexiletine*	MEXILETINE	
\$\$\$\$ Propafenone*	RYTHMOL	
<b>ANTIHYPERTENSIVE</b>		
<i>ACE Inhibitors</i>		
\$ Captopril*	CAPTOPRIL	
\$\$ Benazepril*	LOTENSIN	
\$\$ Enalapril*	VASOTEC	
\$\$ Fosinopril*	FOSINOPRIL	
\$\$ Lisinopril*	ZESTRIL	
\$\$ Quinapril*	ACCUPRIL	
\$\$ Ramipril*	ALTACE	
<i>ARBs</i>		
\$\$\$\$ Irbesartan*	AVAPRO	QL = 30 tabs / month
\$\$\$ Losartan potassium*	COZAAR	QL = 30 tabs / month
\$\$\$\$ Valsartan	DIOVAN	QL = 30 tabs / month
<b>Prior Authorization Required</b>		
<i>Adrenolytics - Central</i>		
\$ Clonidine*	CATAPRES	AL = 18 years and over; No patches
\$ Guanfacine*	TENEX	AL = 18 years and over
<i>**Please note, extended release clonidine (Kapvay) and extended release guanfacine (Intuniv) for children ages 6-17 are covered under the mental health benefit; outside of that age range would require prior authorization as a non-formulary medication.**</i>		
\$ Methyldopa*	METHYLDOPA	
<i>Adrenolytics - Peripheral</i>		
\$ Reserpine*	RESERPINE	
<i>Alpha Blockers</i>		
\$\$ Doxazosin*	CARDURA	
\$ Prazosin*	MINIPRESS	
\$\$\$\$ Tamsulosin*	FLOMAX	
\$\$\$ Terazosin*	TERAZOSIN	
<i>Vasodilators</i>		
\$ Hydralazine*	APRESOLINE	
\$ Minoxidil*	MINOXIDIL	Topical not covered
\$\$\$\$ Ambrisentan	LETAIRIS	
<b>Prior Authorization Required</b>		
<i>Beta Blocker Combinations</i>		
\$ Atenolol & Chlorthalidone*	TENORETIC	
\$\$\$ Metoprolol & HCTZ*	LOPRESSOR HCT	
\$ Propranolol & HCTZ*	PROPRANOLOL & HCTZ	no LA
<i>ACE and ACE II Inhibitors &amp; Diazides</i>		
\$\$\$\$ Irbesartan & HCTZ*	AVALIDE	QL = 30 tabs / month
\$\$ Lisinopril & HCTZ*	ZESTORETIC	
\$\$\$ Losartan potassium/HCTZ*	HYZAAR	QL = 30 tabs / month
\$\$\$\$ Valsartan & HCTZ*	DIOVAN HCT	QL = 30 tabs / month
<b>Prior Authorization Required</b>		
<i>Adrenolytics-Central &amp; Thiazides</i>		
\$ Methyldopa & HCTZ*	METHYLDOPA & HCTZ	
\$\$ Clonidine & Chlorthalidone*	CLOPRPRES	
<i>Vasodilators &amp; Thiazides</i>		
\$ Hydralazine & HCTZ*	HYDRALAZINE & HCTZ	
<b>DIURETICS</b>		
<i>Carbonic Anhydrase Inhibitors</i>		
\$ Acetazolamide*	DIAMOX	no sequels
\$\$\$ Methazolamide*	METHAZOLAMIDE	

**MC-Rx/Jai Medical Systems Therapeutic Formulary**

<u>Generic Name</u>	<u>Brand Name</u>	<u>Annotation</u>
<i>Loop Diuretics</i>		
\$ Furosemide*	LASIX	
<i>Potassium Sparing Diuretics</i>		
\$ Spironolactone*	ALDACTONE	
<i>Thiazides</i>		
\$ Chlorothiazide*	DIURIL	
\$ Chlorthalidone*	CHLORTHALIDONE	
\$ Hydrochlorothiazide*	HYDROCHLOROTHIAZIDE	
\$ Methyclothiazide*	METHYCLOTHIAZIDE	
\$ Metolazone*	ZAROXOLYN	
\$ Indapamide*	INDAPAMIDE	
<i>Combination Diuretics</i>		
\$ Spironolactone & HCTZ*	ALDACTAZIDE	
\$ Triamterene & HCTZ*	MAXZIDE	
<i>Osmotic Diuretics</i>		
\$ Glycerin Supp*	GLYCERIN	adult, infant, child
<b><u>PRESSORS</u></b>		
<i>Emergency Kits</i>		
\$\$\$\$ Epinephrine	EPI-PEN, EPI-PEN JR, ADRENACLICK	
<b><u>ANTHYPERLIPIDEMIC</u></b>		
<i>Bile Sequestrants</i>		
\$\$\$ Cholestyramine*	QUESTRAN, LIGHT	cans only
\$\$\$ Colestipol*	COLESTID	cans only
<i>Misc.</i>		
\$ Niacin*	NIACIN	OTC (slow release)
\$ Niacin CR*	NIASPAN	
\$\$\$\$ Ezetimibe	ZETIA	QL= 30/30 days
\$\$\$\$ Fenofibric Acid	FIBRICOR	35mg, 45mg, 105mg, 135mg; Step Therapy
\$\$\$ Fenofibrate tablets*	LOFIBRA	54mg and 160mg
\$\$\$ Fenofibrate*	TRICOR	48mg and 145mg
\$\$\$\$ Fenofibrate	LIPOFEN, TRIGLIDE	134mg and 200mg
\$\$\$\$ Fenofibrate micronized	ANTARA	134mg and 200mg
\$\$\$\$ Fenofibric acid*	TRILIPIX, FIBRICOR	Step Therapy; 35mg, 45mg, 105mg, 135mg
\$\$ Gemfibrozil*	LOPID	
\$\$\$\$ Omega-3-acid ethyl esters*	LOVAZA	
<i>HMG CoA Reductase Inhibitors</i>		
\$\$\$\$ Amlodipine & Atorvastatin*	CADUET	
\$\$\$\$ Atorvastatin*	LIPITOR	
\$\$\$\$ Fluvastatin*	LESCOL	
\$\$ Lovastatin*	MEVACOR	
\$\$\$\$ Niacin & Lovastatin	ADVICOR	
\$ Pravastatin*	PRAVACHOL	
\$\$\$\$ Niacin-Simvastatin	SIMCOR	
\$\$\$\$ Rosuvastatin Calcium	CRESTOR	
\$\$\$ Simvastatin*	ZOCOR	
\$\$\$\$ Sacubitril & Valsartan	ENTRESTO	
\$\$\$\$ Simvastatin*	ZOCOR	80mg only
\$\$\$\$ Ezetimibe + Simvastatin	VYTORIN	
<i>PCSK9 Inhibitors</i>		
\$\$\$\$ Evolocumab	REPATHA	140mg/ml
<b>Prior Authorization Required</b>		

**V. RESPIRATORY AGENTS**

**ANTIHISTAMINES**

<i>Antihistamines - Ethanolamines</i>		
\$ Diphenhydramine*	BENADRYL	OTC product

**MC-Rx/Jai Medical Systems Therapeutic Formulary**

<u>Generic Name</u>	<u>Brand Name</u>	<u>Annotation</u>
<i>Antihistamines - Non-Sedating</i>		
\$ Clemastine*	TAVIST	<i>Pediatric formulation</i>
\$\$ Loratadine*	ALAVERT, CLARITIN	<i>OTC product</i>
\$\$ Loratadine / Pseudoephedrine*	CLARITIN-D 12hr, 24hr	<i>OTC product</i>
\$\$ Cetirizine*	ZYRTEC	<i>chew tabs/liquid AL ≤ 18</i>
\$\$ Cetirizine tabs*	ZYRTEC	
\$\$ Fexofenadine*	ALLEGRA OTC, ALLEGRA SUSP,	<i>30 or 60 per 30 days</i>
	ALLEGRA ODT	
\$\$ Fexofenadine / Pseudoephedrine*	ALLEGRA-D OTC 12hr, 24hr	<i>30 or 60 per 30 days</i>
<i>Antihistamines - Phenothiazines</i>		
\$ Promethazine*	PROMETHAZINE	<i>tabs/liquid</i>
		<i>tabs only AL ≥ 2 years</i>

**SYSTEMIC AND TOPICAL NASAL PRODUCTS**

*Nasal Antihistamines*

\$\$\$\$ Azelastine*	ASTELIN	
<b>Prior Authorization Required</b>		

*Nasal Steroids*

\$\$ Flunisolide*	NASALIDE
\$\$ Triamcinolone*	NASACORT AQ
\$\$\$ Fluticasone*	FLONASE
\$\$\$\$ Mometasone furoate	NASONEX

*Mucolytics*

\$\$ Acetylcysteine*	MUCOMYST
----------------------	----------

**ANTI-ASTHMATIC**

*Anticholinergics*

\$\$ Ipratropium*	ATROVENT NASAL
\$\$\$ Ipratropium	ATROVENT HFA
\$\$\$ Tiotropium	SPIRIVA

\$\$\$\$ Acclidinium Bromide	TUDORZA PRESSAIR	<i>QL = 1 inh / 30 days</i>
<b>Prior Authorization Required</b>		

*Anti-Inflammatory Agents*

\$\$\$ Cromolyn (inhalation)*	INTAL
\$ Cromolyn (nasal)*	NASALCROM

\$\$\$\$ Omalizumab	XOLAIR
<b>Prior Authorization Required</b>	

*Beta Adrenergics*

\$\$ Albuterol	PROVENTIL HFA, VENTOLIN HFA, PROAIR HFA
----------------	--

\$\$ Albuterol*	ALBUTEROL NEBULIZER SOLUTION	<i>0.5% (5mg/mL) and 0.083% (2.5mg/3ml)</i>
-----------------	------------------------------	---

\$\$\$\$ Olodaterol	STRIVERDI
\$\$\$ Salmeterol	SEREVENT DISKUS
<b>Prior Authorization Required</b>	

*Adrenergic Combinations*

\$\$\$\$ Ipratropium-Albuterol	COMBIVENT RESPIMAT
\$\$\$\$ Albuterol-Ipratropium*	DUONEB
\$\$\$\$ Tiotropium-Olodaterol	STIOLTO

\$\$ Umeclidinium-Vilanterol	ANORO ELLIPTA	
\$\$\$ Salmeterol-Fluticasone	ADVAIR, ADVAIR HFA	
\$\$\$ Budesonide-Formoterol	SYMBICORT	<i>AL ≥ 6 years</i>
\$\$\$ Fluticasone-Umeclidinium-Vilanterol	TRELEGY	
<b>Prior Authorization Required</b>		

*Steroid Inhalants*

\$\$\$\$ Fluticasone	FLOVENT HFA
\$\$\$\$ Budesonide	PULMICORT FLEXHALER
\$\$\$\$ Budesonide*	PULMICORT RESPULES

\$\$\$\$ Beclomethasone Dipropionate	QVAR	<i>AL ≤ 4 years; QL = 1 box / 30 days</i>
--------------------------------------	------	---

*Sympathomimetic Agents*

\$ Pseudoephedrine HCL*	PSEUDOEPHEDRINE	<i>OTC product</i>
-------------------------	-----------------	--------------------

*Mixed Adrenergics*

\$\$\$\$ Epinephrine	EPI-PEN, EPI-PEN JR, ADRENAClick
----------------------	----------------------------------

**MC-Rx/Jai Medical Systems Therapeutic Formulary**

<u>Generic Name</u>	<u>Brand Name</u>	<u>Annotation</u>
<i>Xanthines</i>		
\$ Aminophylline*	AMINOPHYLLINE	
\$\$ Theophylline*	THEO-24, THEOCHRON	
<i>Leukotriene Receptor Antagonists</i>		
\$\$\$ Montelukast Sodium*	SINGULAIR	
<b><u>COUGH/COLD/ALLERGY</u></b>		
<i>Expectorants</i>		
\$ Guaifenesin*	GUAIFENESIN	OTC product
\$ Guaifenesin/DM*	GUAIFENESIN DM	OTC product
<i>Cough/Cold/Allergy Combinations</i>		
\$ Brompheniramine*	BROMPHENIRAMINE	Pediatric formulation
\$ Brompheniramine / Pseudoephedrine*	BROMPHENIRAMINE / PSEUDOEPHEDRINE	
\$ Chlorpheniramine*	CHLORPHENIRAMINE	Pediatric formulation
\$ Phenylephrine*	SUDAFED	Pediatric formulation
\$ Pseudoephedrine-Bromphen-DM*	PSEUDOEPHED-BROMPHEN DM	
\$ Pseudoephedrine-Chlorphen-DM*	PEDIA RELIEF LIQ COUGH/COLD	
\$ Pseudoephedrine-DM liquid*	TRIAMINIC AM LIQ CGH/DECON	
\$ Pseudoephedrine-DM soln*	PSEUDOEPHEDRINE-DM SOLN	
\$ GG/Codeine sol*	GUIATUSS AC	
\$ Benzonatate*	TESSALON, TESSALON PERLES	
\$\$ Pseudoephedrine-GG*	PSEUDO-G / PSI	
\$ Pseudoephedrine HCL*	PSEUDOEPHEDRINE	OTC product

**VI. GASTROINTESTINAL AGENTS**

**LAXATIVES**

<i>Osmotic Laxatives</i>		
\$ Polyethylene Glycol powder*	MIRALAX	
<i>Surfactant Laxatives</i>		
\$ Docusate Sodium*	COLACE	OTC product
<i>Stimulant Laxatives</i>		
\$ Bisacodyl*	DULCOLAX	OTC product / caps only
\$ Sennosides*	SENOKOT	OTC product
\$ Sennosides/Docusate*	SENNA-S	OTC product
<i>Bulk Laxatives</i>		
\$ Polycarbophil Calcium*	FIBERCON	OTC product
\$ Psyllium*	METAMUCIL	OTC product
<i>Miscellaneous Laxatives</i>		
\$ Glycerin*	GLYCERIN	OTC product
\$ Lactulose	LACTULOSE	
\$ Magnesium Citrate*	CITROMA	OTC product
\$ PEG-Electrolyte*	GOLYTELY	
\$\$ PEG350/SodSul/Nacl/Kcl/Asb/C*	MOVIPREP	
\$\$ PEG350/SodSul/Nacl/Kcl/Asb/C	PLENVU	
\$ PEG3350/SodSulf,Bicarb,Cl/Kcl	GAVILYTE - C, GAVILYTE - G	
\$\$ Sod Sulf/Pot Chloride/Mag Sulf	SUTAB	
\$\$\$ Sodium/Potassium/Mag Sulfates*	SUPREP	
\$\$\$\$ Lubiprostone	AMITIZA	
<b>Prior Authorization Required</b>		

**ANTIARRHEALS**

<i>Antiperistaltic Agents</i>		
\$ Diphenoxylate w/ Atropine*	LOMOTIL	
\$ Loperamide*	IMODIUM	OTC product
<i>Misc Antidiarrheal Agents</i>		
\$ Bismuth Subsalicylate*	PEPTO-BISMOL	no tabs, OTC
\$\$\$ Octreotide Acetate*	SANDOSTATIN	
<b>Prior Authorization Required</b>		

**ANTACIDS**

<i>Antacids - Aluminum Salts</i>		
\$ Aluminum Hydroxide Gel*	ALUMINUM HYDROXIDE	OTC product

**MC-Rx/Jai Medical Systems Therapeutic Formulary**

<u>Generic Name</u>	<u>Brand Name</u>	<u>Annotation</u>
<i>Antacids - Calcium Salts</i> \$ Calcium Carbonate*	OS-CAL	OTC product
<i>Antacid Combinations</i> \$ Al Hydrox-Mag Carb* \$ Aluminum & Magnesium Hydroxide*	MAALOX MYLANTA	no tabs, OTC no tabs, OTC
<b><u>ULCER DRUGS</u></b>		
<i>Belladonna Alkaloids</i> \$ Hyoscyamine Sulfate*	LEVSIN	tablets or SL only
<i>Quaternary Anticholinergics</i> \$ Propantheline Bromide*	PROPANTHELINE BROMIDE	
<i>Antispasmodics</i> \$ Dicyclomine*	BENTYL	
<i>H-2 Antagonists</i> \$ Famotidine* \$ Ranitidine*	PEPCID ZANTAC	tabs only no caps
<i>Proton Pump Inhibitors</i> \$ Esomeprazole Magnesium \$\$ Omeprazole* \$\$ Lansoprazole* \$\$\$ Lansoprazole* \$\$\$ Pantoprazole* \$\$\$\$ Lansoprazole*	NEXIUM 24 HR OTC PRILOSEC OTC PREVACID PREVACID (Generic) PROTONIX PREVACID SOLU-TAB	OTC OTC OTC RX
<b>Prior Authorization Required</b>		
<i>Misc. Anti-Ulcer</i> \$\$ Sucralfate*	CARAFATE TABLETS	
<b><u>ANTIEMETICS</u></b>		
<i>Antiemetics - Anticholinergic</i> \$ Meclizine* \$\$ Prochlorperazine*	MECLIZINE PROCHLORPERAZINE	no SR
<i>5-HT3 Receptor Antagonists</i> \$\$\$\$ Ondansetron* \$\$\$\$ Ondansetron Suspension*	ZOFRAN TABLETS, ZOFRAN ODT ZOFRAN SUSPENSION	QL = 10 tabs per fill QL = 50 mls per fill
<i>Neurokinin 1 Receptor</i> \$\$\$\$ Aprepitant	EMEND	
<b>Prior Authorization Required</b>		
<i>Other</i> Doxylamine Succinate/Pyridoxine HCL	DICLEGIS	QL= 40 / 10 days
<b><u>DIGESTIVE AIDS</u></b>		
<i>Digestive Aids - Mixtures</i> \$\$\$\$ Pancrelipase (Lip-Prot-Amyl) DR	CREON	
<b><u>MISC. GI</u></b>		
<i>GI Stimulants</i> \$ Metoclopramide*	REGLAN	no 5mg tabs
<i>Inflammatory Bowel Agents</i> \$\$\$\$ Mesalamine \$\$\$\$ Mesalamine* \$ Sulfasalazine*	PENTASA ROWASA AZULFIDINE	no EN tabs

**MC-Rx/Jai Medical Systems Therapeutic Formulary**

Generic Name

Brand Name

Annotation

**VII. GENITOURINARY**

**URINARY ANTIINFECTIVES**

\$ Methenamine Mandelate*	MANDELAMINE
\$\$\$ Nitrofurantoin*	FURADANTIN
\$\$ Nitrofurantoin Macrocrystals*	MACROBID
\$ Trimethoprim*	TRIMETHOPRIM

**URINARY ANTISPASMODICS**

\$ Bethanechol*	URECHOLINE	
\$\$\$ Finasteride*	PROSCAR	
\$\$\$ Flavoxate*	FLAVOXATE	
\$ Hyoscyamine*	LEVSINEX	
\$ Oxybutynin*	DITROPAN	
\$ Oxybutynin ER*	DITROPAN XL	QL = 30/30 days
\$\$\$\$ Tolterodine Tartrate	DETROL	Step Therapy
\$\$\$\$ Fesoterodine Fumarate	TOVIAZ	Step Therapy
\$\$\$\$ Trospium*	TROSPIUM	Step Therapy
\$\$\$\$ Solifenacin	VESICARE	Step Therapy
\$\$\$\$ Darifenacin Hydrobromide	ENABLEX	
\$\$\$\$ Mirabergon	MYRBETRIQ	

**Prior Authorization Required**

**VAGINAL PRODUCTS**

*Vaginal Antiinfectives*

\$\$ Clindamycin*	CLEOCIN
\$ Nystatin*	NYSTATIN
\$\$ Sulfanilamide	AVC
\$\$ Metronidazole*	METROGEL-VAGINAL

**Prior Authorization Required**

*Imidazole-Related Antifungals*

\$ Butoconazole Nitrate*	GYNAZOLE-1	OTC product
\$ Clotrimazole Vag*	MYCELEX	OTC product
\$ Miconazole*	MONISTAT	OTC product

*Vaginal Antiinfective Combinations*

\$ Triple Sulfas Vaginal*	TRIPLE SULFAS VAGINAL
---------------------------	-----------------------

**MISCELLANEOUS GENITOURINARY PRODUCTS**

*Citrates*

\$ Sodium Citrate & Citric Acid*	ORACIT
----------------------------------	--------

*Urinary Analgesics*

\$ Phenazopyridine*	PYRIDIUM
---------------------	----------

**VIII. CENTRAL NERVOUS SYSTEM DRUGS**

**ANTIPSYCHOTICS**

*Phenothiazines*

\$\$ Prochlorperazine*	PROCHLORPERAZINE	no SR
------------------------	------------------	-------

**HYPNOTICS**

*Barbiturate Hypnotics*

\$ Butabarbital	BUTISOL
\$ Mephobarbital	MEBARAL
\$ Phenobarbital*	PHENOBARBITAL

*Antihistamine Hypnotics*

\$ Diphenhydramine*	BENADRYL	OTC product
---------------------	----------	-------------

**MC-Rx/Jai Medical Systems Therapeutic Formulary**

Generic Name

Brand Name

Annotation

**IX. ANALGESICS & ANESTHETICS**

**ANALGESICS - NonNarcotic**

*Salicylates*

\$ Aspirin zero order\*  
 \$\$ Salsalate\*

ZORPRIN  
 DISALCID

*Salicylate Combinations*

\$ Aspirin Enteric Coated\*  
 \$ Aspirin with Buffers\*  
 \$\$ Choline & Mag Salicylate\*

ECOTRIN  
 ASPIRIN BUFFERED  
 CHOLINE & MAG SALICYLATE

OTC product  
 OTC product

*Analgesics Other*

\$ Acetaminophen\*

TYLENOL

OTC product

*Analgesics - Sedatives*

\$ Butalbital/APAP/Caffeine \*  
 \$ Butalbital/Aspirin/Caffeine\*

FIORICET  
 FIORINAL

50/325/40 mg only  
 50/325/40 mg only

**ANALGESICS - Narcotic**

**QUANTITY LIMITS APPLY TO ALL NARCOTIC ANALGESICS. PLEASE SEE WEBSITE FOR FULL LIST OF QUANTITY LIMITS: [jaimedicalsystems.com/providers/pharmacy](http://jaimedicalsystems.com/providers/pharmacy).**

**The initial fill of an opioid (initial fill = no opioid fills in the last 90 days) is limited to no more than a 7-day supply. After that it is limited to no more than 14-day supplies unless PA is approved.**

**\*\*PA required for methadone for pain and all extended-release opioid formulations and for quantities greater than 90 MME or to exceed quantity limits. Special PA forms are available at [jaimedicalsystems.com/providers/pharmacy](http://jaimedicalsystems.com/providers/pharmacy)\*\***

*Narcotic Agonists*

\$ Codeine Phosphate\*  
 \$ Codeine Sulfate\*  
 \$\$\$ Hydromorphone\*  
 \$ Meperidine\*  
 \$\$\$ Morphine Sulfate\*  
 \$\$\$ Oxycodone\*  
 \$\$\$ Oxycodone\*

CODEINE PHOSPHATE  
 CODEINE SULFATE  
 DILAUDID  
 DEMEROL  
 MORPHINE SULFATE  
 OXYCODONE  
 ROXICODONE

5mg caps  
 5mg, 10mg, 15mg, 30mg  
 tabs and 20mg/mL oral  
 soln

\$\$\$ Tramadol\*

ULTRAM

\$\$\$\$ Tramadol/APAP\*

ULTRACET

\$ Methadone*	METHADONE	Attestation PA only
\$\$\$ Morphine Sulfate SR*	MS CONTIN	Attestation PA only
\$\$\$\$ Tramadol ER*	ULTRAM ER	
\$\$\$\$ Fentanyl*	DURAGESIC	
\$\$\$\$ Oxycodone CR*	OXYCONTIN	

**Prior Authorization Required**

*Narcotic Combinations*

\$ Oxycodone w/ Acetaminophen\*

PERCOCET

5/500 tabs and caps;  
 5/325 tabs and soln

*Codeine Combinations*

\$ Acetaminophen w/ Codeine\*  
 \$ Acetaminophen w/ Codeine Sol\*

TYLENOL / CODEINE  
 ACETAMINOPHEN W / COD

120-12 mg / 5ml

*Hydrocodone Combinations*

\$\$ Hydrocodone w/ Acetaminophen\*  
 \$\$ Hydrocodone w/ Acetaminophen\*

VICODIN, LORTAB, NORCO  
 XODOL

5/325, 7.5/325, 10/325  
 5/300 mg tabs

**ANTI-RHEUMATIC**

*NSAID's*

\$\$ Diclofenac\*  
 \$\$ Etodolac\*  
 \$\$ Fenoprofen\*  
 \$\$\$ Flurbiprofen\*  
 \$ Ibuprofen\*  
 \$ Indomethacin\*  
 \$ Meloxicam\*  
 \$ Naproxen\*  
 \$ Naproxen Sodium\*  
 \$ Piroxicam\*  
 \$\$ Sulindac\*

VOLTAREN  
 ETODOLAC  
 NALFON  
 FLURBIPROFEN  
 MOTRIN  
 INDOCIN  
 MOBIC  
 NAPROSYN  
 ANAPROX  
 FELDENE  
 SULINDAC

no SR or supp.

no EC

**MC-Rx/Jai Medical Systems Therapeutic Formulary**

<u>Generic Name</u>	<u>Brand Name</u>	<u>Annotation</u>
COX-2 Inhibitor \$\$\$\$ Celecoxib	CELEBREX	QL = 60 caps / 30 days; Step Therapy
Anti-Rheumatic Antimetabolite \$\$\$\$ Methotrexate*	RHEUMATREX	

**GOUT**

\$ Allopurinol*	ZYLOPRIM	
\$\$\$\$ Colchicine	COLCRYS	
Uricosurics \$ Probenecid*	PROBENECID	

**LOCAL ANESTHETICS**

\$ Lidocaine*	LIDOCAINE	2% soln, 3%, 5% cream
Lidocaine/Prilocaine	EMLA	2.5/2.5%
\$\$\$\$ Lidocaine*	LIDODERMPATCHES	QL = 90 patches /30 days

**Prior Authorization Required**

**MIGRAINE PRODUCTS**

\$\$\$ Ergoloid mesylates*	HYDERGINE	
\$\$\$\$ Sumatriptan tablets*	IMITREX	QL = 9 tabs/30 days
\$\$\$\$ Sumatriptan injection*	IMITREX	QL = 2 injections/30 days
\$\$\$\$ Sumatriptan nasal*	IMITREX	QL = 6 sprays/30 days
\$\$\$\$ Sumatriptan-naproxen	TREXIMET	QL = 9 tabs/30 days
\$\$\$\$ Rizatriptan tablets*	MAXALT	QL = 6 tabs/30 days
\$\$\$\$ Zolmitriptan tablets*	ZOMIG	QL = 6 tabs/30 days, tabs only

**Prior Authorization Required**

**X. NEUROMUSCULAR AGENTS**

**ANTICONSULSANT**

Hydantoins \$\$ Phenytoin*	DILANTIN	
Succinimides \$\$ Ethosuximide*	ZARONTIN	
Miscellaneous Anticonvulsants \$\$\$ Primidone*	MYSOLINE	

**ANTIPARKINSONIAN**

*COMT Inhibitors*

\$\$\$ Entacapone*	COMTAN	
--------------------	--------	--

**Prior Authorization Required**

*Dopaminergic*

\$ Amantadine*	AMANTADINE	
\$\$\$ Bromocriptine*	PARLODEL	no postpartum use
\$\$ Ropinirole*	REQUIP	

**Prior Authorization Required**

*Levodopa Combinations*

\$\$\$ Carbidopa-Levodopa*	SINEMET, CR	no 100-25 CR
----------------------------	-------------	--------------

*Monoamine Oxidase Inhibitor*

\$\$\$\$ Selegiline*	ELDEPRYL	
----------------------	----------	--

**MUSCULOSKELETAL THERAPY AGENTS**

*Central Muscle Relaxants*

\$\$ Baclofen*	BACLOFEN	
\$ Cyclobenzaprine*	CYCLOBENZAPRINE	
\$ Methocarbamol*	ROBAXIN	

*Direct Muscle Relaxants*

\$\$\$\$ Dantrolene*	DANTRIUIM	
----------------------	-----------	--

**Prior Authorization Required**

**MC-Rx/Jai Medical Systems Therapeutic Formulary**

<u>Generic Name</u>	<u>Brand Name</u>	<u>Annotation</u>
<i>Fibromyalgia</i>		
\$\$\$\$ Milnacipran	SAVELLA	
<b>Prior Authorization Required</b>		
<i>Muscle Relaxant Combinations</i>		
\$ Methocarbamol w/ Aspirin*	METHOCARBAMOL w/ASA	

**ANTIMYASTHENIC AGENTS**

<i>Antimychasthenic Agents</i>		
\$\$\$ Pyridostigmine*	MESTINON	
<i>Benzothiazoles</i>		
\$\$\$\$ Riluzole*	RILUTEK	
<b>Prior Authorization Required</b>		

**XI. NUTRITIONAL PRODUCTS**

**VITAMINS**

<i>Water Soluble Vitamins</i>		
\$ Niacin*	NIACIN	
<i>Oil Soluble Vitamins</i>		
\$ Vitamin A*	VITAMIN A	
<i>Vitamin D</i>		
\$\$ Calcitriol*	ROCALTROL	<i>Vitamin D3</i>
\$\$ Ergocalciferol*	DRISDOL	<i>Vitamin D2</i>
\$\$ Cholecalciferol*	VITAMIN D3	
<i>Vitamin K</i>		
\$\$ Phytonadione	VITAMIN K	QL = 5 tabs / 30 days

**MULTIVITAMINS**

\$ Folic Acid & Vitamin B Complex*	NEPHROCAPS	
\$ Multiple Vitamin*	ONE-A-DAY	<i>OTC product</i>
\$ Multiple Vitamin w/ Minerals*	AP-ZEL, BACMIN, CENTRUM	
\$ Pediatric Vitamins*	PEDIATRIC VITAMINS	<i>OTC product</i>
\$ Pediatric Multivitamins*	POLY-VI-SOL	<i>up to 16 years only</i>
\$ Pediatric Multivitamins w/Iron*	POLY-VI-SOL / IRON	<i>up to 16 years only</i>
\$ Pediatric Multivitamins w/Fluoride*	TRI-VI-FLOR	<i>up to 16 years only</i>
\$ Pediatric Multivitamins w/Fluoride and Iron*	TRI-VI-FLOR / IRON	<i>up to 16 years only</i>
\$ Pediatric Vitamin ADC*	TRI-VI-SOL	<i>up to 16 years only</i>
\$ Pediatric Vitamin ADC w/Iron*	TRI-VI-SOL / IRON	<i>up to 16 years only</i>
\$ Prenatal MV & Min w/FE-FA*	PRENATAL-1	
\$ Prenatal Vitamins*	PRENATABS RX	

**CITRATES**

\$ Sodium Citrate & Citric Acid*	ORACIT	
----------------------------------	--------	--

**MINERALS & ELECTROLYTES**

<i>Calcium</i>		
\$ Calcium Acetate*	PHOSLO	<i>caps only</i>
\$ Calcium Carbonate*	OS-CAL	<i>OTC product</i>
<i>Fluoride</i>		
\$ Sodium Fluoride*	LURIDE	
<i>Potassium</i>		
\$ Potassium Chloride Capsule*	MICRO-K	
\$ Potassium Chloride Liquid*	POTASSIUM CHLORIDE LIQUID	
\$ Potassium Chloride Tablet*	KLOR-CON	
<i>Electrolyte Mixtures</i>		
\$ Oral Electrolytes Packets*	CERALYTE, CERASPORT	
\$ Oral Electrolytes*	PEDIALYTE	<i>OTC product</i>

**MC-Rx/Jai Medical Systems Therapeutic Formulary**

Generic Name

Brand Name

Annotation

**DIETARY PRODUCTS**

\$\$ Infant Foods	ENFAMIL / SIMILAC	OTC product
\$\$ Phenyl-Free*	PHENYL-FREE	OTC product

**MISCELLANEOUS NUTRITIONAL PRODUCTS**

\$\$ Nutritional Supplements ENSURE, PEDIASURE, BOOST, VIVONEX <b>Prior Authorization Required</b> For enteral access only. For members without enteral access, follow the DME process. (Nutritional Supplements are not limited to this list)
--

**XII. HEMATOLOGICAL AGENTS**

**HEMATOPOIETIC AGENTS**

*Cobalamines*

\$ Cyanocobalamin*	VITAMIN B-12	1,000mcg tabs only
\$ Folic Acid*	FOLIC ACID	
\$\$\$ Leucovorin Calcium*	LEUCOVORIN	
\$ Thiamine	THIAMINE	

\$ Cyanocobalamin* \$ Hydroxocobalamin* \$\$\$\$ Pegfilgrastim-pbbk \$\$\$\$ Filgastrim-Ayow VITAMIN B-12 HYDROXOCOBALAMIN FYLNETRA RELEUKO <b>Prior Authorization Required</b>	injection injection injection
---	-------------------------------------

*Iron*

\$ Ferrous Gluconate*	FERGON	OTC product
\$ Ferrous Sulfate*	FEOSOL	OTC product

*Hematopoietic Growth Factors*

\$\$\$\$ Darbepoetin <b>Prior Authorization Required</b>	ARANESP QL = 4 injections / month
---	--------------------------------------

*Erythropoietins*

\$\$\$\$ Epoetin Alfa <b>Prior Authorization Required</b>	EPOGEN 2,000U, 3,000U, 4,000U, 10,000U - QL = 12 injections / month; 20,000U, 40,000U - QL = 4 injections / month
--	--

**ANTICOAGULANTS**

*Coumarin Anticoagulants*

\$\$ Warfarin Sodium*	COUMADIN
-----------------------	----------

*Heparin Agents*

\$\$\$\$ Enoxaparin*	LOVENOX
\$\$\$\$ Apixaban	ELIQUIS
\$\$\$\$ Rivaroxaban	XARELTO

*Thrombin Inhibitors*

\$\$\$\$ Dabigatran	PRADAXA
---------------------	---------

**HEMOSTATICS**

*Hemostatics - Topical*

\$\$\$\$ Thrombin <b>Prior Authorization Required</b>	THROMBIN
--	----------

**MISC. HEMATOLOGICAL**

*Antihemophilic Products*

\$\$\$\$ Antihemophilic Factor (Human) \$\$\$\$ Antihemophilic Factor (Recombinate) \$\$\$\$ Antiinhibitor Coagulant Complex \$\$\$\$ Antithrombin III (Human) <b>Prior Authorization Required</b>	KOATE-DVI, HP, HEMOFIL M RECOMBINATE FEIBA VH THROMBATE III
--	--

**MC-Rx/Jai Medical Systems Therapeutic Formulary**

<u>Generic Name</u>	<u>Brand Name</u>	<u>Annotation</u>
<i>Platelet Aggregation Inhibitors</i>		
\$\$\$ Clopidogrel*	PLAVIX	
<i>Phosphodiesterase III Inhibitors</i>		
\$\$\$\$ Cilostazol	PLETAL	
<i>Hematorheological</i>		
\$\$ Pentoxifylline*	TRENTAL	
<b>Prior Authorization Required</b>		

**XIII. BEHAVIORAL HEALTHAGENTS**

**MISCELLANEOUS**

<i>Reversible Acetylcholinesterase inhibitor</i>		
\$\$\$\$ Donepezil*	ARICEPT	
\$\$\$\$ Galantamine*	RAZADYNE / RAZADYNE ER	
\$\$\$\$ Rivastigmine*	EXELON	
<b>Prior Authorization Required</b>		

<i>Miscellaneous</i>		
\$\$\$\$ Clonidine Extended Release*	KAPVAY	<i>Please refer to Introduction page I-5</i>
\$\$\$\$ Guanfacine Extended Release*	INTUNIV	
\$\$\$ Memantine	NAMENDA	
<b>Prior Authorization Required</b>		

**ANTICONVULSANT**

<i>Misc. Anticonvulsants</i>		
\$\$\$ Primidone*	MYSOLINE	

**XIV. TOPICAL AGENTS**

**OPHTHALMIC**

<i>Antibiotics</i>		
\$\$\$ Bacitracin*	AK-TRACIN	
\$\$\$ Ciprofloxacin*	CILOXAN	
\$ Erythromycin*	ROMYCIN	
\$ Gentamicin Sulfate*	GENTAK	
\$\$\$ Moxifloxacin Hydrochloride	VIGAMOX	<i>AL ≤ 18 years</i>
\$ Ofloxacin	OCUFLOX	
\$ Polymyxin B-Trimethoprim*	POLYTRIM	
\$\$\$ Gatifloxacin*	ZYMAXID	
<b>Prior Authorization Required</b>		

<i>Anti Allergic</i>		
\$ Ketotifen Fumarate Ophth Soln*	ZADITOR	
\$\$ Lodoxamide Tromethamine	ALOMIDE	<i>QL = 10 mls / 30 days</i>
\$\$\$ Olopatadine HCL Ophth soln 0.1%	PATANOL	<i>QL = 10 mls / 30 days</i>
\$\$\$\$ Olopatadine HCL Ophth soln 0.2%	PATADAY	<i>QL = 10 mls / 30 days</i>
\$\$\$\$ Azelastine 0.05% eye drops	(GENERIC) OPTIVAR	<i>QL = 12 mls / 30 days</i>

<i>Sulfonamides</i>		
\$ Sodium Sulfacetamide*	BLEPH-10	

<i>Antivirals</i>		
\$\$\$ Trifluridine*	VIROPTIC	

<i>Antiinfective Combinations</i>		
\$ Bacitracin-Polymyxin B*	POLYSPORIN	
\$ Neomycin-Bac Zn-Polymyxin*	NEOMYCIN-BAC ZN-POLYMIXIN	
\$ Neomycin-Polymy-Gramicidin*	NEOSPORIN	

<i>Beta-Blockers</i>		
\$\$\$\$ Betaxolol*	BETOPTIC, BETOPTIC S	
\$ Timolol*	BETIMOL, TIMOPTIC	<i>no XE</i>
\$ Dorzolamide HCL-Timolol Maleate*	COSOPT	

<i>Steroids</i>		
\$\$ Dexamethasone*	DEXAMETHASONE	
\$\$ Prednisolone Acetate*	PRED FORTE, MILD	

**MC-Rx/Jai Medical Systems Therapeutic Formulary**

<u>Generic Name</u>	<u>Brand Name</u>	<u>Annotation</u>
<i>Immunomodulators</i>		
\$\$\$\$ Cyclosporine	RESTASIS	
<b>Prior Authorization Required</b>		
<i>Steroid Combinations</i>		
\$ Bacitracin-Polymyxin-Neomycin-HC*	BACITRACIN-POLYMYXIN-NEOMYCIN-HC	
\$ Neomycin-Polymyxin-Dexamethasone*	MAXITROL	
\$\$ Tobramycin-Dexamethasone*	TOBRADEX	
\$\$\$ Neomycin-Polymyxin-HC*	CORTISPORIN	
\$\$\$ Sulfacetamide Sod-Prednisolone*	BLEPHAMIDE	
<i>Cycloplegics</i>		
\$ Atropine Sulfate*	ISOPTO ATROPINE	
<i>Decongestants</i>		
\$ Naphazoline*	NAPHAZOLINE	
\$\$ Phenylephrine*	MYDRIN	
<i>Ophthalmic NSAID's</i>		
\$ Diclofenac Sodium*	VOLTAREN	
\$\$ Flurbiprofen*	OCUFEN	
<i>Miotics - Direct Acting</i>		
\$ Pilocarpine*	ISOPTO-CARPINE	
\$\$ Brimonidine Tartrate	ALPHAGAN 0.2%, ALPHAGAN P 0.15%	<i>no Ocusert QL = 10 mls / 30 days</i>
<i>Prostaglandins</i>		
\$\$\$ Latanoprost*	XALATAN	
<i>Carbonic Anhydrase Inhibitors</i>		
\$\$ Dorzolamide*	TRUSOPT	
<b><u>OTIC</u></b>		
<i>Steroids</i>		
\$ Hydrocortisone w/Acetic Acid*	ACETASOL HC	<i>QL = 20 mls / 30 days</i>
<i>Antibiotics &amp; Steroid-Antibiotic Combinations</i>		
\$ Neomycin-Polymyxin-HC*	CORTISPORIN	<i>QL = 20 mls / 30 days</i>
<i>Antibiotics</i>		
\$\$\$ Ofloxacin*	OFLOXACIN	<i>QL = 20 mls / 30 days</i>
<i>Anti Infective</i>		
\$ Carbamide Peroxide*	DEBROX	
<i>Analgesic Combinations</i>		
\$ Benzocaine & Antipyrine*	A/B OTIC	
<b><u>MOUTH &amp; THROAT (Local)</u></b>		
<i>Antiinfectives - Throat</i>		
\$\$\$ Clotrimazole*	CLOTRIMAZOLE TROCHE	
\$ Nystatin*	NYSTATIN	
<b><u>ANORECTAL</u></b>		
<i>Rectal Steroids</i>		
\$ Hydrocortisone*	ANUSOL-HC	<i>2.5% cream</i>
\$\$ Hydrocortisone*	PROCTOCREAM	<i>2.5% cream</i>
<b><u>DERMATOLOGICAL</u></b>		
<i>Antibiotics - Topical</i>		
\$\$ Bacitracin*	BACITRACIN	<i>OTC product</i>
\$ Gentamicin Sulfate*	GENTAMICIN	
\$\$\$ Metronidazole*	METROGEL	
\$\$\$ Mupirocin*	BACTROBAN	
\$ Neomycin Sulfate*	NEOMYCIN	
<i>Antibiotic Mixtures Topical</i>		
\$ Neomycin-Bacitracin-Polymyxin*	NEOSPORIN	<i>OTC product</i>
<i>Antibiotic Steroid Combinations</i>		
\$\$ Neomycin-Polymyxin-HC*	CORTISPORIN	

**MC-Rx/Jai Medical Systems Therapeutic Formulary**

<u>Generic Name</u>	<u>Brand Name</u>	<u>Annotation</u>
<i>Imidazole-Related Antifungals (Topical)</i>		
\$\$ Clotrimazole Topical*	LOTRIMIN	OTC product
\$ Miconazole*	MONISTAT	OTC product
<i>Antifungals</i>		
\$ Nystatin*	NYSTATIN	no powder
<i>Antifungals - Topical Combinations</i>		
\$\$ Nystatin-Triamcinolone*	NYSTATIN-TRIAMCINOLONE	
<i>Antipsoriatics</i>		
\$\$\$\$ Calcipotriene*	DOVONEX	
\$\$\$\$ Ixekizumab	TALTZ	
\$\$\$\$ Risankizumab-Rzaa	SKYRIZI	
<b>Prior Authorization Required</b>		
<i>Antiseborrheic Products</i>		
\$ Sulfacetamide Sodium*	SULFACETAMIDE SODIUM	
<i>Burn Products</i>		
\$ Silver Sulfadiazine*	SILVADENE	
<i>Tar Products</i>		
\$ Coal Tar*	COAL TAR SHAMPOO	1% only
<i>Enzymes - Topical</i>		
\$\$\$ Collagenase	SANTYL	QL = 90g
<i>Keratolytics/Antimitotics</i>		
\$\$\$\$ Podofilox*	CONDYLOX	
\$\$\$\$ Urea*	KERALAC, UMECTA	
\$\$\$\$ Urea 45%*	URAMAXIN GEL 45%	
<i>Local Anesthetics - Topical</i>		
\$ Lidocaine viscous*	LIDOCAINE VISCOUS	
\$\$ Diclofenac*	VOLTAREN	1% gel
<i>Scabicides &amp; Pediculocides</i>		
\$ Lindane*	LINDANE	
\$\$ Permethrin*	ELIMITE	
\$\$ Permethrin*	NIX	OTC product
<i>Misc. Topical</i>		
\$\$ Ammonium Lactate*	LAC-HYDRIN	cream & lotion
\$\$\$ Fluorouracil*	EFUDEX	2% and 5% cream only
\$\$\$ Tacrolimus oint*	PROTOPIC	
\$\$\$ Pimecrolimus	ELIDEL	
\$\$\$\$ Dupilumab	DUPIXENT	
<b>Prior Authorization Required</b>		
<i>Antiviral Topical</i>		
\$\$\$\$ Acyclovir	ZOVIRAX	ointment & suspension
<b>Prior Authorization Required</b>		
<i>Corticosteroids - Topical</i>		
\$ Betamethasone Dipropionate*	BETAMETHASONE DIPROPIONATE	
\$ Betamethasone Valerate*	BETAMETHASONE VALERATE	
\$ Clobetasol Propionate*	TEMOVATE	
\$ Desonide*	DESOWEN	
\$ Fluocinonide*	FLUOCINONIDE	
\$ Fluocinonide Acetonide*	SYNALAR	
\$ Hydrocortisone*	HYDROCORTISONE	OTC product
\$ Triamcinolone Acetonide*	KENALOG	Topical and Injectable
\$ Triamcinolone Acetonide in Orabase*	TRIAM. ACET. IN ORABASE	
<i>Acne Products</i>		
\$ Benzoyl Peroxide*	BENZAC W	
\$\$ Tretinoin*	RETIN-A	AL ≤ 32; no Micro
\$\$\$ Adapalene*	DIFFERIN	AL ≤ 21; only Gel or Cream
<i>Acne Antibiotics</i>		
\$\$ Clindamycin Phosphate*	CLEOCIN	
\$\$ Erythromycin Gel*	ERYGEL	

**MC-Rx/Jai Medical Systems Therapeutic Formulary**

Generic Name

Brand Name

Annotation

**XV. MISCELLANEOUS PRODUCTS**

**ANTIDOTES**

\$ Ipecac*	IPECAC	OTC product
\$ Charcoal Activated	CHARCOCAPS	OTC product

**DIAGNOSTIC PRODUCTS**

*Diagnostic Reagents*

\$ Acetone Tablets	ACETEST
\$ Acetone Test*	KETOSTIX
\$ Glucose Urine Test*	CLINITEST
\$\$ Glucose Blood*	GLUCOSE BLOOD

**MEDICAL DEVICES**

*Parenteral Therapy Supplies*

\$ Disposable Needles & Syringes*	B-D INSULIN SYRINGE
\$ Insulin Pen Needles	Insulin Pen Needles

*Diabetic Supplies*

\$\$\$ Blood Glucose Monitoring Tests*	GLUCOMETER	Contour, Contour Next, and Contour Next EZ
\$ Calibration Solution*	CALIBRATION SOLUTION	
\$ Lancet Device	GLUCOLET / AUTOLET	
\$ Lancets*	LANCETS	

\$\$\$\$ Blood Glucose Monitor Test	FREESTYLE LIBRE
<b>Prior Authorization Required</b>	

*Misc. Devices*

\$ Alcohol Swabs*	ALCOHOL PADS	
Spacer	OPTICHAMBER	QL = 1 / 180 days

*\*\*Only specific Optichamber devices covered under pharmacy benefit; Other brands may be available under DME benefit with PCP referral\*\**

**CONTRACEPTIVES**

\$ Condoms		*prescription not required for latex condoms
------------	--	--

**ASSORTED CLASSES**

*Chelating Agents*

\$\$\$\$ Penicillamine	CUPRIMINE
\$\$\$\$ Succimer	CHEMET

<b>Prior Authorization Required</b>	
-------------------------------------	--

*Immunosuppressive Agents*

\$\$\$\$ Cyclosporine Microsize*	NEORAL
\$\$\$\$ Sirolimus*	RAPAMUNE
\$\$\$\$ Tacrolimus*	PROGRAF

*Inosine Monophosphate Dehydrogenase Inhibitors*

\$\$\$\$ Mycophenolate Mofetil*	CELLCEPT
\$\$\$\$ Mycophenolate Sodium*	MYFORTIC

*Multiple Sclerosis – Adjuvants*

\$\$\$\$ Teriflunomide	AUBAGIO	
\$\$\$\$ Dimethyl Fumarate	TECFIDERA	QL = 60 tabs / 30 days
\$\$\$\$ Dalfampridine	AMPYRA	QL = 60 tabs / 30 days
\$\$\$\$ Interferon Beta-1a	AVONEX	QL = 60 tabs / 30 days
\$\$\$\$ Glatiramer Acetate	COPAXONE	QL = 60 tabs / 30 days
\$\$\$\$ Interferon Beta-1a	REBIF	QL = 60 tabs / 30 days
\$\$\$\$ Interferon Beta-1b	BETASERON	QL = 60 tabs / 30 days
<b>Prior Authorization Required</b>		

*Purine Analogs*

\$\$\$ Azathioprine*	IMURAN
----------------------	--------

*K Removing Resin*

\$\$\$\$ Sodium Polystyrene Sulfonate*	KAYEXALATE
--	------------

**MC-Rx/Jai Medical Systems Therapeutic Formulary**

*Rheumatology Biologics*

\$\$\$\$ Adalimumab-adaz, -bwwd	HADLIMA, UNBRANDED HYRIMOZ
\$\$\$\$ Etanercept	ENBREL
<b>Prior Authorization Required</b>	

*Janus Kinase (JAK) Inhibitors*

\$\$\$\$ Upadacitinib	RINVOQ
<b>Prior Authorization Required</b>	

## Prior Authorization Guidelines

**GENERIC:** ACARBOSE

**BRAND:** PRECOSE<sup>®</sup>

**INDICATION:**

- (1) Type 2 diabetes mellitus

**Criteria:**

- (a) Failure of maximal doses of *one* oral sulfonylurea (e.g., glyburide 20mg daily or equivalent). Failure is defined as Hemoglobin A1c > 7.0.

**GENERIC:** ACLIDINIUM BROMIDE AEROSOL POWDER

**BRAND:** TUDORZA PRESSAIR<sup>®</sup>

**INDICATION:**

- (1) Long-term maintenance treatment of bronchospasm associated with COPD (including bronchitis and emphysema)

**Criteria:**

- (a) Diagnosis of COPD **and**
- (b) Must be greater than 18 years of age **and**
- (c) Documented inadequate response or intolerance to Spiriva

**GENERIC:** ACYCLOVIR TOPICAL OINTMENT/SUSPENSION

**BRAND:** ZOVIRAX<sup>®</sup> 5%

**INDICATIONS:**

- (1) Herpes genitalis
- (2) Oral herpes infection

**Criteria:**

- (a) Herpes genitalis – for initial episode only; **or**
- (b) Oral herpes infection – for immunocompromised patients *only*.

**Additional Criteria for Suspension:**

- (c) Patient is <17 years of age; **or**
- (d) Unable to ingest solid dosage form (e.g. capsules) due to dysphagia

**GENERIC:** ADALIMUMAB-BWWD, ADALIMUMAB-ADAZ

**BRAND:** HADLIMA<sup>®</sup>, HYRIMOZ<sup>®</sup> (UNBRANDED)

**INDICATIONS:**

- (1) Moderate to severely active rheumatoid arthritis (RA)
- (2) Moderately to severely Active Polyarticular Juvenile Idiopathic Arthritis (JIA)
- (3) Psoriatic arthritis (PsA)
- (4) Ankylosing spondylitis (AS)
- (5) Moderate to severely active Crohn's disease (CD)
- (6) Moderately to Severely Active Ulcerative Colitis (UC)
- (7) Moderately to Severely Active Plaque Psoriasis (Ps)
- (8) Moderately to Severely Active Hidradenitis Suppurativa (HS)
- (9) Uveitis

**Criteria:**

- (a) The patient had a NEGATIVE tuberculin skin test, or if positive, has received treatment for latent TB prior to therapy; **and**
- (b) The patient does not have a clinically important active infection

**Additional Criteria for RA, JIA, and PsA:**

- (c) The patient has failed or is intolerant to one formulary NSAID **and**

## **Prior Authorization Guidelines**

(d) The patient has failed or is intolerant to one formulary DMARD

### **Additional Criteria for AS:**

(c) Physician documents that patient failed treatment with at least two NSAIDs for at least three months, except if NSAIDs are contraindicated or if patient has presented toxicity or intolerance.

### **Additional Criteria for CD and UC:**

(c) The patient has failed or is intolerant to infliximab; or

(d) The patient has failed or is intolerant to mesalamine or sulfasalazine; and

(e) The patient has failed or is intolerant to corticosteroids; and

(f) The patient has failed or is intolerant to an immunomodulator (e.g., methotrexate, 6-mercaptopurine or azathioprine)

### **Additional Criteria for Ps**

(c) Document that the patient has an incomplete response or intolerance or contraindicated to one appropriate systemic agent (ex: MTX, cyclosporine, acitretin) or phototherapy or biologic agents.

### **Additional Criteria for Hs**

(c) Documentation of evidence failure with the previous treatment including antibiotics, hormonal therapies or oral retinoid at least for 90 days.

### **GENERIC: ALOGLIPTIN**

#### **Step Therapy Criteria:**

Recent trial of metformin or sulfonylurea or thiazolidinedione - Cumulative days' supply for more than sixty (60) days within the last one-hundred and eighty (180) days with at least one (1) cumulative fill.

### **GENERIC: AMBRISENTAN**

#### **INDICATION:**

(1) Indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1)

#### **Criteria:**

(a) Documentation of pulmonary arterial hypertension (PAH) (WHO Group 1)

### **GENERIC: ANTIHEMOPHILIC FACTORS**

**BRAND:** KOATE-DVI<sup>®</sup>, FEIBA VH<sup>®</sup>, RECOMBINATE<sup>®</sup>, THROMBATE III<sup>®</sup>

#### **INDICATION:**

(2) Hemophilia A

#### **Criteria:**

(a) Diagnosis of Hemophilia A

### **GENERIC: APREPITANT**

**BRAND:** EMEND<sup>®</sup>

#### **INDICATION:**

(1) Nausea and vomiting

#### **Criteria:**

(a) For the prevention of post-operative nausea and vomiting; **or**

(b) For the prevention of chemotherapy-induced nausea and vomiting

## Prior Authorization Guidelines

**GENERIC:** AZELASTINE NASAL SPRAY

**BRAND:** ASTELIN<sup>®</sup>

**INDICATIONS:**

- (1) Perennial allergic rhinitis
- (2) Seasonal allergic rhinitis

**Criteria:**

- (a) Patient is  $\geq 5$  years of age with one of the above diagnoses; **and**
- (b) Failure of at least one formulary nasal steroid after a period of at least two months on the maximum dose appropriate and tolerated by the patient

**GENERIC:** BUDESONIDE/FORMOTEROL

**BRAND:** SYMBICORT<sup>®</sup>

**INDICATION:**

- (1) Maintenance treatment of asthma in patients 6 years of age and older
- (2) Maintenance Treatment of Chronic Obstructive Pulmonary Disease

**Criteria:**

**Criteria for Asthma:**

- (a) Currently on, but not controlled by an inhaled corticosteroid for more than sixty (60) days; **and**
- (b) The patient must be reevaluated after 6 months

**Criteria for COPD:**

- (a) Currently on, but not controlled by a LAMA for more than sixty (60) days; **and**
- (b) The patient must be reevaluated after 6 months

\* *For members currently with an approved prior authorization for Symbicort, claims will process as long as the member has filled Symbicort within the last 4 months. No yearly renewal will be needed for compliant members. Prior authorization will be required for members new to the plan, new to Symbicort therapy or with no claims history of Symbicort within the last 4 months. Once approved, 90-day supplies are allowed.*

**GENERIC:** CALCITONIN-SALMON

**BRAND:** MIACALCIN<sup>®</sup>

**INDICATIONS:**

- (1) Mild to moderate Paget's disease of bone
- (2) Osteoporosis

**Criteria:**

- (a) Failure, contraindication or intolerance to adequate trial of oral bisphosphonate; **and**
- (b) One of the following:
  - (1) Bone density measurement  $\geq 2.5$  standard deviations below the mean for normal, young adults of same gender (T-score  $\leq -2.5$ ); **or**
  - (2) History of an osteoporotic vertebral fracture; **or**
  - (3) Postmenopausal woman with low bone mineral density defined by T-score between -2.0 and -2.5 AND one of the following risk factors for fracture:
    - (a) Thinness or low body mass index defined by weight  $< 127$  lb (57.7 kg) or BMI  $< 21$  kg/m<sup>2</sup>
    - (b) History of fragility fracture since menopause
    - (c) History of hip fracture in a parent
  - (4) Diagnosis of Paget's disease of bone
- (c) Patients receiving glucocorticoids in daily dosages of  $> 7.5$ mg prednisone daily (see table) AND who have bone density measurement  $> 1$  standard deviations below the mean for normal, young adults of same gender (T-score  $< -1.0$ )

## Prior Authorization Guidelines

<b>Glucocorticoid Potency Equivalencies</b>			
<b>Glucocorticoid</b>	<b>Approximate equivalent dose (mg)</b>	<b>Relative anti-inflammatory (glucocorticoid) potency</b>	<b>Relative mineralocorticoid potency</b>
<i>Short-acting</i>			
Cortisone	25	0.8	2
Hydrocortisone	20	1	2
<i>Intermediate-acting</i>			
Prednisone	5	4	1
Prednisolone	5	4	1
Triamcinolone	4	5	0
Methylprednisolone	4	5	0
<i>Long-acting</i>			
Dexamethasone	0.75	20-30	0
Betamethasone	0.6-0.75	20-30	0

Table adapted from Facts and Comparisons® 1999:122

\* For injectable medications administered by a healthcare professional, please refer to the “Specialty Medication Guidelines” in the beginning of this formulary.

\* If documentation of osteoporosis is available, please submit with PA request.

**GENERIC:** CELECOXIB

**BRAND:** CELEBREX®

**Step Therapy Criteria:**

Single trial of at least 7 days of NSAIDs in the past 30 days

**GENERIC:** CYANOCOBALAMIN (HYDROXOCOBALAMIN)

**BRAND:** VITAMIN B-12®

**INDICATION:**

(1) Vitamin B-12 deficiency

**Criteria:**

- (a) Patients who lack intrinsic factor; **or**
- (b) Patients who are on long-term PPI therapy; **or**
- (c) Patients with a partial or complete gastrectomy.

\* For injectable medications administered by a healthcare professional, please refer to the “Specialty Medication Guidelines” in the beginning of this formulary.

**GENERIC:** CYCLOSPORINE OPHTHALMIC EMULSION 0.05%

**BRAND:** RESTASIS

**INDICATION:**

(1) Increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca

**Criteria:**

- (a) Failure of, intolerance to, contraindication, or previous use to artificial tears, or equivalent

## **Prior Authorization Guidelines**

**GENERIC:** DALFAMPRIDINE

**BRAND:** AMPYRA<sup>®</sup>

**INDICATION:**

(1) Improved walking speed in patients with multiple sclerosis

**Criteria:**

- (a) Diagnosis of multiple sclerosis; **and**
- (b) Prescribed by a neurologist; **and**

**GENERIC:** DANTROLENE

**BRAND:** DANTRIUUM<sup>®</sup>

**INDICATION:**

(1) Spasticity resulting from upper motor neuron disorders

**Criteria:**

- (a) Demonstrated failure of, or intolerance to, Baclofen (Lioresal<sup>®</sup>).

**GENERIC:** DAPAGLIFLOZIN

**BRAND:** FARXIGA<sup>®</sup>

**INDICATION:**

- (1) Type 2 diabetes mellitus
- (2) To reduce the risk of hospitalization and/or death for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors or heart failure with reduced ejection fraction (NYHA class II-IV).
- (3) To reduce the risk of sustained eGFR decline, end stage kidney disease, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease at risk of progression.

**Criteria for Type 2 diabetes mellitus:**

- (a) Diagnosis of Type 2 diabetes mellitus
- (b) Has not achieved adequate glycemic control on the following:
  - (1) Metformin (alone or in combination)

**Criteria for heart failure:**

- (a) Diagnosis of heart failure with reduced ejection fraction.
- (b) Has not achieved adequate symptom control with the following:
  - (1) ACE/ARB or ARNI, and
  - (2) Beta Blocker

**Criteria for Chronic Kidney Disease:**

- (a) Diagnosis of Chronic Kidney Disease
- (b) Has not achieved adequate symptom control with the following:
  - (1) ACE/ARB,
- (c) NOT on dialysis

**GENERIC:** DARBEPOETIN ALFA

**BRAND:** ARANESP<sup>®</sup>

**INDICATIONS:**

- (1) Anemia with cancer chemotherapy (nonmyeloid)
- (2) Anemia due to chronic renal failure

**Criteria:**

- (a) Ensure patient's iron stores are adequate (Ferritin  $\geq$  100 ng/mL and/or Transferrin saturation  $\geq$  20%) or patient is being treated with iron; **and**
- (b) Adequate blood pressure control; **and**

**Chronic kidney disease patients:**

- (a) Initiate treatment when hemoglobin is  $<$ 10g/dL; **or**

**Anemia due to chemotherapy in cancer:**

- (a) Initiate treatment only if hemoglobin is  $<$ 10g/dL; **and**

## **Prior Authorization Guidelines**

(b) Anticipated duration of myelosuppressive chemotherapy is  $\geq 2$  months

### **For renewals:**

(a) **Chronic kidney disease patients:**

- (1) With dialysis Hbg <11; **or**
- (2) Without dialysis Hbg <10

(b) **Anemia due to chemotherapy in cancer patients:**

- (1) Hbg <11

**GENERIC:** DARIFENACIN

**BRAND:** ENABLEX<sup>®</sup>

### **INDICATION:**

- (1) Overactive bladder

### **Criteria:**

- (a) Failure of Oxybutynin

**GENERIC:** DESMOPRESSIN

**BRAND:** DDAVP<sup>®</sup>

### **INDICATIONS:**

- (1) Central cranial diabetes insipidus (CCDI)
- (2) Primary nocturnal enuresis

### **Criteria:**

- (a) Diagnosis of CCDI; **or**
- (b) For the treatment of enuresis, age 6 to 18 years; **and**
- (c) Failure of behavior modification for 6 months (e.g., alarms, no beverages after 5pm, special diapers, etc.)

*\* Renewals for the indication of nocturnal enuresis will require the documentation of a retrial of behavior modification.*

**GENERIC:** DIMETHYL FUMERATE

**BRAND:** TECFIDERA<sup>®</sup>

### **INDICATION:**

- (1) Diagnosis of a relapsing form of Multiple Sclerosis

### **Criteria:**

- (a) Prescribed by neurologist, and
- (b) Not requesting combination of any 2 agents together: Copaxone, Betaseron, Avonex, Tysabri, Gilenya, Aubagio or Tecfidera.

**GENERIC:** DONEPEZIL

**BRAND:** ARICEPT<sup>®</sup>

### **INDICATION:**

- (1) Alzheimer's disease: for the treatment of dementia.

### **Criteria:**

- (a) Dementia must be confirmed by clinical evaluation

**GENERIC:** DULAGLUTIDE

**BRAND:** TRULICITY<sup>®</sup>

### **INDICATION:**

- (1) Adjunct to diet and exercise to improve glycemic control in patients with type II diabetes mellitus

## **Prior Authorization Guidelines**

- (2) To reduce the risk of major adverse cardiovascular events in adults with type II diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors

### **Criteria:**

- (a) Diagnosis of type II diabetes mellitus; **and**  
(b) Must have tried at least 2 antidiabetic agents such as metformin, sulfonylureas, thiazolidinedione or insulin and not achieved adequate glycemic control despite treatment or intolerant to other antidiabetic medications

**GENERIC:** DUPIUMAB

**BRAND:** DUPIXENT<sup>®</sup>

### **INDICATION:**

- (1) Treatment of pediatric patients 6 months and older, who have had an inadequate response or intolerance to topical drug products, with active atopic dermatitis (AD).  
(2) Treatment of pediatric patients 6 years and older, characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma, with moderate-to-severe asthma.  
(3) Treatment of adult patients, as an add-on maintenance treatment, chronic rhinosinusitis with nasal polyposis (CRSwNP).  
(4) Treatment of pediatric patients 12 years and older with eosinophilic esophagitis (EoE).  
(5) Treatment of adult patients with prurigo nodularis (PN).

### **Criteria:**

- (a) For pediatric patients 6 months and older with AD and PN  
i. Previous treatment, or intolerance of, with TCS for more than sixty (60) days; and  
ii. Previous treatment, or intolerance of, with TCI for more than sixty (60) days  
(b) For pediatric and adult patients 6 years and older with asthma  
i. Previous treatment, or intolerance of, with Xolair for more than sixty (60) days; and  
ii. Patients must be reevaluated after 6 months  
(c) For adult patients with CRSwNP  
i. Previous treatment, or intolerance of, with Xolair for more than sixty (60) days; and  
ii. Previous treatment, or intolerance of, with oral corticosteroid  
(d) For pediatric patients 12 years and older with EoE  
i. Confirmed diagnosis with endoscopic esophageal biopsy showing the presence of eosinophils ( $\geq 15$  eosinophils per high-power field); and  
ii. Previous treatment with proton-pump inhibitor (PPI) for more than sixty (60) days; and  
iii. Previous treatment with oral corticosteroid; and  
iv. Attestation of dietary modifications (e.g., avoidance of food allergen triggers)

**GENERIC:** ELBASVIR-GRAZOPREVIR

**BRAND:** ZEPATIER<sup>®</sup>

### **INDICATION:**

- (1) Chronic Hepatitis C

### **Criteria:**

- (a) Preferred for genotypes 1 and 4  
(b) Must follow the clinical criteria as set by the Maryland Department of Health  
(c) Special Hepatitis C PA request forms, treatment plan template, preferred status information, and full criteria can be obtained at <http://www.jaimedicalsystems.com/providers/pharmacy/> or by contacting MC-Rx at 1-800-555-8513

## **Prior Authorization Guidelines**

**GENERIC:** EMPAGLIFLOZIN

**BRAND:** JARDIANCE<sup>®</sup>

**INDICATION:**

- (1) Type II Diabetes Mellitus
- (2) To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with hearth failure
- (3) To reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease

**Criteria for Type 2 diabetes mellitus:**

- (a) Failure of metformin, a sulfonyleurea, or pioglitazone

**Criteria for heart failure:**

- (a) Diagnosis of heart failure
- (b) Has not achieved adequate symptom control with the following:
  - (1) ACE/ARB or ARNI, and
  - (2) Beta Blocker

**GENERIC:** EMPAGLIFLOZIN-LINAGLIPTIN

**BRAND:** GLYXAMBI<sup>®</sup>

**INDICATION:**

- (1) Type II Diabetes Mellitus

**Criteria:**

- (a) For use when an SGLT2 and a DPP-4 Inhibitor is appropriate.

**GENERIC:** ENTACAPONE

**BRAND:** COMTAN<sup>®</sup>

**INDICATION:**

- (1) As an adjunct to levodopa/carbidopa to treat patients with idiopathic Parkinson's disease

**Criteria:**

- (a) Diagnosis of idiopathic Parkinson's disease; **and**
- (b) Patient is receiving concomitant levodopa/carbidopa therapy.

**GENERIC:** EPOETIN ALFA

**BRAND:** EPOGEN<sup>®</sup>

**INDICATIONS:**

- (1) Anemia with cancer chemotherapy (nonmyeloid)
- (2) Anemia due to chronic renal failure
- (3) Anemia of HIV infection associated with zidovudine
- (4) Reduction of allogenic blood transfusion for elective, noncardiac, nonvascular surgery

**Criteria:**

- (a) Patient's iron stores are adequate (Ferritin  $\geq 100$  mcg/mL and/or Transferrin saturation  $\geq 20\%$ ) or patient is being treated with iron; **and**
- (b) Adequate blood pressure control

**Chronic kidney disease patients:**

- (c) Initiate treatment when hemoglobin is  $< 10$  g/dL (3-month approval)

**Anemia due to chemotherapy in cancer patients:**

- (c) Initiate treatment only if hemoglobin  $< 10$  g/dL and anticipated duration of myelosuppressive chemotherapy is  $\geq 2$  months

**Anemia due to zidovudine in HIV-infected patients:**

- (c) Initiate treatment when hemoglobin is  $< 10$  g/dL

**Surgical procedure - Transfusion of blood product, Allogeneic;**

**Prophylaxis:**

- (c) Patient's pre-operative Hgb  $> 10$  to  $\leq 13$  g/dL (14-day approval)

## Prior Authorization Guidelines

### For renewals:

#### Chronic kidney disease patients:

- (a) With dialysis Hbg <11
- (b) Without dialysis Hbg <10

#### Anemia due to chemotherapy in cancer patients:

- (a) Hbg <11

#### Anemia due to zidovudine in HIV-infected patients:

- (a) Hbg <11

**GENERIC:** ETANERCEPT

**BRAND:** ENBREL<sup>®</sup>

#### **INDICATIONS:**

- (1) Moderate to severely active rheumatoid arthritis
- (2) Moderate to severely active polyarticular juvenile rheumatoid arthritis
- (3) Psoriatic spondylitis
- (4) Ankylosing spondylitis
- (5) Plaque psoriasis

#### **Criteria:**

- (a) The patient had a **NEGATIVE** tuberculin skin test, or if positive, has received treatment for latent TB prior to Enbrel therapy; **and**
- (b) The patient does not have a clinically important active infection

#### **Additional Criteria for RA:**

- (c) The patient has failed or is intolerant to one formulary NSAID **and**
- (d) The patient has failed or is intolerant to one formulary DMARD

#### **Additional Criteria for Plaque Psoriasis:**

- (c) Involvement of  $\geq 10\%$  body surface area (BSA)

**GENERIC:** EVOLOCUMAB

**BRAND:** REPATHA<sup>®</sup>

#### **INDICATION:**

- (1) Primary hyperlipidemia
- (2) High cholesterol in the blood
- (3) Heterozygous familial hypercholesterolemia (HeFH)
- (4) Reduce the risk of heart attack, stroke, and certain types of heart surgery in patients.
- (5) Atherosclerotic cardiovascular disease (ASCVD)
- (6) Homozygous familial hypercholesterolemia

#### **Criteria:**

- (a) Documentation of positive clinical response
- (b) Comprehensive counseling regarding diet
- (c) Not used in combination with another type 9 (PCSK9) INHIBITOR

**GENERIC:** EXENATIDE

**BRAND:** BYDUREON<sup>®</sup>

#### **INDICATION:**

- (1) Adjunctive therapy of type 2 diabetes mellitus

#### **Criteria:**

- (a) Diagnosis of type 2 diabetes; **and**
- (b) Failure or intolerance to sulfonylureas and/or metformin at optimal dosing. Failure defined as Hemoglobin A1c  $\geq 7.0$ ; **and**
- (c) Patient  $\geq 10$  years of age

## **Prior Authorization Guidelines**

**GENERIC:** FENOFIBRIC ACID 35MG, 105MG, 45MG, AND 135 MG

**Step Therapy Criteria:**

Recent trial of formulary product generic Fenofibrate - Cumulative days supply for more than sixty (60) days within the last one-hundred and eighty (180) days with at least one (1) cumulative fill

**GENERIC:** FENTANYL TRANSDERMAL PATCH

**BRAND:** DURAGESIC<sup>®</sup>

**INDICATION:**

(1) Persistent, moderate to severe chronic pain OR cancer-related pain that requires continuous, around-the-clock opioid (narcotic) administration for an extended period of time

**Criteria:**

- (a) Diagnosis of persistent, moderate to severe chronic or cancer-related pain requiring continuous, around-the-clock opioid administration for an extended period of time; **and**
- (b) Patient unable to take medications by mouth; **or**
- (c) Failure of or intolerance/contraindication to a long-acting oral opiate (narcotic) medication (controlled-release morphine, oxycodone, or oxymorphone)
- (d) Completion of Opioid Prior Authorization/Attestation Form required, available at <http://www.jaimedicalsystems.com/providers/pharmacy/>

**GENERIC:** FESOTERODINE FUMARATE

**Step Therapy Criteria:**

Recent trial of formulary product generic Oxybutynin - Cumulative days' supply for more than sixty (60) days within the last one-hundred and eighty (180) days with at least one (1) cumulative fill

**GENERIC:** FILGRASTIM-AYOW

**BRAND:** RELEUKO<sup>®</sup>

**INDICATIONS:**

- (1) Prevention of neutropenia in patients receiving myelosuppressive chemotherapy for nonmyeloid malignancies
- (2) Patients undergoing peripheral blood progenitor cell collection and therapy
- (3) Patients with severe chronic neutropenia

**Criteria:**

- (a) The patient is undergoing peripheral blood progenitor cell collection and therapy; or
- (b) Diagnosis of severe chronic neutropenia with an absolute neutrophil count (ANC) < 1,000; or
- (c) ANC nadir of < 1,000 neutrophils to previous chemotherapy. Once this has been documented, approval will be given for prophylaxis for all future chemo cycles.

*\* For injectable medications administered by a healthcare professional, please refer to the "Specialty Medication Guidelines" in the beginning of this formulary.*

*\* Please indicate estimated duration of therapy*

**GENERIC:** FLASH GLUCOSE SENSOR

**BRAND:** FREESTYLE LIBRE<sup>®</sup>

**INDICATIONS:**

(1) Treatment of patients indicated for the management of diabetes in persons aged 4 years and older.

**Criteria:**

- (a) Diagnosed with Type I or Type II Diabetes mellitus; and
- (b) Actively seeing an Endocrinologist (at least one visit within past 6 months); and
- (c) Blood glucose testing at least 4x/day for more than sixty (60) days; and

## **Prior Authorization Guidelines**

- (d) Insulin injections at least 3x/day; and
- (e) The member must have been assessed by the prescriber for ability to adhere to the CGM monitor regimen and any adherence/compliance issues must have been addressed and resolved by the prescriber; and
- (f) Frequent adjustments to amount of injected insulin based on glucose testing results; and
- (g) Wide variance in blood sugar levels OR unexplained or severe hypoglycemia OR hypoglycemic unawareness

**GENERIC:** FLUCONAZOLE

**BRAND:** DIFLUCAN<sup>®</sup>

(PA required after 150mg x2 tablet dispensed)

**INDICATIONS:**

- (1) Vaginal candidiasis
- (2) Cryptococcal meningitis
- (3) Serious systemic Candida infections
- (4) Oropharyngeal and esophageal candidiasis

**Criteria:**

- (a) Any of the above diagnoses; **except**
- (b) For the diagnosis of oropharyngeal candidiasis, failure of nystatin therapy; **and**
- (c) For the diagnosis of vaginal candidiasis, patients who are immunocompromised and/or have recurrent or refractory infections.

**GENERIC:** FLUTICASONE/UMECLINDIUM/VILANTEROL

**BRAND:** TRELEGY<sup>®</sup>

**INDICATION:**

- (1) Maintenance treatment of asthma in patients 18 years of age and older
- (2) Maintenance treatment of patients with chronic obstructive pulmonary disease (COPD)

**Criteria for Asthma:**

- (a) Currently on, but not adequately controlled by an two (2) or more inhaled medium to high dose LABA+ICS for more than sixty (60) days; and
- (b) Patients must be reevaluated after 6 months

**Criteria for COPD:**

- (a) Currently on, but not adequately controlled by an two (2) or more inhaled medium to high dose LABA+ICS for more than sixty (60) days; and
- (b) Currently on, but not adequately controlled by an inhaled LAMA or LAMA+LABA for more than sixty (60) days
- (c) Patients must be reevaluated after 6 months

**GENERIC:** GALANTAMINE HYDROBROMIDE

**BRAND:** RAZADYNE<sup>®</sup>, RAZADYNE ER<sup>®</sup>

**INDICATION:**

- (1) Alzheimer's disease: for the treatment of dementia

**Criteria:**

- (a) Confirmation by clinical evaluation

**GENERIC:** GATIFLOXACIN

**BRAND:** ZYMAXID<sup>®</sup>

**INDICATION:**

- (1) Bacterial conjunctivitis

**Criteria:**

- (a) Failure of, contraindication to, or intolerance to ciprofloxacin ophthalmic formulation.

## **Prior Authorization Guidelines**

**GENERIC:** GLATIRAMER ACETATE

**BRAND:** COPAXONE<sup>®</sup>

**INDICATIONS:**

- (1) Relapsing-remitting Multiple Sclerosis
- (2) To prevent or slow the development of clinically definite Multiple Sclerosis in patients who have experienced a first clinical episode and have MRI features consistent with Multiple Sclerosis

**Criteria:**

- (a) Prescribed by neurologist; and
- (b) Not requesting combination therapy of any 2 agents together: Copaxone, Betaseron, Avonex, Tysabri, Rebif, Gilenya, Aubagio, or Tecfidera

**GENERIC:** GLECAPREVIR-PIBRENTASVIR

**BRAND:** MAVYRET<sup>®</sup>

**INDICATION:**

- (1) Chronic Hepatitis C

**Criteria:**

- (a) Preferred for genotypes 1, 2, 3, 4, 5 and 6
- (b) Must follow the clinical criteria as set by the Maryland Department of Health
- (c) Special Hepatitis C PA request forms, treatment plan template, preferred status information, and full criteria can be obtained at <http://www.jaimedicalsystems.com/providers/pharmacy/> or by contacting MC-Rx at 1-800-555-8513

**GENERIC:** HYDROXOCOBALAMIN

**INDICATION:**

- (1) Vitamin B-12 deficiency

**Criteria:**

- (a) Patients who lack intrinsic factor; **or**
- (b) Patients who are on long-term PPI therapy; **or**
- (c) Patients with a partial or complete gastrectomy.

**GENERIC:** INTERFERON ALFA

**BRAND:** ROFERON-A<sup>®</sup>, INTRON-A<sup>®</sup>, and ALFERON N<sup>®</sup>

**INDICATIONS:**

- (1) Hairy cell leukemia
- (2) AIDS-related Kaposi's sarcoma
- (3) Chronic Hepatitis B or C
- (4) Malignant melanoma

**Criteria:**

- (a) Any of the above diagnoses.

\* *For injectable medications administered by a healthcare professional, please refer to the "Specialty Medication Guidelines" in the beginning of this formulary.*

## **Prior Authorization Guidelines**

**GENERIC:** INTERFERON BETA

**BRAND:** AVONEX<sup>®</sup>, BETASERON<sup>®</sup>, REBIF<sup>®</sup>

**INDICATIONS:**

- (1) Diagnosis of a relapsing form of Multiple Sclerosis; **or**
- (2) First clinical demyelinating event with MRI evidence consistent with Multiple Sclerosis

**Criteria:**

- (a) Prescribed by neurologist; **and**
- (b) If patient has a history of or is currently being treated for severe psychiatric disorders, suicidal ideation or severe depression, this condition is well controlled; **and**
- (c) Not requesting combination of any 2 agents together: Copaxone, Betaseron, Avonex, Tysabri, Rebif, Gilenya, Aubagio, or Tecfidera

\* For injectable medications administered by a healthcare professional, please refer to the "Specialty Medication Guidelines" in the beginning of this formulary.

**GENERIC:** ITRACONAZOLE

**BRAND:** SPORANOX<sup>®</sup>

**INDICATIONS:**

- (1) Histoplasmosis infections
- (2) Aspergillosis infections
- (3) Blastomycosis

**Criteria:**

- (a) Any of the above diagnoses.

**GENERIC:** IXEKIZUMAB

**BRAND:** TALTZ<sup>®</sup>

**INDICATIONS:**

- (1) Treatment of pediatric patients aged  $\geq 6$  years with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
- (2) Treatment of adult patients with active psoriatic arthritis
- (3) Treatment of adults with active ankylosing spondylitis.
- (4) Adults with active non-radiographic axial spondyloarthritis (nrAxSpA) with objective signs of inflammation.

**Criteria:**

1. First Prescription and every 12 months: The patient had a NEGATIVE tuberculin skin test, or if positive, has received treatment for latent TB prior to treatment.
2. For adult patients with plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and nrAxSpA
  - a. Previous treatment, or intolerance of, with Enbrel for more than sixty (60) days; and
  - b. Previous treatment, or intolerance of, with formulary Humira biosimilar for more than sixty (60) days

**GENERIC:** LANSOPRAZOLE

**BRAND:** PREVACID SOLU-TAB<sup>®</sup>

**INDICATION:**

- (1) Gastroesophageal reflux disease (GERD), heartburn, gastric ulcer, and duodenal ulcer.

**Criteria:**

- (a) Unable to ingest a solid dosage form (e.g. oral tablet or capsule) due to one of the following:
  - (1) Age
  - (2) Oral/motor difficulties
  - (3) Dysphagia
  - (4) Patient utilizes a feeding tube for medication administration

## Prior Authorization Guidelines

**GENERIC:** LEDIPASVIR-SOFOSBUVIR

**BRAND:** HARVONI<sup>®</sup>

**INDICATION:**

- (1) Chronic Hepatitis C

**Criteria:**

- (a) Generic tablet only
- (b) Must follow the clinical criteria as set by the Maryland Department of Health
- (c) Special Hepatitis C PA request forms, treatment plan template, preferred status information, and full criteria can be obtained at <http://www.jaimedicalsystems.com/providers/pharmacy/> or by contacting MC-Rx at 1-800-555-8513

**GENERIC:** LEUPROLIDE

**BRAND:** LUPRON<sup>®</sup>

**INDICATIONS:**

- (1) Advanced prostate cancer
- (2) Central precocious puberty
- (3) Endometriosis
- (4) Uterine leiomyomata (fibroids)

**Criteria:**

- (a) Diagnosis of advanced prostate cancer, precocious puberty or fibroids; **or**
- (b) For the diagnosis of endometriosis, failure of NSAIDS **and** oral contraceptives **or** endometriosis diagnosed by laparoscopy.

**Gender Affirming Treatment:**

For all requests for gender affirming care, please refer to the Gender-Affirming Treatment Services Under the Maryland Medicaid Program document (for a copy of the criteria see our website at <https://jaimedicalsystems.com/providers/pharmacy/>.) Please ensure that all necessary documentation required under the criteria is included to show consent for treatment and medical necessity (documentation requirements may vary depending on patient age, type of treatment requested, and specialty of requesting provider).

*\* Note: This agent is ordinarily administered at the physician's office. For injectable medications administered by a healthcare professional, please refer to the "Specialty Medication Guidelines" in the beginning of this formulary*

**GENERIC:** LIDOCAINE PATCH 5%

**BRAND:** LIDODERM PATCH 5%<sup>®</sup>

**INDICATION:**

- (1) Relief of pain associated with post-herpetic neuralgia.

**Criteria:**

- (a) Skin application site is intact, and
- (b) For the relief of pain associated with post-herpetic neuralgia;  
**and**
- (c) Failure, adverse reaction, or contraindication to two prescription analgesics, including formulary lidocaine topical cream or gel.

**GENERIC:** LIRAGLUTIDE

**BRAND:** VICTOZA<sup>®</sup>

**INDICATION:**

- (1) Adjunct to diet and exercise to improve glycemic control in patients 10 years and older with type II diabetes mellitus
- (2) To reduce the risk of major adverse cardiovascular events in adults with type II diabetes

## **Prior Authorization Guidelines**

(3) . mellitus and established cardiovascular disease.

**Criteria:**

- (a) Diagnosis of type II diabetes mellitus; **and**
- (b) Must be under the care of a healthcare provider skilled with the use of insulin and supported by a diabetes educator; **and**
- (c) Must have tried at least 2 antidiabetic agents such as metformin, sulfonylureas, thiazolidinedione, or insulin and not achieved adequate glycemic control despite treatment or intolerant to other antidiabetic medications; **and**
- (d) NO personal or family history of medullary thyroid carcinoma

**GENERIC:** LUBIPROSTONE

**BRAND:** AMITIZA<sup>®</sup>

**INDICATION:**

- (1) Chronic idiopathic constipation
- (2) Irritable bowel syndrome
- (3) Opioid-induced constipation

**Criteria:**

- (a) Must have a diagnosis of either chronic idiopathic constipation, irritable bowel syndrome, or opioid-induced constipation; **and**
- (b) Failure of Miralax, Senna-S, and/or lactulose

**GENERIC:** MEMANTINE

**BRAND:** NAMENDA<sup>®</sup>

**INDICATION:**

- (1) Alzheimer's disease: for treatment of moderate-to-severe cases of dementia

**Criteria:**

- (a) Dementia must be confirmed by clinical evaluation; **and**
- (b) Documented dementia is either moderate or severe

**GENERIC:** METHADONE

**BRAND:** METHADONE

**INDICATION:**

- (1) Persistent, moderate to severe chronic pain that requires around-the-clock opioid (narcotic) administration for an extended period of time; not intended as an as-needed analgesic.

**Criteria:**

- (a) Completion of Opioid Prior Authorization/Attestation Form required, available at <http://www.jaimedicalsystems.com/providers/pharmacy/>

**GENERIC:** METRONIDAZOLE 0.75% VAGINAL GEL

**BRAND:** METROGEL<sup>®</sup>

**INDICATION:**

- (1) Bacterial vaginosis

**Criteria:**

- (a) Pregnancy; **or**
- (b) Intolerance to oral metronidazole

**GENERIC:** MILNACIPRAN

**BRAND:** SAVELLA<sup>®</sup>

**INDICATION:**

- (1) Moderate to severe fibromyalgia

## **Prior Authorization Guidelines**

### **Criteria:**

- (a) Diagnosis of fibromyalgia; **and**
- (b) Documented failure or contraindication to:
  - (1) Pain relievers (e.g. Tramadol); **or**
  - (2) Muscle Relaxants (e.g. cyclobenzaprine, Baclofen)

**GENERIC:** MIRABEGRON

**BRAND:** MYRBETRIQ<sup>®</sup>

### **INDICATION:**

- (1) Overactive bladder
- (2) Neurogenic detrusor over-activity (NDO) in pediatric patients

### **Criteria:**

- (a) Failure of Oxybutynin
- (b) Age 3 years and older and weighing 35kg or more (NDO)

**GENERIC:** MORPHINE SULFATE SUSTAINED-RELEASE

**BRAND:** MS CONTIN<sup>®</sup>

### **INDICATION:**

- (1) Persistent, moderate to severe chronic pain OR cancer-related pain that requires continuous, around-the-clock opioid (narcotic) administration for an extended period of time; not intended as an as needed analgesic

### **Criteria:**

- (a) Completion of Opioid Prior Authorization/Attestation Form required, available at <http://www.jaimedicalsystems.com/providers/pharmacy/>

**GENERIC:** MOXIFLOXACIN

**BRAND:** AVELOX<sup>®</sup>

### **INDICATIONS:**

- (1) Acute bacterial sinusitis
- (2) Acute bacterial exacerbations of chronic bronchitis
- (3) Mild to moderate pelvic inflammatory disease
- (4) Complicated/Uncomplicated skin and skin structure infections
- (5) Community-acquired pneumonia
- (6) Complicated intra-abdominal infections

### **Criteria:**

In patients  $\geq 18$  years of age with any of the above listed indications when:

- (a) Cultures show sensitivity to Avelox<sup>®</sup> only; **or**
- (b) Patient discharged on Avelox<sup>®</sup> from the hospital and needs to complete regimen on an outpatient basis

**GENERIC:** NAFARELIN

**BRAND:** SYNAREL<sup>®</sup>

### **INDICATIONS:**

- (1) Central precocious puberty
- (2) Endometriosis

### **Criteria:**

- (a) Diagnosis of central precocious puberty; **or**
- (b) For the diagnosis of endometriosis in patients  $\geq 18$  years of age, failure of NSAIDs **and** oral contraceptives, **or** endometriosis diagnosed by laparoscopy.

### **Gender Affirming Treatment:**

For all requests for gender affirming care, please refer to the Gender-Affirming Treatment Services Under the Maryland Medicaid Program document (for a copy of the criteria see our website at

## **Prior Authorization Guidelines**

[https://jaimedicalsystems.com/providers/pharmacy/.](https://jaimedicalsystems.com/providers/pharmacy/)) Please ensure that all necessary documentation required under the criteria is included to show consent for treatment and medical necessity (documentation requirements may vary depending on patient age, type of treatment requested, and specialty of requesting provider).

**GENERIC:** NUTRITIONAL SUPPLEMENTS

**BRAND:** ENSURE<sup>®</sup>, PEDIASURE<sup>®</sup>, BOOST<sup>®</sup>, VIVONEX<sup>®</sup>

**INDICATION:**

- (1) Nutritional supplementation

**Criteria:**

- (a) Patient must have enteral access via one of the following: nasogastric (NG) tube, nasoduodenal (ND) tube, nasojejunal (NJ) tube, percutaneous endoscopic gastrostomy (PEG) or percutaneous endoscopic jejunostomy (PEJ).

*To obtain nutritional supplements (e.g., Ensure or Pediasure) for members without enteral access, please follow the DME process. For assistance accessing the DME process, please contact Customer Service at 1-888-524-1999.*

**GENERIC:** OCTREOTIDE

**BRAND:** SANDOSTATIN<sup>®</sup>

**INDICATIONS:**

- (1) Symptomatic treatment of severe diarrhea and flushing episodes associated with metastatic carcinoid tumors
- (2) Profuse, watery diarrhea associated with vasoactive intestinal peptide (VIP) secreting tumors
- (3) To reduce the blood levels of growth hormone and IGF-I associated with acromegaly

**Criteria:**

- (a) Any of the above diagnoses; **and**
- (b) For the diagnosis of acromegaly, the patient has had an inadequate response to, or cannot be treated with surgical resection, pituitary irradiation **and** bromocriptine at maximally tolerated doses.

*For injectable medications administered by a healthcare professional, please refer to the “Specialty Medication Guidelines” in the beginning of this formulary.*

**GENERIC:** OLODATEROL HCL

**BRAND:** STRIVERDI<sup>®</sup>

**INDICATION:**

- (1) Maintenance Treatment of Chronic Obstructive Pulmonary Disease

**Criteria:**

- (a) Currently on, but not controlled by a LAMA for more than sixty (60) days; and
- (b) The patient must be reevaluated after 6 months

**GENERIC:** OMALIZUMAB

**BRAND:** XOLAIR<sup>®</sup>

**INDICATION:**

- (1) Treatment of moderate to severe persistent asthma in patients 6 years of age and older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids.
- (2) Treatment of adult patients, as an add-on maintenance treatment, chronic rhinosinusitis with nasal polyposis (CRSwNP).
- (3) Treatment of adults and adolescents 12 years of age and older who remain symptomatic despite H1 antihistamine treatment with chronic spontaneous urticaria (CSU).

**Criteria:**

- (a) For pediatric patients 6 years and older with asthma

### **Prior Authorization Guidelines**

- i. Documentation of baseline (pre-omalizumab treatment) serum total IgE level greater than or equal to 30 IU/mL and less than or equal to 1300 IU/mL
  - ii. Documentation of positive skin test or in vitro reactivity to a perennial aeroallergen
  - iii. Previous treatment, or intolerance of, with two (2) or more inhaled medium to high dose LABA+ICS for more than sixty (60) days; and
  - iv. Patients must be reevaluated after 6 months
- (b) For adult patients with asthma
- i. Documentation of baseline (pre-omalizumab treatment) serum total IgE level greater than or equal to 30 IU/mL and less than or equal to 1300 IU/mL
  - ii. Documentation of positive skin test or in vitro reactivity to a perennial aeroallergen
  - iii. Previous treatment, or intolerance of, with LAMA+LABA+ICS for more than sixty (60) days; and
  - iv. Patients must be reevaluated after 6 months
- (c) For adult patients with CRSwNP
- i. Previous treatment, or intolerance of, with two (2) or more intranasal corticosteroid for more than ninety (90) days; and
  - ii. Previous treatment, or intolerance of, with oral corticosteroid
- (d) For pediatric patients 12 years and older with CSU
- i. Previous treatment with two (2) H1-antihistamines for more than sixty (60) days within the past ninety (90) days

**GENERIC:** OXYCODONE, CONTROLLED-RELEASE

**BRAND:** OXYCONTIN®

**INDICATION:**

- (1) Persistent, moderate to severe chronic pain **or** cancer-related pain that requires continuous, around-the-clock opioid (narcotic) administration for an extended period of time; not intended as an as-needed analgesic.

**Criteria:**

- (a) Persistent, moderate to severe chronic pain **or** cancer-related pain that requires around-the-clock analgesia for an extended period of time; **and**
- (b) For chronic pain, failure, intolerance, or contraindication to at least 2 short-acting formulary narcotic analgesics and controlled-release morphine (MS Contin, others). For cancer pain, failure intolerance, or contraindication to controlled-release morphine (MS Contin, others).
- (c) Completion of Opioid Prior Authorization/Attestation Form required, available at <http://www.jaimedicalsystems.com/providers/pharmacy/>

**GENERIC:** PEGFILGRASTIM-PBBK

**BRAND:** FYLNETRA®

**INDICATIONS:**

- (1) Prevention of neutropenia in patients receiving myelosuppressive chemotherapy for nonmyeloid malignancies
- (2) Patients undergoing peripheral blood progenitor cell collection and therapy
- (3) Patients with severe chronic neutropenia

**Criteria:**

- (a) The patient is undergoing peripheral blood progenitor cell collection and therapy; or
- (b) Diagnosis of severe chronic neutropenia with an absolute neutrophil count (ANC) < 1,000; or
- (c) ANC nadir of < 1,000 neutrophils to previous chemotherapy. Once this has been documented, approval will be given for prophylaxis for all future chemo cycles.

*\* For injectable medications administered by a healthcare professional, please refer to the "Specialty Medication Guidelines" in the beginning of this formulary.*

*\* Please indicate estimated duration of therapy*

## **Prior Authorization Guidelines**

**GENERIC:** PEGINTERFERON ALFA-2A

**BRAND:** PEGASYS®

### **INDICATIONS:**

- (1) Use in combination with ribavirin or ribavirin and other Direct-Acting Antivirals for the treatment of chronic Hepatitis C
- (2) Treatment of chronic Hepatitis C in patients coinfecting with HIV whose HIV is clinically stable.
- (3) Treatment of patients with HBeAg positive and HBeAg negative chronic Hepatitis B

### **Criteria:**

#### **(In combination with ribavirin or ribavirin and other Direct-Acting Antivirals)**

- (a) Diagnosis as indicated above including any applicable labs and/or tests
- (b) Clinically documented chronic Hepatitis C with detectable HCV RNA levels > 50 IU/mL
- (c) Age ≥ 3 years
- (d) Liver biopsy (unless contraindicated) indicates some fibrosis and inflammatory necrosis
- (e) Intolerant to Peg-Intron
- (f) If HIV positive, patient is clinically stable.

#### **(For chronic Hepatitis B)**

- (a) Documented HBeAg positive or negative chronic Hepatitis B
- (b) Compensated liver disease
- (c) Evidence of viral replication
- (d) Evidence of liver inflammation
- (e) Not contraindicated

**GENERIC:** PENTOXIFYLLINE

**BRAND:** TRENTAL®

### **INDICATION:**

- (1) Intermittent claudication

### **Criteria:**

- (a) Pain on walking or ABI < 0.8; **or**
- (b) Diabetic foot ulcer; **or**
- (c) Gangrene; **or**
- (d) Risk of, or existing, amputation.

**GENERIC:** PIMECROLIMUS

**BRAND:** ELIDEL®

### **INDICATION:**

- (1) Second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adults and children 2 years of age and older, who have failed to respond adequately to other topical prescription treatments, or when treatments are not advisable.

### **Criteria:**

- (a) Documented failure of optimal dosing/adequate duration; **or**
- (b) Intolerance or contraindication to at least one formulary topical corticosteroid; **and**
- (c) Diagnosis of mild to moderate atopic dermatitis; **and**
- (d) Using for short-term and non-continuous treatment.

**GENERIC:** RALOXIFENE

**BRAND:** EVISTA®

### **INDICATION:**

- (1) Treatment and prevention of osteoporosis in postmenopausal women

### **Criteria:**

- (a) Personal or family history of breast cancer; **or**
- (b) Intolerable side effects to at least one formulary estrogen.

## **Prior Authorization Guidelines**

**GENERIC:** REPAGLINIDE

**BRAND:** PRANDIN

**INDICATION:**

(1) Type 2 diabetes mellitus

**Criteria:**

- (a) Diagnosis of Type 2 diabetes mellitus
- (b) Has not achieved adequate glycemic control on at least ONE of the following:
  - (1) Metformin (alone or in combination)
  - (2) A Sulfonylurea (alone or in combination)
  - (3) A preferred DPP-4 inhibitor
- (c) Contraindication to metformin, a sulfonylurea, OR a preferred DPP-4 Inhibitor

**GENERIC:** RIBAVIRIN

**BRAND:** REBETOL<sup>®</sup>

**INDICATION:**

(1) Indicated **only** in combination with a recombinant interferon alfa-2a or alfa-2b product or in combination with other Direct-Acting Antivirals for the treatment of chronic Hepatitis C.

**Criteria:**

- (a) Diagnosis of chronic Hepatitis C; **and**
- (b) Patient is receiving concomitant recombinant interferon alfa-2a or alfa-2b therapy or other Direct-Acting Antivirals.

**GENERIC:** RIFAXIMIN 550 MG

**BRAND:** XIFAXAN<sup>®</sup> 550 MG

**INDICATION:**

- (1) Reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults
- (2) Treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults

**Criteria:**

- (a) Hepatic encephalopathy
  - Failure of, intolerance to, contraindication, or previous use to lactulose at maximally tolerated doses
- (b) IBS-D
  - Failure of, intolerance to, contraindication, or previous use to loperamide
  - For renewals: the patient has a ten (10) or more week treatment-free period

**GENERIC:** RILUZOLE

**BRAND:** RILUTEK<sup>®</sup>

**INDICATION:**

(1) Amyotrophic lateral sclerosis (ALS)

**Criteria:**

- (a) Diagnosis of ALS.

**GENERIC:** RISANKIZUMAB

**BRAND:** SKYRIZI<sup>®</sup>

**INDICATION:**

- (1) Treatment of adult patients with moderate-to-severe plaque psoriasis (Ps) who are candidates for systemic therapy or phototherapy.
- (2) Treatment of adult patients with active psoriatic arthritis (PsA)
- (3) Treatment of adults with moderately to severely active Crohn's disease (CD).

**Criteria:**

## **Prior Authorization Guidelines**

- (a) First Prescription and every 12 months: The patient had a NEGATIVE tuberculin skin test, or if positive, has received treatment for latent TB prior to treatment.
- (b) For adult patients with Ps and PsA - Previous treatment, or intolerance of, with Taltz for more than sixty (60) days
- (c) For adult patients with CD - Previous treatment, or intolerance of, with formulary Humira biosimilar for more than sixty (60) days.

**GENERIC:** RIVASTIGMINE TARTRATE

**BRAND:** EXELON<sup>®</sup>

**INDICATION:**

- (1) Alzheimer's disease: for the treatment of dementia

**Criteria:**

- (a) Confirmation by clinical evaluation

**GENERIC:** RIZATRIPTAN

**BRAND:** MAXALT<sup>®</sup>

**INDICATION:**

- (1) Acute treatment of migraine headache

**Criteria:**

- (a) Failure of, intolerance to, or contraindication to one traditional formulary agent (NSAID's, ergotamine, or combination analgesic); **or**
- (b) Unsuccessful concurrent or previous use of migraine prophylaxis medications (e.g., beta-blockers, calcium channel blockers, tri-cyclic antidepressants or anticonvulsants); **and**
- (c) Patient is not currently using ergotamine or another 5-HT1 Receptor Agonist.

**GENERIC:** ROPINIROLE

**BRAND:** REQUIP<sup>®</sup>

**INDICATIONS:**

- (1) For the treatment of signs and symptoms of idiopathic Parkinson's disease.
- (2) Moderate to severe primary Restless Leg Syndrome.

**Criteria:**

- (a) Diagnosis of idiopathic Parkinson's disease; **or**
- (b) Diagnosis of Restless Leg Syndrome and normal iron stores (serum ferritin and/or iron-binding saturation)

**GENERIC:** SALMETEROL / FLUTICASONE

**BRAND:** ADVAIR<sup>®</sup> / ADVAIR HFA<sup>®</sup>, WIXELA<sup>®</sup>, SALMETEROL / FLUTICASONE

**INDICATION:**

- (1) Long-term, twice-daily maintenance treatment of asthma in patients 4 years of age and older.
- (2) Maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease.

**Criteria for Asthma:**

- (a) Currently on, but not controlled by an inhaled corticosteroid for more than sixty (60) days; and
- (b) The patient must be reevaluated after 6 months

**Criteria for COPD:**

- (a) Currently on, but not controlled by a LAMA for more than sixty (60) days; and
- (b) The patient must be reevaluated after 6 months

*\* For members currently with an approved prior authorization for Advair, claims will process as long as the member has filled Advair within the last 4 months. No yearly renewal will be needed for compliant members. Prior authorization will be required for members new to the plan, new to Advair therapy, or with no claim history of Advair within the last 4 months. Once approved, 90-day supplies are allowed.*

## **Prior Authorization Guidelines**

**GENERIC:** SALMETEROL XINAFOATE

**BRAND:** SEREVENT DISKUS®

**INDICATIONS:**

- (1) Maintenance treatment of asthma and prevention of bronchospasm in adults and children 4 years of age and older
- (2) Prevention of exercise-induced bronchospasm in patients 4 years of age and older
- (3) Serevent Diskus® is indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease

**Criteria for Asthma:**

- (a) Currently on, but not controlled by an inhaled corticosteroid for more than sixty (60) days; and
- (b) Patients must be reevaluated after 6 months

**Criteria for COPD:**

- (a) Currently on, but not controlled by a LAMA for more than sixty (60) days; and
- (b) The patient must be reevaluated after 6 months

**GENERIC:** SILDENAFIL

**BRAND:** REVATIO®

**INDICATION:**

- (1) Pulmonary Arterial Hypertension (PAH)

**Criteria:**

- (a) For the treatment of PAH; **and**
- (b) Current utilization of nitrates is contraindicated; **and**
- (c) Age limit of 2 years and younger for the solution

**GENERIC:** SIMVASTATIN 80mg

**BRAND:** ZOCOR®

**INDICATIONS:**

- (1) Heterozygous or homozygous familial hypercholesterolemia
- (2) Familial type 3 hyperlipoproteinemia
- (3) Hypertriglyceridemia
- (4) Primary hypercholesterolemia, or mixed hyperlipidemia
- (5) Decrease cardiovascular event risk in patients with high coronary event risk
- (6) Cerebrovascular accident prophylaxis

**Criteria:**

- (a) Age ≤ 65 years
- (b) Male gender (female gender predisposed to myopathy including rhabdomyolysis)
- (c) Controlled hypothyroidism
- (d) Normal renal function
- (e) Documentation of all cholesterol lowering agents tried and failed must be provided.

**GENERIC:** SITAGLIPTIN PHOSPHATE

**BRAND:** JANUVIA®

**Step Therapy Criteria:**

Recent trial of formulary product Alogliptin - Cumulative days' supply for more than sixty (60) days with at least one (1) fill within the last one-hundred and eighty (180) days.

## **Prior Authorization Guidelines**

**GENERIC:** SOFOSBUVIR-VELPATASVIR

**BRAND:** EPCLUSA<sup>®</sup>

**INDICATION:**

(1) Chronic Hepatitis C

**Criteria:**

- (a) Generic tablets only
- (b) Preferred for genotypes 1, 2, 3, 4, 5 and 6
- (c) Must follow the clinical criteria as set by the Maryland Department of Health
- (d) Special Hepatitis C PA request forms, treatment plan template, preferred status information, and full criteria can be obtained at <http://www.jaimedicalsystems.com/providers/pharmacy/> or by contacting MC-Rx at 1-800-555-8513

**GENERIC:** SOFOSBUVIR-VELPATASVIR-VOXILAPREVIR

**BRAND:** VOSEVI<sup>®</sup>

**INDICATION:**

(1) Chronic Hepatitis C

**Criteria:**

- (a) For retreatment only
- (b) Must follow the clinical criteria as set by the Maryland Department of Health
- (c) Special Hepatitis C PA request forms, treatment plan template, preferred status information, and full criteria can be obtained at <http://www.jaimedicalsystems.com/providers/pharmacy/> or by contacting MC-Rx at 1-800-555-8513

**GENERIC:** SOLIFENACIN SUCCINATE

**Step Therapy Criteria:**

Recent trial of formulary product generic Oxybutynin - Cumulative days' supply for more than sixty (60) days within the last one-hundred and eighty (180) days with at least one (1) cumulative fill

**GENERIC:** SOMATROPIN

**BRAND:** HUMATROPE<sup>®</sup>

**INDICATIONS:**

- (1) Growth failure in children due to inadequate growth hormone (GH) secretion
- (2) Idiopathic short stature in children defined by height standard deviation (SD) score less than or equal to -2.25 and growth rate not likely to attain normal adult height
- (3) Short stature in children associated with Turner syndrome

**Criteria:**

- (a) Patient with open epiphyses (as confirmed by radiograph of wrist and hand) who has not reached final height; **and**
- (b) Medication prescribed by an endocrinologist; **and**
- (c) Patient meets one of the following criteria:
  - (1) Growth Hormone Deficiency (GHD) with diagnosis confirmed by one of the following:
    - i. Severe short stature defined as patient's height at  $\geq 2$  SD below the population mean
    - ii. Patient's height  $\geq 1.5$  SD below the midparental height (average of mother's and father's heights)
    - iii. Patient's height  $\geq 2$  SD below the mean and a 1-year height velocity more than 1 SD below the mean for chronologic age or (in children 2 years of age or older) a 1-year decrease of more than 0.5 SD in height
    - iv. In the absence of short stature, a 1-year height velocity more than 2 SD below the mean or a 2-year height velocity more than 1.5 SD below the mean (may occur in GHD manifesting during infancy or in organic, acquired GHD)

## **Prior Authorization Guidelines**

- v. Signs indicative of an intracranial lesion
  - vi. Signs of multiple pituitary hormone deficiencies
  - vii. Neonatal symptoms and signs of GHD
  - (2) Idiopathic short stature with patient's height at  $\geq 2.25$  SD below the mean height for normal children of the same age and gender
  - (3) Short stature associated with Turner syndrome and height below the 5<sup>th</sup> percentile of normal growth curve
- \* *To continue therapy, requests will be reviewed every six months.  
For injectable medications administered by a healthcare professional, please refer to the "Specialty Medication Guidelines" in the beginning of this formulary.*

**GENERIC:** SUCCIMER

**BRAND:** CHEMET<sup>®</sup>

### **INDICATIONS:**

- (1) Treatment of lead poisoning in children with blood lead levels > 45 mcg/dl
- (2) Unlabeled uses: Succimer may be beneficial in the treatment of other heavy metal poisonings

### **Criteria:**

- (a) Diagnosis of lead poisoning with blood levels > 45mcg/dl; **and**
- (b) Child is hospitalized; **or**
- (c) Child was started on the medication in the hospital and needs to continue upon discharge.

**GENERIC:** TACROLIMUS

**BRAND:** PROTOPIC<sup>®</sup>

### **INDICATION:**

- (1) Moderate to severe atopic dermatitis

### **Criteria:**

- (a) Patient must be non-immunocompromised **and**
- (b) Must be at least 2 years of age or older for the 0.03% strength; **or**
- (c) 16 years of age or older for 0.1% strength **and**
- (d) Diagnosis of atopic dermatitis
- (e) Documented failure of 2 different topical corticosteroids of medium to high potency in the past 90 days
- (f) Must be prescribed by a dermatologist, allergist, or for children, a pediatrician

**GENERIC:** TERIFLUNOMIDE

**BRAND:** AUBAGIO<sup>®</sup>

### **INDICATION:**

- (1) Diagnosis of a relapsing form of Multiple Sclerosis

### **Criteria:**

- (a) Prescribed by neurologist; **and**
- (b) Not requesting combination of any 2 agents together: Copaxone, Betaseron, Avonex, Tysabri, Rebif, Gilenya, Aubagio, or Tecfidera.

**GENERIC:** TESTOSTERONE

**BRAND:** ANDROGEL<sup>®</sup>, TESTIM<sup>®</sup>

### **INDICATION:**

- (1) Hypogonadism

### **Criteria:**

- (a) Must be prescribed by an Endocrinologist or Urologist
- (b) Initial therapy: The patient has documented low testosterone concentration
- (c) Renewal: The patient has documented therapeutic concentration to confirm response

### **Gender Affirming Treatment:**

## **Prior Authorization Guidelines**

For all requests for gender affirming care, please refer to the Gender-Affirming Treatment Services Under the Maryland Medicaid Program document (for a copy of the criteria see our website at <https://jaimedicalsystems.com/providers/pharmacy/>.) Please ensure that all necessary documentation required under the criteria is included to show consent for treatment and medical necessity (documentation requirements may vary depending on patient age, type of treatment requested, and specialty of requesting provider).

**GENERIC:** THROMBIN

**BRAND:** THROMBIN

**INDICATION:**

(1) Hemostasis

**Criteria:**

(a) Diagnosis of a bleeding disorder

**GENERIC:** TOLTERODINE TARTRATE

**Step Therapy Criteria:**

Recent trial of formulary product generic Oxybutynin - Cumulative days supply for more than sixty (60) days within the last one-hundred and eighty (180) days with at least one (1) cumulative fill

**GENERIC:** TRAMADOL ER

**BRAND:** ULTRAM ER<sup>®</sup>

**INDICATION:**

(1) Pain, chronic (moderate to severe)

**Criteria:**

(a) For patients who have a contraindication or failure of tramadol regular release tablets  
(b) Completion of Opioid Prior Authorization/Attestation Form required, available at <http://www.jaimedicalsystems.com/providers/pharmacy/>

**GENERIC:** TROSPIUM CHLORIDE

**Step Therapy Criteria:**

Recent trial of formulary product generic Oxybutynin - Cumulative days supply for more than sixty (60) days within the last one-hundred and eighty (180) days with at least one (1) cumulative fill

**GENERIC:** UMECLIDINIUM BROMIDE/VILANTEROL RIFENATATE

**BRAND:** ANORO ELLIPTA<sup>®</sup>

**INDICATION:**

(1) Chronic obstructive pulmonary disease (COPD): maintenance of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema.

**Criteria:**

(a) Currently on, but not controlled by a LAMA for more than sixty (60) days; and  
(b) The patient must be reevaluated after 6 months

**GENERIC:** UPADACITINIB

**BRAND:** RINVOO<sup>®</sup>

**INDICATIONS:**

(1) Treatment of adult patients, who have had an inadequate response or intolerance to one or more TNF blockers, with rheumatoid arthritis (RA).

## **Prior Authorization Guidelines**

- (2) Treatment of adult patients, who have had an inadequate response or intolerance to one or more TNF blockers, with active psoriatic arthritis (PsA).
- (3) Treatment of pediatric patients 12 years and older, who have had an inadequate response or intolerance to other systemic drug products, including biologics, with active atopic dermatitis (AD).
- (4) Treatment of adult patients, who have had an inadequate response or intolerance to one or more TNF blockers, with active ulcerative colitis (UC).
- (5) Treatment of adult patients, who have had an inadequate response or intolerance to one or more TNF blockers, with active ankylosing spondylitis (AS).
- (6) Treatment of adult patients, who have had an inadequate response or intolerance to one or more TNF blockers, with active non-radiographic axial spondyloarthritis (nr-axSpA).

### **Criteria:**

- (a) First Prescription and every 12 months:
  - i. The patient had a NEGATIVE tuberculin skin test, or if positive, has received treatment for latent TB prior to treatment.
  - ii. The patient had a NEGATIVE hepatitis B and C viral screening
- (b) For adult patients with RA
  - i. Previous treatment, or intolerance of, with Enbrel for more than sixty (60) days; and
  - ii. Previous treatment, or intolerance of, with formulary Humira biosimilar for more than sixty (60) days
- (c) For adult patients with PsA
  - i. Previous treatment, or intolerance of, with Enbrel for more than sixty (60) days; and
  - ii. Previous treatment, or intolerance of, with formulary Humira biosimilar for more than sixty (60) days; and
  - iii. Previous treatment, or intolerance of, with Taltz for more than sixty (60) days
- (d) For pediatric patients 12 years and older with AD
  - i. Previous treatment, or intolerance of, with Dupixent, or intolerance of, for more than sixty (60) days
- (e) For adult patients with UC
  - i. Previous treatment, or intolerance of, with formulary Humira biosimilar for more than sixty (60) days
- (f) For adult patients with AS and nr-asSpA
  - i. Previous treatment, or intolerance of, with Taltz for more than sixty (60) days

**GENERIC:** VALSARTAN, VALSARTAN-HCTZ

**BRAND:** DIOVAN<sup>®</sup>, DIOVAN-HCT<sup>®</sup>

### **INDICATION:**

- (1) Hypertension

### **Criteria for Valsartan:**

- (a) Failure or contraindication of 2 formulary ARBs (Irbesartan, Losartan)

### **Criteria for Valsartan-HCTZ:**

- (a) Failure or contraindication of 2 formulary ARB-HCTZ combinations (Irbesartan-HCTZ, Losartan-HCTZ)

**GENERIC:** ZOLMITRIPTAN TABLETS

**BRAND:** ZOMIG<sup>®</sup>

### **INDICATION:**

- (1) Acute treatment of migraine headache

### **Criteria:**

- (a) Failure of, intolerance to, or contraindication to one traditional formulary agent (NSAID, ergotamine, or combination analgesic); **or**
- (b) Unsuccessful concurrent or previous use of migraine prophylaxis medications (e.g., beta-blockers, calcium channel blockers, tri-cyclic antidepressants or anticonvulsants); **and**
- (c) Patient is not currently using ergotamine or another 5-HT<sub>1</sub> Receptor Agonist

<u>Product Name</u>	<u>Page</u>	<u>Product Name</u>	<u>Page</u>
A/B OTIC	19	Aluminum Hydroxide Gel*	11
Abacavir	3	AMANTADINE	15
Abacavir-Lamivudine	3	Amantadine*	3
Abacavir-Lamivudine-Zidovudine	3	AMARYL	6
Acarbose*	6	Ambrisentan	8
ACCUPRIL	8	AMETHYST	5
ACETAMINOPHEN W / COD	14	AMINOPHYLLINE	11
Acetaminophen w/ Codeine Sol*	14	Aminophylline*	11
Acetaminophen w/ Codeine*	14	Amiodarone*	8
Acetaminophen*	14	AMITIZA	11
ACETASOL HC	19	Amlodipine & Atorvastatin*	9
Acetazolamide*	8	Amlodipine & Benazepril*	7
ACETEST	21	Amlodipine*	7
Acetone Tablets	21	Ammonium Lactate*	20
Acetone Test*	21	Amox & K Clavulanate*	1
Acetylcysteine*	10	Amoxicillin*	1
ACIPHEX	12	AMOXIL	1
Acidinium Bromide	10	AMPICILLIN	1
ACTONEL	7	Ampicillin*	1
ACTOPLUS MET, ACTOPLUS MET XR	6	AMPYRA	21
ACTOS	6	ANAPROX	14
Acyclovir	20	Anastrozole*	4
Acyclovir*	3	ANDROGEL	4
ADALAT CC	7	ANDROID	4
Adalimumab-adaz, -bwwd	22	ANORO ELLIPTA	10
Adapalene*	20	ANTARA	9
ADMELOG	6	Antihemophilic Factor (Human)	17
ADRENALICK	9	Antihemophilic Factor (Recombinate)	17
ADRENALICK	10	Antiinhibitor Coagulant Complex	17
ADVAIR, ADVAIR HFA	10	Antithrombin III (Human)	17
ADVICOR	9	ANUSOL-HC	19
Afatinib Dimaleate	4	Apixaban	17
AK-TRACIN	18	Aprepitant	12
Al Hydrox-Mag Carb*	12	APRESOLINE	8
ALAVERT	10	AP-ZEL	16
Albendazole	2	ARALEN	1
ALBENZA	2	ARANESP	17
Albuterol	10	ARICEPT	18
ALBUTEROL NEBULIZER SOLUTION	10	ARIMIDEX	4
Albuterol*	10	AROMASIN	4
Albuterol-Ipratropium*	10	ASPIRIN BUFFERED	14
ALCOHOL PADS	21	Aspirin Enteric Coated*	14
Alcohol Swabs*	21	Aspirin with Buffers*	14
ALDACTAZIDE	9	Aspirin zero order*	14
ALDACTONE	9	ASTELIN	10
Alendronate + Cholecalciferol	7	Atazanavir	3
Alendronate*	7	Atazanavir and Cobicistat	3
ALFERON N	4	Atazanavir Sulfate	3
ALKERAN	3	Atenolol & Chlorthalidone*	8
ALLEGRA OTC, ODT, SUSPENSION	10	Atenolol*	7
ALLEGRA-D OTC 12hr, 24hr	10	Atorvastatin*	9
Allopurinol*	15	Atropine Sulfate*	19
Alogliptin	6	ATRIPLA (Generic)	3
ALOMIDE	18	ATROVENT HFA	10
ALPHAGAN 0.2%, ALPHAGAN P 0.15%	19	ATROVENT NASAL	10
ALTACE	8	AUBAGIO	21
Aluminum & Magnesium Hydroxide*	12	AUGMENTIN	1
ALUMINUM HYDROXIDE	11	AVALIDE	8
		AVAPRO	8
		AVC	13
		AVIANE	5

<u>Product Name</u>	<u>Page</u>	<u>Product Name</u>	<u>Page</u>
AVELOX	1	Budesonide*	10
AVONEX	21	Budesonide-Formoterol	10
AYGESTIN	5	Busulfan	3
Azathioprine*	21	Butabarbital	13
Azelastine* (Nasal)	10	BUTISOL	13
Azelastine 0.05% eye drops	18	Butalbital/APAP/Caffeine *	14
Azithromycin suspension*	1	Butalbital/Aspirin/Caffeine *	14
Azithromycin*	1	Butoconazole Nitrate*	13
AZULFIDINE	2	BYDUREON	6
AZULFIDINE	12	CADUET	9
BACITRACIN (Topical)	19	CALAN, SR	7
Bacitracin* Ophthalmic	18	Calcipotriene*	20
Bacitracin* Topical	19	Calcitonin (Salmon)	6
BACITRACIN-POLYMYXIN-NEOMYCIN-HC	19	Calcitonin (Salmon)*	6
Bacitracin-Polymyxin B*	18	Calcitriol*	16
Bacitracin-Polymyxin-Neomycin-HC*	19	Calcium Acetate*	16
BACLOFEN	15	Calcium Carbonate*	12
Baclofen*	15	Calcium Carbonate*	16
BACMIN	16	CALIBRATION SOLUTION	21
BACTRIM / DS	2	Calibration Solution*	21
BACTROBAN	19	Capecitabine*	4
BASAGLAR	6	CAPTOPRIL	8
B-D INSULIN SYRINGE	21	Captopril*	8
Beclomethasone Dipropionate	10	CARAFATE SUSPENSION	12
BENADRYL	9	CARAFATE TABLETS	12
BENADRYL	13	Carbamide Peroxide*	19
Benazepril*	8	Carbidopa-Levodopa*	15
BENTYL	12	CARDIZEM/CD	7
BENZAC W	20	CARDURA	8
Benzocaine & Antipyrine*	19	Carvedilol*	7
Benzonatate*	11	CASODEX	4
Benzoyl Peroxide*	20	CATAPRES	8
BETAMETHASONE DIPROPIONATE	20	CEFACLOR	1
Betamethasone Dipropionate*	20	CEFDINIR	1
BETAMETHASONE VALERATE	20	Cefdinir*	1
Betamethasone Valerate*	20	Cefixime	1
BETAPACE	7	CEFPROZIL	1
BETASERON	21	Cefprozil*	1
Betaxolol	7	CEFTIN	1
Betaxolol*	18	Ceftriaxone*	1
Bethanechol*	13	Cefuroxime*	1
BETIMOL	18	CELEBREX	15
BETOPTIC, BETOPTIC S	18	Celecoxib	15
BEYAZ	5	CELLCEPT	21
BIAXIN	1	CENTRUM	16
Bicalutamide*	4	Cephalexin*	1
BICILLIN	1	CEPHRADINE	1
Bictegravir/Emtricitabine/TAF	3	Cephradine*	1
BIKTARVY	3	CERALYTE, CERASPORT	16
Bisacodyl*	11	Cetirizine tabs*	10
Bismuth Subsalicylate*	11	Cetirizine*	10
BLEPH-10	18	Charcoal Activated	21
BLEPHAMIDE	19	CHARCOCAPS	21
Blood Glucose Monitoring Tests*	21	CHEMET	21
BONIVA	7	Chlorambucil	3
BREVICON	5	Chlorhexidine*	2
Brimonidine Tartrate	19	Chloroquine*	1
Bromocriptine*	15	Chlorothiazide*	9
BROMPHENIRAMINE	11	CHLORPHENIRAMINE	11
BROMPHENIRAMINE /	11	Chlorpheniramine*	11
Brompheniramine / Pseudoephedrine*	11	CHLORTHALIDONE	9
Brompheniramine*	11	Chlorthalidone*	9
Budesonide	10	Cholecalciferol*	16

<u>Product Name</u>	<u>Page</u>	<u>Product Name</u>	<u>Page</u>
Cholestyramine*	9	Cromolyn (nasal)*	10
CHOLINE & MAG SALICYLATE	14	CRYSELLE	5
Choline & Mag Salicylate*	14	CUPRIMINE	21
Cilostazol	18	Cyanocobalamin*	17
CILOXAN	18	CYCLESSA	5
CIPRO	1	CYCLOBENZAPRINE	15
Ciprofloxacin*	1	Cyclobenzaprine*	15
Ciprofloxacin*	18	Cyclophosphamide*	3
CITROMA	11	Cycloserine	2
Clarithromycin*	1	Cyclosporine Microsize*	21
CLARITIN	10	CYTOMEL	6
CLARITIN-D 12hr, 24hr	10	CYTOVENE	2
Clemastine*	10	CYTOXAN	3
CLEOCIN (Vaginal)	13	Dabigatran	17
CLEOCIN (Topical)	20	Dalfampridine	21
CLEOCIN	1	DANAZOL	4
CLIMARA	5	Danazol*	4
Clindamycin Phosphate*	20	DANTRIUM	15
Clindamycin*	1	Dantrolene*	15
Clindamycin*	13	Dapagliflozin	6
CLINITEST	21	DAPSONE	2
Clobetasol Propionate*	20	Dapsone*	2
Clonidine & Chlorthalidone*	8	DARAPRIM	1
Clonidine*	8	Darbepoetin	17
Clonidine*	18	Darifenacin Hydrobromide	13
Clopidogrel*	18	Darunavir and Cobicistat	3
CLORPRES	8	Darunavir Ethanolate	3
Clotrimazole Topical*	20	Darunavir / Cobicistat / FTC / TAF	3
CLOTRIMAZOLE TROCHE	19	DDAVP	7
Clotrimazole Vag*	13	DEBROX	19
Clotrimazole*	19	DEMEROL	14
COAL TAR SHAMPOO 1%	20	DEPO-PROVERA, DEPO-SQ PROVERA	5
Coal Tar*	20	DESCOVY	3
Codeine Phosphate	14	Desmopressin*	7
Codeine Sulfate	14	DESOGEN	5
COLACE	11	Desogest-Eth Estrad & Eth Estrad	5
Colchicine	15	Desogest-Ethin Est*	5
COLCRYS	15	Desogestrel & Ethinyl Estradiol*	5
COLESTID	9	Desonide*	20
Colestipol*	9	DESOWEN	20
Collagenase	20	DETROL	13
COMBIVENT RESPIMAT	10	DEXAMETHASONE (Ophthalmic)	18
COMBIVIR	3	Dexamethasone* Ophthalmic	18
COMPLERA	3	Dexamethasone*	4
COMTAN	15	DIABETA	6
Condoms	21	DIAMOX	8
CONDYLOX	20	DICLEGIS	12
Conjugated Estrogens &	5	Diclofenac*	14
COPAXONE	21	Diclofenac* 1% Gel	20
CORDARONE	8	Diclofenac Sodium* Ophthalmic	19
COREG	7	DICLOXACILLIN SODIUM	1
CORTEF	4	Dicloxacin Sodium*	1
CORTISONE	4	Dicyclomine*	12
Cortisone*	4	DIFFERIN	20
CORTISPORIN (Ophthalmic)	19	DIFLUCAN	2
CORTISPORIN (Otic)	19	Digoxin*	7
CORTISPORIN (Topical)	19	DILACOR/XR	7
COSOPT	18	DILANTIN	15
COUMADIN	17	DILAUDID	14
COZAAR	8	Diltiazem*	7
CREON	12	Dimethyl Fumarate	21
CRESTOR	9	DIOVAN	8
Cromolyn (inhalation)*	10	DIOVAN HCT	8

<u>Product Name</u>	<u>Page</u>	<u>Product Name</u>	<u>Page</u>
Diphenhydramine*	9	ENTRESTO	9
Diphenhydramine*	13	EPCLUSA (Generic)	3
Diphenoxylate w/ Atropine*	11	Epinephrine	9
Dipyridamole*	7	Epinephrine	10
DISALCID	14	EPI-PEN, EPI-PEN JR	9
Disopyramide*	8	EPI-PEN, EPI-PEN JR	10
Disposable Needles & Syringes*	21	EPIVIR	3
DITROPAN, DITROPAN XL	13	Epoetin Alfa	17
DIURIL	9	EPOGEN	17
Docusate Sodium*	11	EPZICOM	3
DOLISHALE	5	Ergocalciferol*	16
Dolutegravir	3	Ergoloid mesylates*	15
Dolutegravir / Abacavir / Lamivudine	3	Erlotinib	4
Dolutegravir / Lamivudine	3	ERYGEL	20
Dolutegravir / Rilpivirine	3	ERY-TAB	1
Donepezil*	18	ERYTHROCIN	1
Dorzolamide HCL-Timolol Maleate*	18	Erythromycin Base*	1
Dorzolamide*	19	ERYTHROMYCIN ESTOLATE	1
DOVATO	3	Erythromycin Estolate*	1
DOVONEX	20	Erythromycin Ethylsuccinate*	1
Doxazosin*	8	Erythromycin Gel*	20
Doxycycline*	1	Erythromycin Stearate*	1
Doxylamine Succinate/Pyridoxine HCL	12	Erythromycin* (Ophthalmic)	18
DRISDOL	16	ERYTHROMYCIN/SULFISOXAZOLE	2
Drospirenone-Eth Estrad Levomefolate	5	Erythromycin/Sulfisoxazole*	2
Drospirenone-Ethinyl Estradiol*	5	Esomeprazole Magnesium	12
DUETACT	6	Esterified Estrogens	5
Dulaglutide	6	ESTRACE	5
DULCOLAX	11	Estradiol TD Patch*	5
DUONEB	10	Estradiol Valerate-Dienogest	5
DUPIXENT	20	Estradiol*	5
Dupilumab	20	Estrogens, Conjugated	5
DURAGESIC	14	ESTROSTEP FE	5
E.E.S.	1	Etanercept	21
ECOTRIN	14	Ethambutol*	2
Efavirenz	3	Ethionamide	2
Efavirenz / Emtricitabine / Tenofovir DF	3	Ethosuximide*	15
EFUDEX	4	Ethinodiol Diacet-Eth Estrad*	5
EFUDEX	20	ETODOLAC	14
Elbasvir-Grazoprevir	3	Etodolac*	14
ELDEPRYL	15	Etonogestrel-Ethinyl Estradiol	5
ELIDEL	20	ETOPOSIDE	4
ELIMITE	20	Etoposide*	4
ELIQUIS	17	Etravirine	3
ELURYNG	5	EVISTA	7
Elvitegravir / Cobicistat / FTC / TAF	3	Evolocumab	9
Elvitegravir / Cobicistat / Emtricitabine / TDF	3	EVOTAZ	3
EMEND	12	EXELON	18
EMLA	15	Exemestane*	4
Empagliflozin	6	Exenatide	6
Empagliflozin/linagliptin	6	Ezetimibe	9
Emtricitabine / Rilpivirine / TAF	3	Ezetimibe + Simvastatin	9
Emtricitabine / Rilpivirine / TDF	3	Famotidine*	12
Emtricitabine / Tenofovir Disoproxil	3	FARXIGA	7
Emtricitabine / Tenofovir Alafenamide	3	FEIBA VH	17
ENABLEX	13	FELDENE	14
Enalapril*	8	FELODIPINE	7
ENBREL	22	Felodipine*	7
ENFAMIL / SIMILAC	17	FEMARA	4
Enoxaparin*	17	FEMCON FE	5
ENSURE, PEDIASURE, BOOST	17	Fenofibrate	9
Entacapone*	15	Fenofibrate acid*	9
ENTECAVIR		Fenofibrate micronized	9

<u>Product Name</u>	<u>Page</u>	<u>Product Name</u>	<u>Page</u>
Fenofibrate tablets*	9	GENTAK	18
Fenofibrate*	9	GENTAMICIN	19
Fenofibric Acid	9	Gentamicin Sulfate* (Ophthalmic)	18
Fenoprofen*	14	Gentamicin Sulfate* Topical	19
Fentanyl*	14	Gentamicin Sulfate*	2
FEOSOL	17	GENVOYA	3
FERGON	17	GG/Codeine sol*	11
Ferrous Gluconate*	17	GILOTRIF	4
Ferrous Sulfate*	17	Glatiramer acetate	21
Fesoterodine Fumarate	13	Glecaprevir-Pibrentasvir	3
Fexofenadine / Pseudoephedrine*	10	GLEEVEC	4
Fexofenadine*	10	Glimepiride*	6
FIASP	6	Glipizide*	6
FIBERCON	11	Glucagon	6
FIBRICOR	9	GLUCOLET / AUTOLET	21
Filgrastim	17	GLUCOMETER	21
Filgrastim-Ayow	17	GLUCOPHAGE/XR	6
Finasteride*	13	GLUCOSE BLOOD	21
FIORICET	14	Glucose Blood*	21
FIORINAL	14	Glucose Urine Test*	21
FLAGYL	2	GLUCOTROL/XL	6
FLAVOXATE	13	Glyburide*	6
Flavoxate*	13	GLYCERIN	11
Flecainide*	8	GLYCERIN (Suppository)	9
FLOMAX	8	Glycerin Supp*	9
FLONASE	10	Glycerin*	11
FLO-PRED	4	GLYNASE	6
FLOVENT HFA	10	GLYXAMBI	6
Fluconazole*	2	GOLYTELY	11
FLUDROCORTISONE	4	GRIFULVIN V	2
Fludrocortisone*	4	Griseofulvin Microsize*	2
Flunisolide* (nasal)	10	Griseofulvin Ultramicrosize*	2
FLUOCINONIDE	20	GRIS-PEG	2
Fluocinonide Acetonide*	20	GUAIFENESIN	11
Fluocinonide*	20	GUAIFENESIN DM	11
Fluorouracil*	4	Guaifenesin*	11
Fluorouracil*	20	Guaifenesin/DM*	11
FLURBIPROFEN	14	Guanfacine*	8
Flurbiprofen* (ophthalmic)	19	Guanfacine*	18
Flurbiprofen*	14	GUIATUSS AC	11
FLUTAMIDE	4	GYNAZOLE-1	13
Flutamide*	4	HADLIMA	22
Fluticasone (inhaled)	10	HARVONI (generic)	3
Fluticasone* (nasal)	10	HUMALOG	6
Fluvastatin*	9	HUMATROPE ONLY	7
Folic Acid & Vitamin B Complex*	16	HUMULIN 50/50	6
Folic Acid*	17	HUMULIN 70/30	6
FORTEO	7	HUMULIN N	6
FOSAMAX	7	HUMULIN R	6
FOSAMAX PLUS D	7	HYDERGINE	15
Fosamprenavir	3	HYDRALAZINE & HCTZ	8
FOSINOPRIL	8	Hydralazine & HCTZ*	8
Fosinopril*	8	Hydralazine*	8
FREESTYLE LIBRE	21	HYDREA	4
FURADANTIN	13	HYDROCHLOROTHIAZIDE	9
Furosemide*	9	Hydrochlorothiazide*	9
Galantamine*	18	Hydrocodone w/ Acetaminophen*	14
Ganciclovir*	2	HYDROCORTISONE	20
GARAMYCIN	2	Hydrocortisone w/Acetic Acid* (Otic)	19
Gatifloxacin*	18	Hydrocortisone*	19
GAVILYTE	11	Hydrocortisone*	19
GAVILYTE	11	Hydrocortisone*	20
Gemfibrozil*	9	Hydromorphone*	14

<u>Product Name</u>	<u>Page</u>	<u>Product Name</u>	<u>Page</u>
HYDROXOCOBALAMIN	17	KAPVAY	18
Hydroxocobalamin*	17	KAYEXALATE	21
Hydroxychloroquine*	1	KEFLEX	1
Hydroxyurea*	4	KENALOG	20
Hyoscyamine	13	KERALAC	20
Hyoscyamine Sulfate*	12	Ketoconazole*	2
HYRIMOZ (UNBRANDED)	22	KETOSTIX	21
HYZAAR	8	Ketotifen Fumarate Ophth Soln*	18
Ibandronate*	7	KLOR-CON	16
Ibuprofen*	14	KOATE-DVI, HP, HEMOFIL M	17
ICLEVIA	5	Labetalol*	7
Imatinib Mesylate	4	LAC-HYDRIN	20
IMDUR	7	LACTULOSE	11
IMITREX	15	LAMISIL	2
IMODIUM	11	Lamivudine	3
IMURAN	21	Lamivudine HBV	3
INDAPAMIDE	9	Lamivudine-Zidovudine	3
Indapamide*	9	Lancet Device	21
INDERAL/LA	7	Lancets*	21
INDOCIN	14	LANOXIN	7
Indomethacin*	14	Lansoprazole*	12
Infant Foods	17	LASIX	9
Insulin Aspart	6	Latanoprost*	19
Insulin Glargine	6	Ledipasvir-Sofosbuvir*	3
Insulin Glargine-aglr	6	LESCOL	9
Insulin Glargine-yfgn	6	LETAIRIS	8
Insulin Isophane	6	Letrozole*	4
Insulin Lispro	2	LEUCOVORIN	17
Insulin Pen Needles	21	Leucovorin Calcium*	17
Insulin Reg & Isophane	6	LEUKERAN	3
Insulin Reg & NPH	6	Leuprolide	4
Insulin Regular	6	LEVAQUIN	1
INTAL	10	Levofloxacin*	1
INTELENCE	3	Levonorgestrel & Ethinyl Estradiol*	5
Interferon Alfa-2A	4	Levonorgestrel*	5
Interferon Alfa-2B	4	Levonorgestrel-Eth Estradiol*	5
Interferon Alfa-n3	4	Levonorgestrel-Ethinyl Estradiol	5
Interferon Beta-1a	21	Levonorgestrel-Ethinyl Estradiol*	5
Interferon Beta-1b	21	Levothyroxine*	6
INTRON-A	4	LEVOXYL	6
INTUNIV	18	LEVSIN	12
IPECAC	21	LEVSINEX	13
Ipecac*	21	LEXIVA	3
Ipratropium	10	LIDOCAINE	15
Ipratropium*	10	LIDOCAINE VISCOUS	20
Ipratropium-Albuterol	10	Lidocaine viscous*	20
Irbesartan & HCTZ*	8	Lidocaine*	15
Irbesartan*	8	Lidocaine/Prilocaine	15
ISENTRESS	3	LIDODERM PATCHES	15
ISONIAZID	2	LIGHT	9
Isoniazid*	2	LINDANE	20
ISOPTO ATROPINE	19	Lindane*	20
ISOPTO-CARPINE	19	Liothyronine*	6
ISORDIL, ISORDIL TEMBIDS	7	LIPITOR	9
Isosorbide Dinitrate*	7	LIPOFEN	9
Isosorbide Mononitrate*	7	Liraglutide	6
Itraconazole*	2	Lisinopril & HCTZ*	8
Ivermectin*	2	Lisinopril*	8
Ixekizumab	20	LO LOESTRIN FE	5
JANUVIA	6	Lodoxamide Tromethamine	18
JARDIANCE	6	LOESTRIN, LOESTRIN FE	5
JULUCA	3	LOFIBRA	9
KALETRA	3	LOMOTIL	11

<u>Product Name</u>	<u>Page</u>	<u>Product Name</u>	<u>Page</u>
Lomustine	4	Methocarbamol*	15
Loperamide*	11	Methotrexate	4
LOPID	9	Methotrexate*	15
Lopinavir / Ritonavir	3	METHYCLOTHIAZIDE	9
LOPRESSOR	7	Methyclothiazide*	9
LOPRESSOR HCT	8	METHYLDOPA	8
LORABID SUSPENSION	1	METHYLDOPA & HCTZ	8
Loracarbef	1	Methyldopa & HCTZ*	8
Loratadine / Pseudoephedrine*	10	Methyldopa*	8
Loratadine*	10	Methylergonovine*	6
LORTAB	14	Methylprednisolone*	4
Losartan potassium*	8	Methyltestosterone	4
Losartan potassium/HCTZ*	8	Metoclopramide*	12
LOSEASONIQUE	5	Metolazone*	9
LOTENSIN	8	Metoprolol & HCTZ*	8
LOTREL	7	Metoprolol Succinate*	7
LOTRIMIN	20	Metoprolol Tartrate*	7
Lovastatin*	9	METROGEL	19
LOVAZA	9	METROGEL-VAGINAL	13
LOVENOX	17	Metronidazole*	2
Lubiprostone	11	Metronidazole* Vaginal	13
LUPRON	4	Metronidazole* Topical	19
LURIDE	16	MEVACOR	9
LYLEQ	5	MEXILETINE	8
LYSODREN	4	Mexiletine*	8
MAALOX	12	MIACALCIN INJ	6
MACROBID	13	MIACALCIN NASAL	6
Magnesium Citrate*	11	Miconazole*	2
MANDELAMINE	13	Miconazole* Vaginal	13
MATULANE	4	Miconazole* Topical	19
MAVYRET	3	MICRO-K	16
MAXALT	15	Milnacipran	16
MAXITROL	19	MINIPRESS	8
MAXZIDE	9	MINOXIDIL	8
MEBARAL	13	Minoxidil*	8
MECLIZINE	12	Mirabergron	13
Meclizine*	12	MIRALAX	11
MEDROL	4	MIRCETTE	5
Medroxyprogesterone Acetate	5	Mitotane	4
Medroxyprogesterone*	5	MOBIC	14
MEGACE	4	MODICON	5
Megestrol*	4	Mometasone furoate (nasal)	10
Meloxicam*	14	MONISTAT	2
Melphalan	3	MONISTAT (topical)	20
Memantine	18	MONISTAT (Vaginal)	13
MENEST	5	Montelukast Sodium*	11
Meperidine*	14	Morphine Sulfate SR*	14
Mephobarbital	13	Morphine Sulfate*	14
Mercaptopurine*	4	MOTRIN	14
Mesalamine	12	MOVIPREP*	11
Mesalamine*	12	Moxifloxacin Hydrochloride Ophthalmic	18
MESTINON	16	Moxifloxacin*	1
METAMUCIL	11	MS CONTIN	14
Metformin*	6	MUCOMYST	10
Metformin Extended Release	6	Multiple Vitamin w/ Minerals*	16
Methadone*	14	Multiple Vitamin*	16
METHAZOLAMIDE	8	Mupirocin*	19
Methazolamide*	8	MYAMBUTOL	2
Methenamine Mandelate*	13	MYCELEX	13
METHERGINE	6	MYCOBUTIN	2
Methimazole*	6	Mycophenolate Mofetil*	21
Methocarbamol w/ Aspirin*	16	Mycophenolate Sodium*	21
METHOCARBAMOL w/ASA	16	MYDFRIN	19

<u>Product Name</u>	<u>Page</u>	<u>Product Name</u>	<u>Page</u>
MYFORTIC	21	Norethindrone-Ethinyl Estradiol FE	5
MYLANTA	12	Norethindrone-Ethinyl Estradiol*	5
MYLERAN	3	Norethindrone-Mestranol	5
MYRBETRIQ	13	Norgestimate-Ethinyl Estradiol*	5
MYSOLINE	15	Norgestrel-Ethinyl Estradiol*	5
MYSOLINE	18	NORINYL	5
Nafarelin	7	NORPACE, CR	8
NALFON	14	NOR-QD	5
NAMENDA	18	NORVASC	7
NAPHAZOLINE	19	NORVIR	3
Naphazoline*	19	NOVOLIN 70/30	6
NAPROSYN	14	NOVOLIN N	6
Naproxen Sodium*	14	NOVOLIN R	6
Naproxen*	14	NOVOLOG	6
NASACORT AQ	10	NOVOLOG 50-50	6
NASALCROM	10	Nutritional Supplements	17
NASALIDE	10	NUVARING	5
NASONEX	10	Nylia 7/7/7	5
NATAZIA	5	NYSTATIN TAB	2
NECON	5	Nystatin*	2
NEOMYCIN (tablets)	2	Nystatin* (Vaginal)	13
NEOMYCIN	19	Nystatin*	19
Neomycin Sulfate*	2	Nystatin* (Topical)	20
NEOMYCIN-BAC ZN-POLYMYXIN	18	NYSTATIN-TRIAMCINOLONE	20
Neomycin-Bac Zn-Polymyxin*	18	Nystatin-Triamcinolone*	20
Neomycin-Bacitracin-Polymyxin*	19	Octreotide Acetate*	11
Neomycin-Polymyxin-Gramicidin*	18	OCUFEN	19
Neomycin-Polymyxin-Dexamethasone*	19	OCUFLOX	18
Neomycin-Polymyxin-Hydrocortisone*	19	ODEFSEY	3
NEORAL	21	Ofloxacin ophthalmic	18
NEOSPORIN	19	Ofloxacin OTIC	19
NEPHROCAPS	16	OGESTREL	5
NESINA	6	Olodaterol	10
NEULASTA	17	Olopatadine HCL Ophth soln 0.1%	18
Nevirapine	3	Olopatadine HCL Ophth soln 0.2%	18
NEXAVAR	4	Omalizumab	10
NEXIUM 24 HR OTC	12	Omega-3-acid ethyl esters*	9
NIACIN	9	Omeprazole	12
NIACIN	16	Ondansetron tabs, ODT, & Suspension	12
Niacin & Lovastatin	9	ONE-A-DAY	16
Niacin CR*	9	OPTICHAMBER	21
Niacin*	9	OPTIVAR (generic)	18
Niacin*	16	ORACIT	13
Niacin-Simvastatin	9	ORACIT	16
NIASPAN	9	Oral Electrolytes*	16
Nifedipine*	7	Oral Electrolytes Packets*	16
NITRODUR, NITROBID	7	ORAPRED	4
Nitrofurantoin Macrocrystals*	13	ORTHO MICRON	5
Nitrofurantoin*	13	ORTHO NOVUM 7/7/7	5
Nitroglycerin (oral)*	7	ORTHO TRI-CYCLEN / LO	5
Nitroglycerin (topical)*	7	ORTHO-CEPT	5
NITROSTAT	7	ORTHO-CYCLEN	5
NIX	20	OS-CAL	12
NIZORAL	2	OS-CAL	16
NORCO	14	Oseltamivir Phosphate	2
NORDETTE	5	OSMOPREP	11
Norelgestromin-Ethinyl Estradiol*	5	OXACILLIN	1
Norethindrone & Ethinyl Estrad FE*	5	Oxacillin*	1
Norethindrone Ace-Ethinyl Estrad FE*	5	Oxybutynin*, Oxybutynin ER*	13
Norethindrone Ace-Ethinyl Estrad*	5	Oxycodone*	14
Norethindrone Acetate*	5	Oxycodone CR*	14
Norethindrone Ac-Ethinyl Estrad FE*	5	Oxycodone w/ Acetaminophen*	14
Norethindrone*	5	OXYCONTIN	14

<u>Product Name</u>	<u>Page</u>	<u>Product Name</u>	<u>Page</u>
Palivizumab	3	POLY-VI-SOL / IRON	16
Pancrelipase (Lip-Prot-Amyl)	12	Potassium Chloride Capsule*	16
Pancrelipase (Lip-Prot-Amyl) DR	12	POTASSIUM CHLORIDE LIQUID	16
Pantoprazole*	12	Potassium Chloride Liquid*	16
PARLODEL	15	Potassium Chloride Tablet*	16
PATADAY	18	PRADAXA	17
PATANOL	18	PRANDIN	6
PEDIA RELIEF LIQ COUGH/COLD	11	PRAVACHOL	9
PEDIALYTE	16	Pravastatin*	9
PEDIAPRED	4	Prazosin*	8
Pediatric Multivitamins w/Fluoride and Iron	16	PRECOSE	6
Pediatric Multivitamins w/Fluoride	16	PRED FORTE, MILD	18
Pediatric Multivitamins w/Iron	16	Prednisolone Acetate	18
Pediatric Multivitamins	16	Prednisolone Acetate	4
Pediatric Vitamin ADC w/Iron	16	Prednisolone Na Phosphate	4
Pediatric Vitamin ADC*	16	Prednisolone	4
Pediatric Vitamins*	16	PREDNISONE	4
PEG-Electrolyte*	11	Prednisone	4
Pegfilgrastim	17	PRELONE	4
Peginterferon	3	PREMARIN	5
PEG-INTRON, PEGASYS	3	PREMPRO	5
Penicillamine	21	PRENATABS RX	16
Penicillin G Benzathine	1	Prenatal MV & Min w/FE-FA	16
PENICILLIN V POTASSIUM	1	Prenatal Vitamins	16
Penicillin V Potassium*	1	PRENATAL-1	16
PENTASA	12	PREVACID	12
Pentoxifylline*	18	PREVACID SOLU-TAB	12
PEPCID	12	PREZCOBIX	3
PEPTO-BISMOL	11	PREZISTA	3
PERCOCET	14	PRILOSEC OTC	12
PERIOGARD	2	Primidone*	15
Permethrin*	20	PROAIR HFA	10
PERSANTINE	7	PROBENECID	15
Phenazopyridine*	13	Probenecid*	15
PHENOBARBITAL	13	PROCAINAMIDE	8
Phenobarbital*	13	Procainamide*	8
Phenylephrine*	11	Procarbazine	4
Phenylephrine* Ophthalmic	19	PROCARDIA XL	7
PHENYL-FREE	17	PROCHLORPERAZINE	12
Phenyl-Free*	17	Prochlorperazine*	12
Phenytoin*	15	PROCTOCREAM	19
PHOSLO	16	PROGRAF	21
Pilocarpine* Ophthalmic	19	PROMETHAZINE	10
Pimecrolimus	20	Promethazine*	10
PIN - X	2	Propafenone*	8
Pioglitazone*	6	PROPANTHELINE BROMIDE	12
Pioglitazone-Glimepiride	6	Propantheline Bromide*	12
Pioglitazone-Metformin SR	6	PROPRANOLOL & HCTZ	8
Pioglitazone-Metformin	6	Propranolol & HCTZ*	8
Piroxicam	14	Propranolol*	7
PLAN B	5	PROPYLTHIOURACIL	6
PLAN B ONE STEP	5	Propylthiouracil*	6
PLAQUENIL	1	PROSCAR	13
PLAVIX	18	PROTONIX (Generic)	12
PLETAL	18	PROTOPIC	20
PLENVU	11	PROVENTIL HFA	10
Podofilox	20	PROVERA	5
Polycarbophil Calcium	11	PSEUDOEPHED-BROMPHEN DM	11
Polyethylene Glycol powder	11	PSEUDOEPHEDRINE	10
Polymyxin B-Trimethoprim	18	Pseudoephedrine HCL*	10
POLYSPORIN	18	Pseudoephedrine-Bromphen-DM*	11
POLYTRIM	18	Pseudoephedrine-Chlorphen-DM*	11
POLY-VI-SOL	16	Pseudoephedrine-DM liquid*	11

<u>Product Name</u>	<u>Page</u>	<u>Product Name</u>	<u>Page</u>
PSEUDOEPHEDRINE-DM SOLN	11	ROWASA	12
Pseudoephedrine-DM soln*	11	ROXICODONE	14
Pseudoephedrine-GG*	11	RYTHMOL	8
PSEUDO-G / PSI	11	Sacubitril & Valsartan	9
Psyllium*	11	SAFYRAL	5
PULMICORT FLEXHALER	10	Salmeterol	10
PULMICORT RESPULES	10	Salmeterol-Fluticasone	10
PURINETHOL	4	Salsalate*	14
Pyrantel Pamoate*	2	SANDOSTATIN	11
PYRAZINAMIDE	2	SANTYL	20
Pyrazinamide*	2	SAVELLA	16
PYRIDIDIUM	13	SEASONIQUE	5
Pyridostigmine*	16	Selegiline*	15
Pyrimethamine	1	SENNA-S	11
QUARTETTE	5	Sennosides*	11
QUESTRAN	9	Sennosides/Docusate*	11
Quinapril*	8	SENOKOT	11
QUINIDINE SULFATE	8	SEREVENT DISKUS	10
Quinidine Sulfate*	8	SEROMYCIN	2
QVAR	10	Sildenafil Citrate	7
Raloxifene*	7	SILVADENE	20
Raltegravir	3	Silver Sulfadiazine*	20
Ramipril*	8	SIMCOR	9
Ranitidine*	12	Simvastatin*	9
RAPAMUNE	21	SINEMET, CR	15
RAZADYNE / RAZADYNE ER	18	SINGULAIR	11
REBETOL	3	Sirolimus*	21
REBIF	21	Sitagliptin Phosphate	6
RECOMBINATE	17	SKYRIZI	20
REGLAN	12	Sodium Citrate & Citric Acid*	13
RELENZA	2	Sodium Citrate & Citric Acid*	16
RELEUKO	17	Sodium Fluoride*	16
Repaglinide	6	Sodium Polystyrene Sulfonate*	21
REPATHA	9	Sodium Sulfacetamide* Ophthalmic	18
REQUIP	15	Sofosbuvir-Velpatasvir*	3
RESERPINE	8	Sofosbuvir-Velpatasvir-Voxilaprevir	3
Reserpine*	8	Solifenacin	13
RESTASIS	19	Somatropin	7
RETIN-A	20	Sorafenib	4
RETROVIR	3	Sotalol*	7
REVATIO	7	Spacer	21
REYATAZ	3	SPIRIVA	10
RHEUMATREX	15	Spironolactone & HCTZ*	9
RHEUMATREX	4	Spironolactone*	9
Ribavirin*	3	SPORANOX	2
Rifabutin*	2	Stavudine	3
RIFADIN	2	STIOLTO	10
Rifampin*	2	STRIBILD	3
RILUTEK	16	STRIVERDI	10
Riluzole*	16	STROMEKTOL	2
RINVOQ	22	Succimer	21
Risankizumab-Rzaa	20	Sucralfate*	12
Risedronate	7	SUDAFED	11
Rivaroxaban	17	SULFACETAMIDE SODIUM	20
Rivastigmine*	18	Sulfacetamide Sodium* topical	20
Rizatriptan tablets*	15	Sulfacetamide Sod-Prednisolone*	19
ROBAXIN	15	SULFADIAZINE	2
ROCALTROL	16	Sulfadiazine*	2
ROCEPHIN	1	Sulfanilamide	13
ROFERON-A	4	Sulfasalazine*	2
ROMYCIN	18	SULFISOXAZOLE	2
Ropinirole*	15	Sulfisoxazole*	2
Rosuvastatin Calcium	9	SULINDAC	14

<u>Product Name</u>	<u>Page</u>	<u>Product Name</u>	<u>Page</u>
Sulindac*	14	Tolterodine Tartrate	13
Sumatriptan injection*	15	TOPROL XL	7
Sumatriptan nasal*	15	TOUJEO	6
Sumatriptan tablets*	15	TOVIAZ	13
Sumatriptan-naproxen	15	Tramadol ER*	14
SUMYCIN	1	Tramadol*	14
SUPRAX	1	Tramadol/APAP*	14
SUPREP*	11	TRANDATE	7
SUSTIVA	3	TRECATOR	2
SUTAB	11	TRELEGY	10
SYMBICORT	10	TRENTAL	18
SYMTUZA	3	Tretinoin* Topical	20
SYNALAR	20	TREXIMET	15
SYNAREL	7	TRIAM. ACET. IN ORABASE	20
SYNTHROID	6	Triamcinolone* Nasal	10
TABLOID	4	Triamcinolone Acetonide in Orabase*	20
Tacrolimus ointment*	20	Triamcinolone Acetonide*	20
Tacrolimus*	21	TRIAMINIC AM LIQ CGH/DECON	11
TALTZ	20	Triamterene & HCTZ*	9
TAMBOCOR	8	TRICOR	9
TAMIFLU	2	Trifluridine*	18
TAMOXIFEN	4	TRIGLIDE	9
Tamoxifen*	4	TRILIPIX	9
Tamsulosin*	8	TRIMETHOPRIM	2
TAPAZOLE	6	Trimethoprim*	2
TARCEVA	4	Trimethoprim/Sulfamethoxazole*	2
TAVIST	10	TRI-NYMYO	5
TECFIDERA	21	TRIPLE SULFAS VAGINAL	13
TEMOVATE	20	Triple Sulfas Vaginal*	13
TENEX	8	TRIUMEQ	3
Tenofovir Disoproxil Fumarate	3	TRI-VI-FLOR	16
TENORETIC	8	TRI-VI-FLOR / IRON	16
TENORMIN	7	TRI-VI-SOL	16
TERAZOSIN	8	TRI-VI-SOL / IRON	16
Terazosin*	8	TRIVORA	5
Terbinafine*	2	TRIZIVIR	3
Teriflunomide	21	TROSPIUM	13
Teriparatide	7	Tropium*	13
TESSALON	11	TRULICITY	6
TESSALON PERLES	11	TRUSOPT	19
TESTIM	4	TRUVADA (Generic)	3
Testosterone Gel	4	TUDORZA PRESSAIR	10
Testosterone Injectable	4	TYLENOL	14
Tetracycline*	1	TYLENOL / CODEINE	14
THEO-24	11	ULTRACET	14
THEOCHRON	11	ULTRAM	14
Theophylline*	11	ULTRAM ER	14
Thiamine	17	Umeclidinium-Vilanterol	10
Thioguanine	4	UMECTA	20
THROMBATE III	17	Upadacitinib	22
Thrombin	17	URAMAXIN GEL 45%	20
THYQUIDITY	6	Urea*	20
THYROID	6	Urea 45%*	20
Thyroid*	6	URECHOLINE	13
TIMOLOL	7	Valsartan	8
Timolol*	7	Valsartan & HCTZ*	8
Timolol*	18	VASOTEC	8
TIMOPTIC	18	VENTOLIN HFA	10
Tiotropium	10	Verapamil*	7
Tiotropium-Olodaterol	10	VESICARE	13
TIVICAY	3	VIBRAMYCIN	1
TOBRADEX	19	VICODIN	14
Tobramycin-Dexamethasone*	19	VICTOZA	6

<u>Product Name</u>	<u>Page</u>	<u>Product Name</u>	<u>Page</u>
VIGAMOX	18		
VIRAMUNE	3		
VIREAD	3		
VIROPTIC	18		
VITAMIN A	16		
Vitamin A*	16		
VITAMIN B-12 tablets	17		
VITAMIN B-12 Injectable	17		
Vitamin D2	16		
VITAMIN D3	16		
VITAMIN K	16		
VIVONEX	17		
VOLTAREN	14		
VOLTAREN Ophthalmic	19		
VOLTAREN 1% Gel	20		
VOSEVI	3		
VYTORIN	9		
Warfarin Sodium*	17		
XALATAN	19		
XELODA	4		
XIFAXAN	1		
XODOL	14		
XOLAIR	10		
XULANE	5		
YASMIN	5		
YAZ	5		
ZADITOR	18		
ZAFEMY	5		
Zanamivir	2		
ZANTAC	12		
ZARONTIN	15		
ZAROXOLYN	15		
ZEPATIER	3		
ZERIT	3		
ZESTORETIC	8		
ZESTRIL	8		
ZETIA	9		
ZIAGEN	3		
Zidovudine	3		
ZITHROMAX	1		
ZOCOR	9		
ZOFRAN Tablets, Suspension, ODT	12		
Zolmitriptan tablets*	15		
ZOMIG	15		
ZORPRIN	14		
ZOVIA	5		
ZOVIRAX	3		
ZOVIRAX	20		
ZYLOPRIM	15		
ZYMAXID	18		
ZYRTEC	10		

**Product Name**

**Page**

**Product Name**

**Page**